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A B S T R A C T
Background
Visual field defects are estimated to affect 20% to 57% of people who have had a stroke. Visual field defects can affect functional ability
in activities of daily living (commonly affecting mobility, reading and driving), quality of life, ability to participate in rehabilitation, and
depression and anxiety following stroke. There are many interventions for visual field defects, which are proposed to work by restoring the
visual field (restitution); compensating for the visual field defect by changing behaviour or activity (compensation); substituting for the
visual field defect by using a device or extraneous modification (substitution); or ensuring appropriate diagnosis, referral and treatment
prescription through standardised assessment or screening, or both.
Objectives
To determine the effects of interventions for people with visual field defects after stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register, the Cochrane Eyes and Vision Group Trials Register, CENTRAL, MEDLINE, Embase,
CINAHL, AMED, PsycINFO, and PDQT Databse, and clinical trials databases, including ClinicalTrials.gov and WHO Clinical Trials Registry, to
May 2018. We also searched reference lists and trials registers, handsearched journals and conference proceedings, and contacted experts.
Selection criteria
Randomised trials in adults after stroke, where the intervention was specifically targeted at improving the visual field defect or improving
the ability of the participant to cope with the visual field loss. The primary outcome was functional ability in activities of daily living and
secondary outcomes included functional ability in extended activities of daily living, reading ability, visual field measures, balance, falls,
depression and anxiety, discharge destination or residence after stroke, quality of life and social isolation, visual scanning, adverse events,
and death.
Data collection and analysis
Two review authors independently screened abstracts, extracted data and appraised trials. We undertook an assessment of methodolog-
ical quality for allocation concealment, blinding of outcome assessors, method of dealing with missing data, and other potential sources
of bias. We assessed the quality of evidence for each outcome using the GRADE approach.
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Main results
Twenty studies (732 randomised participants, with data for 547 participants with stroke) met the inclusion criteria for this review. However,
only 10 of these studies compared the effect of an intervention with a placebo, control, or no treatment group, and eight had data which
could be included in meta-analyses. Only two of these eight studies presented data relating to our primary outcome of functional abilities
in activities of daily living. One study reported evidence relating to adverse events.
Three studies (88 participants) compared a restitutive intervention with a control, but data were only available for one study (19 partici-
pants). There was very low-quality evidence that visual restitution therapy had no effect on visual field outcomes, and a statistically sig-
nificant effect on quality of life, but limitations with these data mean that there is insufficient evidence to draw any conclusions about the
effectiveness of restitutive interventions as compared to control.
Four studies (193 participants) compared the effect of scanning (compensatory) training with a control or placebo intervention. There
was low-quality evidence that scanning training was more beneficial than control or placebo on quality of life, measured using the Visual
Function Questionnaire (VFQ-25) (two studies, 96 participants, mean difference (MD) 9.36, 95% confidence interval (CI) 3.10 to 15.62).
However, there was low or very-low quality evidence of no effect on measures of visual field, extended activities of daily living, reading,
and scanning ability. There was low-quality evidence of no significant increase in adverse events in people doing scanning training, as
compared to no treatment.
Three studies (166 participants) compared a substitutive intervention (a type of prism) with a control. There was low or very-low quality
evidence that prisms did not have an effect on measures of activities of daily living, extended activities of daily living, reading, falls, or
quality of life, and very low-quality evidence that they may have an effect on scanning ability (one study, 39 participants, MD 9.80, 95% CI
1.91 to 17.69). There was low-quality evidence of an increased odds of an adverse event (primarily headache) in people wearing prisms,
as compared to no treatment.
One study (39 participants) compared the effect of assessment by an orthoptist to standard care (no assessment) and found very low-
quality evidence that there was no effect on measures of activities of daily living.
Due to the quality and quantity of evidence, we remain uncertain about the benefits of assessment interventions.
Authors' conclusions
There is a lack of evidence relating to the effect of interventions on our primary outcome of functional ability in activities of daily living.
There is limited low-quality evidence that compensatory scanning training may be more beneficial than placebo or control at improving
quality of life, but not other outcomes. There is insufficient evidence to reach any generalised conclusions about the effect of restitutive
interventions or substitutive interventions (prisms) as compared to placebo, control, or no treatment. There is low-quality evidence that
prisms may cause minor adverse events.
P L A I N   L A N G U A G E   S U M M A R Y
Interventions for visual field defects in people with stroke
Review question
Are there effective treatments for people who have visual field defects after stroke?
Background
Stroke can cause some people (20% to 57% of people with stroke) to lose the ability to see the entire space in front of them - often one
complete half of the normal field of vision is lost. These problems with seeing are called visual field defects. Visual field defects can make it
difficult for people to function normally - especially moving about freely, avoiding obstacles, reading, driving, and taking part in rehabili-
tation for other stroke-related problems.
We wanted to see whether treatments for visual field defects could improve stroke survivors' abilities in activities of daily living (our primary
outcome of interest), or other (secondary) outcomes. Secondary outcomes that we were interested in included the size of the visual field
defect, independence (in functional abilities), quality of life, ability to scan/search for objects, reading ability, balance and falls, depression
and anxiety, and adverse events.
Study characteristics
We included 20 studies (involving 547 stroke participants) that investigated the effect of treatments for visual field defects. However, only
10 of these studies compared the effect of a particular treatment with no treatment. Three of these studies investigated a type of eye
movement training designed to improve the lost visual field (a 'restitutive' intervention). Four of the included studies investigated the
effect of scanning training, which involves training people to 'scan' across the space in front of them and into the 'lost' visual field, in order
to better cope with their lost vision (a 'compensatory' intervention). Three of the included studies investigated the effect of wearing a
special prism on a pair of glasses, which increases the amount a person can see on their affected side (a 'substitutive' intervention). One of
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the studies investigated the effect of specialised assessment by an orthoptist (a hospital-based vision specialist), compared to standard
care.
Search date
We searched for studies up to May 2018.
Key results
Only two studies presented data relating to how treatment can improve stroke survivors' abilities in activities of daily living, and there
was a lack of consistency across studies that limited our ability to draw clear conclusions. There was insufficient evidence to draw any
conclusions about the effectiveness of restitutive interventions as compared to control. There was low or very low-quality evidence that
scanning training may help improve quality of life, but may have no effect on other outcomes (including adverse events). There was low
or very-low quality evidence that prisms may have an effect on ability to scan (look) for objects, but may cause a range of minor adverse
events (particularly headache) and may have no effect on other outcomes. Limitations with the evidence meant that we could not draw
any conclusions about the benefits of assessment interventions.
Quality of the evidence
The quality of the evidence was low to very low, and in general was insufficient to reach conclusions about the effects of interventions
for people with visual field defects.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Summary of findings: Restitutive interventions versus control
Restitutive interventions compared with control for visual field defects in patients with stroke
Patient or population: stroke survivors with visual field defects
Settings: any rehabilitation setting
Intervention: restitutive interventions
Comparison: control, placebo, or no intervention
Outcomes Relative
effect
(95% CI)
No of Participants
(studies)
Quality of
the evi-
dence
(GRADE)
Comments
Functional ability in
activities of daily liv-
ing
(no data) No studies Insuffi-
cient evi-
dence
 
Visual field
(TAP border position
in degrees of visual
angle from zero verti-
cal meridian)
After intervention
MD 1.02
(-1.37 to
3.41)
19
(1 study, Kasten 2007)
⊕⊝⊝⊝
very low
Reasons for downgrades:
• Risk of bias - study had high ROB for 'other
bias' (relating to potential financial interest
in the intervention), study had uncertain ROB
for allocation concealment and incomplete
outcome data• Indirectness - included participants with di-
agnoses other than stroke• Imprecision - very small study population (n
= 19)
Extended activities
of daily living
(no data) No studies Insuffi-
cient evi-
dence
 
Reading ability (no data) No studies Insuffi-
cient evi-
dence
 
Falls (no data) No studies Insuffi-
cient evi-
dence
 
Quality of life
(improved or not im-
proved - derived from
percentage of those
who reported subjec-
tive improvements of
vision)
OR 13.00
(2.07 to
81.48)
30*
(1 study, Kasten 2007)
*The data used in this analy-
sis were derived from 30 of
the original 38 participants,
which included data from an
additional 19 participants
with optic nerve injury who
had also received the same
interventions in a separate
(but parallel) trial. Partici-
⊕⊝⊝⊝
very low
Reasons for downgrades:
• Risk of bias - study had high ROB for 'other
bias' (relating to potential financial interest
in the intervention), study had uncertain ROB
for allocation concealment and incomplete
outcome data• Indirectness - analysis contained data from a
subset of participants from a separate trial,
who were not relevant to this review• Indirectness - included participants with di-
agnoses other than stroke
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pants with optic nerve injury
do not meet the inclusion cri-
teria for this review.
• Imprecision - very small study population (n
= 19)
Scanning - cancella-
tion
(no data) No studies Insuffi-
cient evi-
dence
 
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
CI: confidence interval
MD: mean difference
n: number
OR: odds ratio
ROB: risk of bias
TAP: Tuebingen Automated Perimeter
 
 
Summary of findings 2.   Summary of findings: Compensative interventions versus control
Compensative interventions compared with control for visual field defects in patients with stroke
Patient or population: stroke survivors with visual field defects
Settings: any rehabilitation setting
Intervention: compensative interventions
Comparison: control, placebo, or no intervention
Outcomes Relative
effect
(95% CI)
No of Partici-
pants
(studies)
Quality of
the evi-
dence
(GRADE)
Comments
Functional ability in ac-
tivities of daily living
(no data) No studies Insuffi-
cient evi-
dence
 
Visual field
(Functional field score and
relative change in visual
field score, combined)
After intervention
SMD -0.11
(-0.92 to
0.70
(no signifi-
cant effect)
95
(2 studies, De
Haan 2015; Rowe
2010)
⊕⊝⊝⊝
very low
Reasons for downgrades:
• Risk of bias - one study judged as high risk of bias for
at least one domain• Inconsistency - one study had baseline differences• Inconsistency - I2 = 75%• Indirectness - studies explored very different com-
pensatory interventions
Extended activities of
daily living
(Mobility questionnaire
and change in Nottingham
EADL, combined)
SMD 0.49
(-0.01 to
0.99)
(no signifi-
cant effect)
97
(2 studies, De
Haan 2015; Rowe
2010)
⊕⊝⊝⊝
very low
Reasons for downgrades:
• Risk of bias - one study judged as high risk of bias for
at least one domain
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After intervention • Indirectness - outcome measures were very differ-
ent; for one study outcome was a mobility measure,
rather than a general measure of EADL• Indirectness - studies explored very different com-
pensatory intervention
s
Reading ability
(Reading speed; various
tests)
After intervention
SMD 0.26
(-0.05 to
0.58)
(no signifi-
cant effect)
162
(4 studies, Aimo-
la 2011; De Haan
2015; Rowe 2010;
Spitzyna 2007)
⊕⊕⊝⊝
low
Reasons for downgrades:
• Risk of bias - three studies judged as high risk of bias
for at least one domain• Indirectness - studies explored very different com-
pensatory intervention
Falls (no data) No studies Insuffi-
cient evi-
dence
 
Quality of life
(National Eye Institute Vi-
sual Function Question-
naire (NEI - VFQ-25) total
score)
After intervention
MD 9.36
(3.10 to
15.62)
(favours
compen-
satory)
96
(2 studies, De
Haan 2015; Rowe
2010)
⊕⊕⊝⊝
low
Reasons for downgrades:
• Risk of bias - two studies judged as high risk of bias
for at least one domain• Indirectness - studies explored very different com-
pensatory interventions
Scanning - cancellation
(cancellation tests - time
to complete)
After intervention
SMD -0.01
(-0.40 to
0.39)
(no signifi-
cant effect)
97
(2 studies, Aimo-
la 2011; De Haan
2015)
⊕⊕⊝⊝
low
Reasons for downgrades:
• Risk of bias - two studies judged as high risk of bias
for at least one domain• Indirectness - studies explored very different com-
pensatory interventions
Adverse events
(number of participants
with reported events dur-
ing intervention period)
OR 5.18
(0.24 to
112.57
(favours
control)
108
(2 studies, De
Haan 2015; Rowe
2010)
(NB. no events
recorded in
De Haan 2015,
which did not
explicitly report
adverse events
as an outcome
measure)
⊕⊕⊝⊝
low
Reason for downgrades:
• Inconsistency - no events from one study, means
pooled result was not estimable for that study; large
confidence intervals• Indirectness - studies explored very different com-
pensatory interventions
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
CI: confidence intervals
EADL: extended activities of daily living
MD: mean difference
Interventions for visual field defects in people with stroke (Review)
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NEI-VFQ-25: National Eye Institute Visual Function Questionnaire
OR: odds ratio
SMD: standardised mean difference
 
 
Summary of findings 3.   Summary of findings: Substitutive interventions versus control
Substitutive interventions compared with control for visual field defects in patients with stroke
Patient or population: stroke survivors with visual field defects
Settings: any rehabilitation setting
Intervention: compensative interventions
Comparison: control, placebo, or no intervention
Outcomes Relative effect
(95% CI)
No of Par-
ticipants
(studies)
Quality of
the evi-
dence
(GRADE)
Comments
Functional ability in
activities of daily liv-
ing
(Barthel Index)
After 4 weeks of treat-
ment
Wearing prisms
MD -4.00 (-17.86 to
9.86)
(no significant effect)
39
(1 study,
Rossi
1990)
⊕⊝⊝⊝
very low
Reasons for downgrades:
• Risk of bias - study judged as high risk of bias for at
least one domain• Indirectness - included data from participants with
neglect• Imprecision - small study population (n = 39)
Visual field
(change in visual field
area & change in error
scores, from baseline)
After intervention
Not wearing prisms
SMD 0.12 (-0.46 to
0.70)
Wearing prisms
SMD 1.12 (0.44 to
1.80)
85
(2 stud-
ies, Rossi
1990;
Rowe
2010)
⊕⊝⊝⊝
very low
Reasons for downgrades:
• Risk of bias - one study judged as high risk of bias for
at least one domain• Indirectness - included data from participants with
neglect• Indirectness - studies cannot be combined due to
differences in testing (wearing/not wearing prisms)
Extended activities of
daily living
(Change in EADL from
baseline; mobility im-
provement scores, in
Logits)
After intervention
Not wearing prisms
SMD 0.20 (-0.44 to
0.85)
Wearing prisms
SMD 0.24 (-0.26 to
0.75)
99
(2 stud-
ies, Bow-
ers 2014;
Rowe
2010)
⊕⊝⊝⊝
very low
Reasons for downgrades:
• Risk of bias - one study judged as high risk of bias for
at least one domain• Indirectness - one study outcome was a mobility
measure, rather than a general measure of EADL• Indirectness - included participants with diagnoses
other than stroke• Indirectness - studies cannot be combined due to
differences in testing (wearing/not wearing prisms)
Reading ability Not wearing prisms
MD 2.80 (-7.13 to
12.73)
(no significant effect)
45
(1 study,
Rowe
2010)
⊕⊕⊝⊝
Low
Reasons for downgrades:
• Imprecision - small study population (n = 45)• Imprecision - wide confidence intervals
Falls
(number of falls)
Wearing prisms 39 ⊕⊝⊝⊝
very low
Reasons for downgrades:
Interventions for visual field defects in people with stroke (Review)
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After intervention OR 1.21, (0.26 to
5.76)
(no significant differ-
ence)
(1 study,
Rossi
1990)
• Risk of bias - study judged as high risk of bias for at
least one domain• Indirectness - included data from participants with
neglect• Imprecision - small study population (n = 39)
Quality of life
(Visual Function Ques-
tionnaire (VFQ-25))
After intervention
Not wearing prisms
MD 8.40 (-4.18 to
20.98)
(no significant effect)
43
(1 study,
Rowe
2010)
⊕⊕⊝⊝
Low
Reasons for downgrades:
• Imprecision - small study population (n = 43)• Imprecision - wide confidence intervals
Scanning - cancella-
tion
(line cancellation er-
rors)
After intervention
Wearing prisms
MD 9.80 (1.91 to
17.69)
(favours substitutive)
39
(1 study,
Rossi
1990)
⊕⊝⊝⊝
very low
Reasons for downgrades:
• Risk of bias - study judged as high risk of bias for at
least one domain• Indirectness - included data from participants with
neglect• Imprecision - small study population (n = 39)• Imprecision - wide confidence intervals
Adverse events
(number of participants
with reported events
during intervention pe-
riod)
OR 87.32 (4.87 to
1564.66)
(favours control)
59
(1 study,
Rowe
2010)
⊕⊕⊝⊝
Low
Reason for downgrades:
• Inconsistency - large confidence intervals• Imprecision - data from only one study
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
EADL: extended activities of daily living
MD: mean difference
OR: odds ratio
SMD: standardised mean difference
VFQ-25: Visual function questionnaire
 
 
Summary of findings 4.   Summary of findings: Assessment/screening interventions versus control
Assessment/screening interventions compared with control for visual field defects in patients with stroke
Patient or population: stroke survivors with visual field defects
Settings: any rehabilitation setting
Intervention: assessment/screening interventions
Comparison: control, placebo, or no intervention
Outcomes Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the evidence
(GRADE)
Comments
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Functional ability in activi-
ties of daily living
(FIM)
After intervention
MD -6.97 (-23.78 to
9.84)
(no significant ef-
fect)
37
(1 study, Jarvis
2012)
⊕⊝⊝⊝
very low
Reasons for downgrades:
• Risk of bias - study judged
as high risk of bias for at
least one domain• Imprecision - small study
population (n = 37)• Imprecision - wide confi-
dence intervals
Visual field (no data) No studies Insufficient evidence  
Extended activities of daily
living
(no data) No studies Insufficient evidence  
Reading ability (no data) No studies Insufficient evidence  
Falls (no data) No studies Insufficient evidence  
Quality of life (no data) No studies Insufficient evidence  
Scanning - cancellation (no data) No studies Insufficient evidence  
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
FIM: Functional Independence Measure
MD: mean difference
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B A C K G R O U N D
Description of the condition
Following stroke, a common visual problem is loss of one-half of the
visual field in both eyes; this is called hemianopia or hemianopsia.
As it affects the same side in both eyes, it is termed a homonymous
hemianopia. For example, leM hemisphere stroke causes the loss
of the nasal field of the leM eye and temporal (outer field) of the
right eye, resulting in an inability to see to the right of the centre of
the field of view. Visual field defects are common following stroke;
the prevalence has been reported as being between 20% and 57%
of people (Ali 2013; Rowe 2007; Rowe 2009). The extent of the loss
within the visual field may vary, from the loss of the entire half of
the visual field to the loss of only a portion of the affected half. It has
been reported that 70% of those with visual field loss will maintain
a small area of central vision (macular sparing) (Kerkhoff 1999).
The association between visual impairment and disability in activ-
ities of daily living has been well-established (Wolter 2006). Visual
field defects can affect functional ability and quality of life follow-
ing stroke (Dombovy 1986; Jongbloed 1986). Studies have demon-
strated that people with visual field defects have an increased risk
of falling (Ramrattan 2001), and that visual field loss is a predictor
of poor functional status at discharge from a stroke unit (Kaplan
1982). People report walking into objects, tripping and falling, feel-
ing unsafe, getting lost, and experiencing panic when in crowded
or unfamiliar areas (Windsor 2008). Stroke survivors may struggle
with reading, and with accomplishing everyday tasks such as shop-
ping and handling their finances (Warren 2009), and they report se-
vere difficulty returning to work, and marked loss of self-confidence
(Rowe 2017).
Visual field loss may also impact on a person's ability to participate
in rehabilitation, to live in their own home, and on depression, anx-
iety, social isolation, and quality of life following stroke (Hepworth
2016; Jones 2006). Visual field defects often co-exist with visual ne-
glect or other perceptual problems. Differentiation between visual
field defects and visual neglect can be difficult (Jones 2006).
Description of the intervention
There are many different treatment and management approaches
available for people with visual field defects. This review consid-
ered any intervention that is specifically targeted at improving the
visual field defect or improving the ability of the person to cope with
the visual field loss.
Treatments for visual field defects can be described as restitution,
compensation or substitution (Hämäläinen 2004; Kerkhoff 2000).
In addition to these types of treatments, this review also consid-
ered assessment and screening interventions that are specifically
targeted at people with visual field defects.
These interventions may include, but are not limited to, the follow-
ing.
• Restitutive interventions: visual field training, contrast sensitiv-
ity training, fusional (binocular vision) training.• Compensatory interventions: saccadic (fast, simultaneous) eye
movement training , training in visual search strategies, train-
ing eye movements for reading, use of eye blinks or colour cues,
training in activities of daily living.
• Substitutive interventions: prisms (Peli 2000; Rossi 1990), eye
patches, adapted lighting, magnification, environmental modi-
fication.• Assessment and screening interventions: standardised visual
assessment, screening and referral for visual assessment and in-
tervention.
These are all complex interventions and, therefore, there can be
substantial variations, even within interventions of the same type.
For example, there can be differences between interventions in re-
lation to the mode of delivery (e.g. therapist-delivered, self-direct-
ed, or computer-based), personnel involved in delivery (e.g. vision
specialists, such as orthoptists; stroke-care rehabilitation profes-
sionals, such as occupational therapists), and in the dose of the in-
tervention (amount of training per day, or per week, and length of
intervention period).
How the intervention might work
Interventions for visual field defects are proposed to work by either
restoring the visual field (restitution); compensating (adapting) for
the visual field defect by changing behaviour or activity (compen-
sation); substituting for the visual field defect by using a device or
extraneous modification (substitution); or ensuring appropriate di-
agnosis, referral and treatment prescription through standardised
assessment or screening, or both.
Restitution
This includes the biochemical events that help restore functional
neural (nervous system) tissue, for example, the reduction of oede-
ma, absorption of blood, restoration of normal neuronal physiol-
ogy and restoration of axon (part of a nerve cell) transport. In the
past, researchers thought that restitutive approaches would have
limited effect in visual rehabilitation (Kerkhoff 2000). However, in
the last decade, reports have suggested that expansion of the vi-
sual field can be achieved with specific interventions after brain or
optic nerve injury (Romano 2008; Sabel 2000; Sahraie 2006). Resti-
tutive interventions include those where there is direct training of
the impaired function or repetitive stimulation of the visual field.
Commercially available treatments, including NovaVision® Visual
Restorative Therapy, give people repeated exposure to stimuli tar-
geting a vision deficit in a direct attempt to help activate the brain
to restore vision (NovaVision 2009).
Compensation
Compensation aims to improve the mismatch between the skills
of those affected and the demands placed on them by their envi-
ronment by teaching them to compensate using a spared or intact
function (Kerkhoff 1999; Kerkhoff 2000; Peli 2000). Interventions
include teaching people compensatory visual search or scanning
techniques, varying from simple training strategies to interventions
using computerised scanning schedules and specially-developed
commercially available tools (such as NVT 2009). When describing
interventions for visual field defects, the term compensation may
be used synonymously with the term adaptation, but we use the
term compensation throughout this review.
Substitution
Substitution involves adaptation of visual components that have
been lost or disrupted through the use of optical devices or envi-
ronmental modifications (Kerkhoff 1999; Kerkhoff 2000; Peli 2000).
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Optical devices can include prisms, which shiM the image received
into an area that can be perceived, and typoscopes, which provide
a guide for eye movements when reading.
Assessment and screening interventions
These may work by ensuring that the visual field defect is appro-
priately diagnosed, enabling other interventions to be prescribed.
In those who have co-existing visual field defects and visual ne-
glect; determining the action of an effective intervention can be
difficult. The co-existence of visual neglect could prevent interven-
tions aimed at the visual field defect from working effectively. For
example, teaching scanning techniques to people with visual field
defects may help them learn to compensate by scanning to the af-
fected field but may not be as effective in people with co-existing
visual neglect.
Why it is important to do this review
The services available to people with visual problems following
stroke are presently inconsistent. There are various treatment and
management approaches that are available for people with visual
field defects. However, these are used to varying degrees in clini-
cal practice (Rowe 2014), and clinicians lack research-based guid-
ance on the choice of treatment (Hanna 2017). There is a recog-
nised need to identify the evidence base for treatments for visual
problems following stroke.There is considerable controversy and
debate about the effectiveness of restitutive interventions (Hor-
ton 2005a; Horton 2005b; Reinhard 2005; Sabel 2006). There are a
number of published reviews of the literature relating to interven-
tions for visual problems following stroke. Barrett 2009 and Riggs
2007 provided reviews of visual problems, which included a small
section relating to visual field problems after stroke; both of these
reviews were limited in their scope and methodological quality.
Bouwmeester 2007 completed a systematic review of the effect of
one intervention (visual training) on visual field defects in people
with brain damage, including stroke. Lane 2008 provided a narra-
tive review of evidence for interventions for visual field loss. Das
2010 provided a narrative review with an emphasis on restitutive in-
terventions, and primarily discussed a range of cohort studies that
used localised, repetitive perceptual training aimed at reversing vi-
sual field loss induced by cortical damage. Hanna 2017 provided a
narrative review of evidence for visual impairments, including visu-
al field defect, summarising evidence from earlier versions of this
review and evidence from non-randomised studies. There is agree-
ment amongst these reviews that there is a need for high-quality
studies of the effectiveness of interventions for visual field defects.
In order to determine the current evidence for the effectiveness of
any treatment or management approaches for stroke patients with
visual field defects, and to enable appropriate planning and priori-
tisation of future primary research, it is essential that there is an
up-to-date high-quality systematic review of the existing evidence
base.
O B J E C T I V E S
The key objective of this review was to determine the effects of in-
terventions for people with visual field defects after stroke.
Research questions• Do interventions for visual field defects improve functional abil-
ity following stroke?
• Are interventions for visual field defects more effective at im-
proving functional ability in people with a visual field defect on-
ly than in those both with a co-existing visual field defect and vi-
sual perceptual problems?
Specific objectives• To determine if in 1) all participants with visual field defects fol-
lowing stroke (with or without visual perceptual problems), 2)
those with visual field defects and no visual perceptual prob-
lems, and 3) those with co-existing visual field defects and visual
perceptual problems:* restitutive interventions are more effective than control,
placebo, or no intervention at improving functional ability in
activities of daily living;* compensative interventions are more effective than control,
placebo, or no intervention at improving functional ability in
activities of daily living;* substitutive interventions are more effective than control,
placebo, or no intervention at improving functional ability in
activities of daily living;* assessment and screening interventions are more effective
than control, placebo, or no intervention at improving func-
tional ability in activities of daily living;* any one active intervention is more effective than any other
active intervention at improving functional ability in activi-
ties of daily living.• To determine if in 1) all participants with visual field defects fol-
lowing stroke (with or without visual perceptual problems), 2)
those with visual field defects and no visual perceptual prob-
lems, and 3) those with co-existing visual field defects and visual
perceptual problems:* restitutive interventions are more effective than control,
placebo, or no intervention at improving secondary out-
comes;* compensatory interventions are more effective than con-
trol, placebo, or no intervention at improving secondary out-
comes;* substitutive interventions are more effective than control,
placebo, or no intervention at improving secondary out-
comes;* assessment and screening interventions are more effective
than control, placebo, or no intervention at improving sec-
ondary outcomes;* any one active intervention is more effective than any other
active intervention at improving secondary outcomes.• To explore the relationship between participant characteristics
and the effect of interventions aimed at improving functional
abilities in activities of daily living using subgroup analysis.• To make specific recommendations for future research into the
effectiveness of interventions for visual field defects based on a
knowledge of the existing evidence base.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and randomised controlled
cross-over trials (the first phase analysed as a parallel-group trial).
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Types of participants
Adult participants (over 18 years of age) after stroke (using the
World Health Organization (WHO) definition of stroke, or a clinical
definition if not specifically stated; that is, signs and symptoms per-
sisting longer than 24 hours) who have been diagnosed as having a
visual field defect.
Where studies included participants with visual field defects due to
reasons other than stroke (e.g. traumatic brain injury), in addition
to participants with visual field defects due to stroke, we includ-
ed these studies. We documented the number of participants with
each clinical diagnosis, and planned to use this information when
exploring heterogeneity.
We defined a visual field defect as a homonymous loss of vision con-
tralateral to the side of the lesion. We accepted a clinical diagnosis
of visual field defect. We documented the method of diagnosing a
visual field defect.
We excluded participants with monocular visual field defects due
to retinal stroke.
Types of interventions
We included any intervention that was specifically targeted at im-
proving the visual field defect or improving the ability of the partici-
pant to cope with the visual field loss. We classified interventions as
either restitution, compensation, substitution, or assessment and
screening (see Description of the intervention).
We compared interventions with no treatment, placebo, and con-
trol, within four specific preplanned comparisons:
• restitutive interventions versus no treatment, placebo, or con-
trol;• compensatory interventions versus no treatment, placebo, or
control;• substitutive interventions versus no treatment, placebo, or con-
trol;• assessment and screening interventions versus standard care.
We considered studies which compared one active intervention
with another active intervention within a narrative synthesis. We
did not plan to conduct any meta-analyses comparing one active
intervention with another active intervention as we anticipated
that there would be substantial variation in the interventions, and
that it would not make sense to combine the results.
Two review authors (CH, AP) independently classified the types of
interventions in each included trial as either restitution, compen-
sation, substitution, or assessment and screening. We anticipat-
ed that we might experience some difficulties in the classification
of some interventions, in particular, the classification of interven-
tions as either restitutory or compensatory, and had planned to
reach consensus through discussion, involving a third review au-
thor when necessary. If there was uncertainty about the action of a
particular intervention, we planned to carry out sensitivity analyses
to explore the effect of removing and including the relevant trial(s).
However, the two independent review authors agreed on all classi-
fications and did not require further discussion with a third review
author.
Types of outcome measures
Where possible, we assessed the outcome at the end of the inter-
vention period and at a follow-up point (ideally six months after
the intervention had finished, but we accepted any follow-up point
after the intervention period had finished, documenting the time
point).
Primary outcomes
Functional ability in activities of daily living (ADL)
We included the following validated scales: Barthel Activities of Dai-
ly Living Index (Mahoney 1965), Functional Independence Measure
(FIM) (Smith 1990), modified Rankin Scale (mRS) (Wilson 2002), Katz
Index of Activities of Daily Living (Katz 1963), and Rehabilitation Ac-
tivities Profile (Van Bennekom 1995). If more than one of these func-
tional ability scales was reported, we used the scale appearing ear-
liest in our list.
Secondary outcomes
We included the following secondary outcomes. We prestated
outcome measurement tools/scales which we anticipated, and
planned that if more than one of the scales or measures was report-
ed, we would use the scale appearing earliest in our list. If addition-
al tools/scales were reported, but none from our prestated list, we
included these.
• Functional ability in extended activities of daily living (EADL):
Nottingham Extended Activities of Daily Living scale (Nouri
1987), Lawton Instrumental Activities of Daily Living (Lawton
1969), Frenchay Activities Index (Holbrook 1983), Rivermead Ac-
tivities of Daily Living (ADL) score (Lincoln 1990).• Reading - reading ability: reading speed (text reading time),
reading accuracy (Wide Range Achievement Test (WRAT)(Wilkin-
son 2006), Gray Oral Reading test (Bryant 2011).• Visual field: visual field outcomes subdivided into 1) gross visual
screening: confrontation tests, Harrington Flocks Visual Screen-
er; 2) kinetic perimetry: Goldmann perimetry, Tangent Screen
measures; 3) static perimetry: Humphrey Automated Perimetry,
Tubinger Automated Perimetry (TAP), High resolution perimetry
(HRP). For perimetry outcomes: when more than one measure
had been taken with the same instrument we reported border
position for the intact visual field and used it for analysis in pref-
erence to hit or detection rate.• Balance: Berg Balance Scale (Berg 1989), Functional Reach (Dun-
can 1990), Get-Up and Go test (Mathias 1986), Standing Balance
test, Step Test, or other standardised balance measure. We did
not include measures of weight distribution or postural sway
during standing as the relationship between ability to maintain
balance and these outcomes is not established.• Falls: number of reported falls, Falls Efficacy Scale (Tinetti 1990).• Depression and anxiety: Hospital Anxiety and Depression scale
(Zigmond 1983), Beck Depressive Inventory (Beck 1987), Gener-
al Health Questionnaire (Goldberg 1979), Geriatric Depression
Scale (Cinnamon 2011).• Discharge destination or residence after stroke: dichotomous
variable - discharged to previous place of residence (i.e. place of
residence prior to stroke) or discharged to alternative destina-
tion.
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• Quality of life and social isolation: EQ5D (Rabin 2001), Health-
related quality of life scale (Williams 1999), Quality of Well Being
scale (Kaplan 1993), SF36 (Garrett 1993).• Visual scanning: cancellation techniques.• Adverse events: any reported adverse events, excluding falls,
death.• Death.
Search methods for identification of studies
See the methods for the Cochrane Stroke Group Specialised reg-
ister. We searched for trials in all languages and arranged for the
translation of trials where necessary.
Electronic searches
We searched the Cochrane Stroke Group Trials Register (May 2018),
the Cochrane Eyes and Vision Group Trials Register (May 2018) and
the following electronic bibliographic databases:
• Cochrane Central Register of Controlled Trials (CENTRAL; 2015,
Issue 1) in the Cochrane Library (accessed May 2018) (Appendix
1);• MEDLINE Ovid (1950 to 16 May 2018) (Appendix 2);• Embase Ovid (1980 to 16 May 2018) (Appendix 3);• CINAHL EBSCO (Cumulative Index to Nursing and Allied Health
Literature; 1982 to 16 May 2018) (Appendix 4);• AMED Ovid (Allied and Complementary Medicine; 1985 to 16 May
2018) (Appendix 5);• PsycINFO (1967 to 16 May 2018) (Appendix 6);• ProQuest Dissertations & Theses (PQDT) database (1861 to 22
March 2015) (Appendix 7).
Searching other resources
In an effort to identify further published, unpublished and ongoing
trials we:
• searched the following registers of ongoing trials:• US National Institutes of Health Ongoing Trials Register Clini-
calTrials.gov (www.clinicaltrials.gov; May 2018) (Appendix 8);• World Health Organization International Clinical Trials Reg-
istry Platform (apps.who.int/trialsearch; May 2018) (Appen-
dix 8);• ISRCTN Registry (www.isrctn.org) (formerly known as
the Current Controlled Trials; www.controlled-trials.com)
(March 2015);• Health Service Research Projects in Progress (wwwcf.nlm.ni-
h.gov/hsr_project/home_proj.cfm) (March 2015);• National Eye Institute Clinical Studies Database (clinical-
studies.info.nih.gov/cgi/protinstitute.cgi?NEI.0.html) (March
2015);• Stroke Trials Registry (www.strokecenter.org/trials/) (March
2015);• handsearched the following journals and conference proceed-
ings:
• Australian Orthoptic Journal (1959 to August 2018);• British Orthoptic Journal (1939 to August 2003);• British and Irish Orthoptic Journal (2004 to August 2018);• International Orthoptic Association (IOA) (www.liver-
pool.ac.uk/orthoptics/research/search.htm) (1967 to August
2018);• International Strabismological Association (ISA) (1966 to Au-
gust 2018);• Proceedings of the European Strabismological Association
(ESA) (1969 to August 2018).
We searched the reference lists of included trials and review articles
about vision after stroke and contacted experts in the field.
Data collection and analysis
One review author (CH or PC) ran all the electronic searches, down-
loaded references into bibliographic software, and removed dupli-
cates. One review author excluded any titles which were obvious-
ly not related to stroke and vision (one of CH, PC, or AP). We ob-
tained the abstracts for remaining references and two review au-
thors (two of CH, AP, PC, SJ, AK) independently considered each of
these abstracts, excluded any studies that were clearly not RCTs or
cross-over trials, and excluded any studies where the intervention
was not specifically aimed at improving the visual field defect or the
participant's ability to cope with the visual field defect. The review
authors resolved any disagreements through discussion, involving
a third review author where necessary. We obtained the full papers
for any studies included at this stage.
Selection of studies
Two review authors independently applied the selection criteria
by considering and documenting the type of studies, type of par-
ticipants, intervention, comparison intervention, and the outcome
measures (two of AP, CH, SJ, AK). Each review author classified stud-
ies as 'include' or 'exclude'. If there was disagreement between
these two review authors, they reached consensus through discus-
sions involving a third review author.
We listed any excluded studies that included participants with visu-
al field defects in the Characteristics of excluded studies table and
provided the reason for exclusion. We did not list studies that were
excluded because they included participants who did not have vi-
sual field defects (i.e. visual neglect, eye-movement disorders, age-
related visual problems) in the Characteristics of excluded studies
table unless the two review authors agreed that there was a clear
reason to do so.
Data extraction and management
We used a pre-designed data extraction form to extract data from
the included studies. Two review authors (two of AP, CH, SJ) inde-
pendently documented the following.
• Methods: study design, method of randomisation.• Participants: number of participants, inclusion criteria, time
since stroke, type, nature and location of lesion. We document-
ed the method of diagnosing the visual field defect and the type
and extent of the visual field loss; the presence or absence of
visual perceptual problems, and the method of diagnosis; and
the country of origin of participants. We documented whether
the included participants had visual field defects only (no visu-
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al neglect), co-existing visual field defects and visual neglect, or
whether the participants were a mixed group (some with and
some without visual neglect). If there was a mixed group of par-
ticipants, we documented whether data were available for the
visual field defect-only group and the group with co-existent vi-
sual field and visual neglect. Where information was available,
we documented the presence or absence of eye movement dis-
orders or low vision, accepting a clinical diagnosis of these.• Interventions: description of interventions given to each treat-
ment group including, if relevant, the duration, intensity, fre-
quency and dose. We classified the type of intervention as resti-
tution, compensation, substitution, or assessment and screen-
ing; and the type of control as no treatment, placebo, control, or
standard care. We documented the professional background of
the person providing the intervention (e.g. occupational thera-
pist, orthoptist).• Outcomes: we documented the primary and secondary out-
comes relevant to this review. If a study used a number of dif-
ferent methods of measuring the same outcome, we noted the
outcome to be used for any subsequent analysis.• Notes: we noted any important confounding variables. If more
than two intervention groups were included in the study, we
noted the method of including these groups in any subsequent
analysis.
In addition, the review authors independently documented, if data
allowed, the following demographics of the included participants:
age, gender, place of residence, type of stroke, side of stroke, time
since stroke, initial visual field defect, and initial functional abili-
ty. The review authors resolved any data extraction discrepancies
through discussion.
Assessment of risk of bias in included studies
Two independent authors (two of AP, CH, SJ) assessed risk of bias
by grading the following domains as 'low risk', 'high risk' or 'unclear
risk' of bias for each included study. We documented this within the
'Risk of bias' tables.
Allocation concealment
Studies with adequate concealment included those that used cen-
tral randomisation at a site remote from the study, computerised
allocation in which records were in a locked readable file that could
be assessed only after entering participant details, or the draw-
ing of opaque envelopes. Studies with inadequate concealment in-
cluded those using an open list or table of random numbers, open
computer systems, or drawing of non-opaque envelopes. Studies
with unclear concealment included those with no or inadequate in-
formation in the report.
Blinding
Adequate concealment included studies which stated that a
masked outcome assessor was used, and that had masking of par-
ticipants and key study personnel and did not identify any 'un-
masking'. Inadequate concealment included studies that did not
use masking of the outcome assessor, personnel, or participants,
where there was incomplete masking, or where the report clear-
ly identified that 'unmasking' occurred during the study. We docu-
mented concealment as unclear if a study did not state, or if there
was insufficient information to judge, whether or not personnel,
participants, and outcome assessors were masked. We acknowl-
edged that for some (but not all) interventions for visual field de-
fects, masking of personnel or participants, or both, is not possible,
and considered the potential for any lack of blinding of personnel
or participants, or both, to introduce bias.
Incomplete outcome data
Studies adequately addressing incomplete outcome data either
had: no missing outcome data; missing outcome data that were
unlikely to be related to true outcome; missing outcome data that
were balanced in numbers across intervention groups, with similar
reasons for missing data across groups; a reported effect size (dif-
ference in means or standardised difference in means) among miss-
ing outcomes that were not enough to have a clinically relevant im-
pact on observed effect size; or missing data that had been imput-
ed using appropriate methods. Studies inadequately addressing
incomplete outcome data either had: missing outcome data that
were likely to be related to true outcome, with either imbalance in
numbers or reasons for missing data across intervention groups;
a reported effect size (difference in means or standardised differ-
ence in means) among missing outcomes enough to induce clini-
cally relevant bias in the observed effect size; as-treated analysis
done with substantial departure of the intervention received from
that assigned at randomisation. We documented addressing of in-
complete outcome data as unclear if there was insufficient report-
ing to allow this to be assessed, or if this was not addressed in the
report.
Other bias
We assessed a study not to be free of other bias if it was assessed to
have at least one important risk of bias, such as: a potential source
of bias related to the specific study design used, an extreme base-
line imbalance, a claim to have been fraudulent, financial associa-
tion with the intervention, or some other problem. If there was in-
sufficient information, or the information provided was unclear, we
documented the risk of other bias as unclear.
We produced a 'Risk of bias' summary figure to illustrate the poten-
tial biases within each of the included studies.
Measures of treatment e:ect
We used the Review Manager software RevMan 5.3 (RevMan 2014)
to carry out statistical analyses to determine the treatment effect
of:
• restitutive interventions (compared to no treatment, control,
placebo, or standard care);• compensatory interventions (compared to no treatment, con-
trol, placebo, or standard care);• substitutive interventions (compared to no treatment, control,
placebo, or standard care);• assessment and screening interventions (compared to standard
care).
We used a random-effects model for all statistical analyses. For
dichotomous, variables we calculated and reported Peto odds ra-
tios (ORs) with 95% confidence intervals (CIs). For continuous data,
we calculated the treatment effect using standardised mean differ-
ences (SMDs) and 95% CIs where studies used different scales for
the assessment of the same outcome, and using mean differences
(MDs) and 95% CIs where all studies used the same method of mea-
suring an outcome.
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The primary outcome of functional ability in activities of daily liv-
ing, and secondary outcomes of functional ability in extended ac-
tivities of daily living, visual field data, balance, depression and anx-
iety, and quality of life and social isolation comprise either ordinal
data from measurement scales, or continuous data. We analysed
these as continuous variables.
Where reported outcomes had a measurement scale where a lower
value is indicative of a better outcome (e.g. depression and anxiety
scales) we multiplied the reported values by -1 so that in all analy-
ses a higher value was indicative of a better outcome.
If studies reported change values and the baseline value was avail-
able, we calculated the value at follow-up (change value - baseline
value). If studies reported change values and the baseline value was
not available, we used these data in meta-analyses but planned
sensitivity analyses to investigate the effect of including the data.
We planned to analyse falls, discharge destination, adverse events,
and deaths as dichotomous variables.
Unit of analysis issues
We anticipated that the majority of trials would have a paral-
lel-group design in which each individual participant was ran-
domised to one of two, or more, treatment groups. Where stud-
ies had two or more active intervention groups eligible for inclu-
sion within the same comparison (against a control, placebo, or no
treatment group), we intended to 'share' the control group data be-
tween the multiple pair-wise comparisons in order to avoid double
counting of participants within an analysis.
If studies used a randomised controlled cross-over design, we
planned to analyse data from the first phase only. We did not antic-
ipate that any studies would use a cluster-randomised design.
Dealing with missing data
If an included study did not report a particular outcome, we did not
include that study in the analysis of that outcome.
If an included study had missing data (e.g. reported means but not
standard deviations for the follow-up data), we took logical steps to
enter an assumed value. Such steps included estimating a standard
deviation (SD) based on a reported standard error and estimating a
follow-up SD based on a baseline value. We performed calculations
of SDs from standard errors and P values using methods described
in section 7.7.3.3 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We planned to do sensitivity analy-
ses to investigate the effect of entering assumed values. We also
contacted authors in an attempt to obtain missing data.
Assessment of heterogeneity
We visually assessed heterogeneity by looking at the extent of over-
lap of the CIs on the forest plots. We considered the P value, con-
sidering that with P < 0.1 there was likely to be heterogeneity. We
considered the I2 statistic. We considered I2 > 50% as substantial
heterogeneity. If I2 > 50%, we explored the individual trial charac-
teristics to identify potential sources of heterogeneity.
Assessment of reporting biases
We attempted to avoid reporting biases by using a comprehensive
search strategy that included searching for unpublished studies
and searching trials registers. We planned to carry out sensitivity
analyses to explore the effect of publication type.
Data synthesis
Two review authors (AP, CH, or SJ) independently extracted data
from the included trials. One review author (AP) entered the data in-
to RevMan 5.3 (RevMan 2014), and the other review author checked
the entries. They resolved any disagreements through discussion,
with reference to the original report.
Subgroup analysis and investigation of heterogeneity
We intended to explore heterogeneity by subgroup analyses to in-
vestigate the effect of:
• time after stroke (zero to three months, three to six months,
more than six months);• type of visual field defect (homonymous hemianopia, other) (We
anticipated that the majority of the participants would have
homonymous hemianopia. However, we documented the type
of visual field defect and planned subgroup analyses to investi-
gate the effect of including participants with types other than
homonymous hemianopia);• extent of visual field loss if homonymous (complete hemi-
anopia, partial hemianopia, quadrantanopia);• presence or absence of visual neglect (no visual neglect, all par-
ticipants with co-existing visual field defects and visual neglect,
mixed group of participants some with and some without visual
neglect);• macular sparing, macular splitting field loss;• type of treatment (e.g. for compensatory interventions: sac-
cadic eye movement, activities of daily living training; for substi-
tutive interventions: prisms, patches, environmental modifica-
tions; for assessment and screening: by orthoptist, occupation-
al therapist, doctor).
We planned to use an established method for subgroup analyses
(Deeks 2001). We planned to carry out these subgroup analyses
when there were six or more studies included in a single analysis,
all with sufficient information to determine the subgroups.
Sensitivity analysis
We planned to carry out sensitivity analysis to explore the effect of
the following methodological features.
• Allocation concealment: we planned to re-analyse data, exclud-
ing trials with inadequate or unclear allocation concealment.• Masking of outcome assessor: we planned to re-analyse data,
excluding trials without or with unclear masking of outcome as-
sessor.• Missing outcome data: we planned to re-analyse the data, ex-
cluding trials with inadequate or unclear methods of dealing
with missing outcome data.• Other bias: we planned to re-analyse the data, excluding trials
assessed to have other bias, or unclear as to whether they had
other bias.• Type of intervention: we planned to re-analyse data, excluding
trials where the classification of the type of intervention was un-
certain.
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• Publication type (peer-reviewed journal, conference abstract or
proceedings, doctoral dissertation): we planned to re-analyse
data including only those trials from peer-reviewed journals.
We planned to carry out these planned sensitivity analyses when
there are six or more studies included in a single analysis.
GRADE assessment and 'Summary of findings' tables
We presented the results of the main preplanned comparisons of
the review in 'Summary of findings' tables;
• restitutive interventions (compared to no treatment, control,
placebo, or standard care): Summary of findings for the main
comparison;• compensatory interventions (compared to no treatment, con-
trol, placebo, or standard care): Summary of findings 2;• substitutive interventions (compared to no treatment, control,
placebo, or standard care): Summary of findings 3;• assessment and screening interventions (compared to standard
care): Summary of findings 4.
Within each 'Summary of findings' table, we summarised data for
the primary outcome of interest (functional ability in activities of
daily living), the six secondary outcomes for which we had identi-
fied the greatest volume of evidence in previous versions of this re-
view (visual field, extended activities of daily living, reading ability,
falls, quality of life, scanning - cancellation), and any data related
to adverse events.
For each of the preplanned comparisons, we assessed quality of
the evidence using the GRADE approach (Guyatt 2011a), consider-
ing each of the following criteria.
• Risk of bias due to flawed design or conduct of studies (Guyatt
2011b).• Imprecision (e.g. when confidence intervals for treatment effect
are wide) (Guyatt 2011d).• Inconsistency (e.g. when point estimates vary widely, I2 is large)
(Guyatt 2011e).• Indirectness (e.g. variations in participants, interventions, com-
parisons, and outcomes) (Guyatt 2011f).• Publication bias (may be explored with the use of funnel plots
and classed as not suspected, suspected, strongly suspected or
very strongly suspected) (Guyatt 2011c).
We documented identified concerns relating to any of the above
criteria, and downgraded the level of evidence accordingly (one
downgrade for each concern, and a maximum of two downgrades
for each of the listed criteria). If there were no downgrades the lev-
el of evidence was high quality, if there was one downgrade the
level of evidence was moderate quality, if there were two down-
grades the level of evidence was low quality, and if there were more
than two downgrades the level of evidence was very low quality.
We used the following definitions of evidence.
• High quality: when further research is very unlikely to change
our confidence in the estimate of effect.• Moderate quality: when further research is likely to have an im-
portant impact on our confidence in the estimate of effect and
may change the estimate.• Low quality: when further research is very likely to have an im-
portant impact on our confidence in the estimate of effect and
is likely to change the estimate.• Very low quality: when we are very uncertain about the estimate.
One review author (AP) assessed quality of evidence, reported iden-
tified concerns, and applied downgrades. Other review authors
checked agreement with these judgements and resolved any dis-
agreements through discussion.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of exclud-
ed studies; Characteristics of ongoing studies, Characteristics of
studies awaiting classification.
Results of the search
Results of the search are shown in Figure 1. Our search strategy
identified 17,224 records from the main electronic databases, and
we identified a further eight studies through our wider search. One
review author (AP, CH or PC) eliminated 15,658 titles that were
clearly irrelevant, and two review authors (AP, CH) applied the in-
clusion criteria to the remaining 1574 abstracts, identifying 178 to
be considered at full text. Of these, we identified a total of 20 studies
for inclusion. In addition, we identified seven ongoing studies (see
Characteristics of ongoing studies), and two studies that require
further assessment (see Characteristics of studies awaiting classifi-
cation).
 
Interventions for visual field defects in people with stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
16
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
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Included studies
We included 20 studies (732 randomised participants, with data
available for 638, of whom 547 (85%) had a diagnosis of ischaemic
or haemorrhagic stroke) in this updated review (Aimola 2011; Bain-
bridge 1994; Bowers 2014; De Haan 2015; Elshout 2016; Gall 2013;
Jarvis 2012; Jobke 2009; Kasten 1998; Kasten 2007; Keller 2010;
Modden 2012; Plow 2010; Poggel 2004; Rossi 1990; Roth 2009; Rowe
2010; Schuett 2012; Spitzyna 2007; Szlyk 2005).
The previous version of this review included 13 studies (344 ran-
domised participants, 285 of whom were participants with stroke)
(Bainbridge 1994; Carter 1983; Jobke 2009; Kasten 1998; Kasten
2007; Plow 2010; Poggel 2004; Rossi 1990; Roth 2009; Spitzyna 2007;
Szlyk 2005; Weinberg 1977; Weinberg 1979). However, we have ex-
cluded three of these studies from this update (Carter 1983, Wein-
berg 1977; Weinberg 1979: see Excluded studies for reason for these
exclusions).
There were only abstracts available for Bainbridge 1994 and Gall
2013. In the previous version, Plow 2010 was based on data from a
conference abstract and ongoing trials register data only; however,
for this update a full paper was available.
We present a brief overview of the studies below. Full descriptions
of the included studies can be found in the Characteristics of includ-
ed studies table and in Table 1 (Demographics of included stud-
ies: settings of included studies), Table 2 (Demographics of includ-
ed studies: demographics of included participants), Table 3 (Demo-
graphics of included studies: visual problems of included partici-
pants), and Table 4 (Outcome measures within included studies).
Study design
Fifteen of the included studies were parallel-group randomised
controlled trials (RCTs), and five were randomised cross-over stud-
ies (Bowers 2014; Elshout 2016; Jobke 2009; Schuett 2012; Szlyk
2005).
Sixteen of the included studies randomised participants to one of
two treatment groups; three had three treatment groups (Kasten
2007; Modden 2012; Rowe 2010); and one was a cross-over AB/BA
design, where A was an active treatment and B a placebo; howev-
er participants were also randomised to receive one of two differ-
ent active treatments, each of which had a related sham treatment
meaning that there were effectively four different treatment groups
(active 1, active 2, sham 1 and sham 2) (Bowers 2014).
Comparison versus control
Ten of the 20 included studies had a control (no treatment, stan-
dard care, or placebo) group, comparing 10 active treatments with
control (Rowe 2010 had two active treatment groups):
• three compared a restitutive intervention with control (Gall
2013; Elshout 2016; Kasten 1998);• four compared a compensatory intervention with control (Aimo-
la 2011; De Haan 2015; Rowe 2010; Spitzyna 2007);• three compared a substitutive intervention with control (Bow-
ers 2014; Rossi 1990; Rowe 2010);• one compared assessment/screening with control (Jarvis 2012).
In Rowe 2010, the two active treatment groups (compensatory and
substitutive interventions) were compared with each other.
Ten of the 20 included studies did not have a control group. Nine
compared two different active treatments, and one had three ac-
tive treatment groups (Modden 2012):
• four compared different restitutive interventions (Jobke 2009;
Kasten 2007; Plow 2010; Poggel 2004);• three compared different compensatory interventions (Keller
2010; Modden 2012; Schuett 2012);• two compared different substitutive interventions (Bainbridge
1994; Szlyk 2005);• two compared compensatory and restitutive interventions
(Modden 2012; Roth 2009).
Interventions studied
Restitutive interventions
Nine studies (239 randomised participants) investigated the effect
of restitutive interventions.
In eight of these studies, the restitutive intervention studied was a
form of computer-based vision restoration therapy:
• Kasten 1998 and Elshout 2016 compared visual restitution ther-
apy with a placebo intervention;• Jobke 2009 and Kasten 2007 compared the effectiveness of two
(or more) types of visual restitution therapy;• Plow 2010 explored the effect of adding transcranial direct cur-
rent stimulation (tDCS) to visual restitution therapy;• Poggel 2004 explored the effect of adding attentional cueing to
visual restitution therapy;• Modden 2012 compared computerised restitution therapy with
two different compensatory interventions;• Roth 2009 compared 'flicker-stimulation training', which the au-
thors described as a "potential" restitutive intervention, with a
compensatory intervention.
In one of these nine included studies, the restitutive intervention
studied was a form of non-invasive brain stimulation using alter-
nating current stimulation. This was compared with a placebo in-
tervention (Gall 2013).
Compensatory interventions
Eight studies (347 randomised participants) investigated the effect
of compensatory interventions:
• Aimola 2011 compared computer-based compensatory training
with a control;• Spitzyna 2007 compared computer-based reading training ("op-
tokinetic nystagmus inducing reading therapy", involving read-
ing scrolling right to leM text) with a control;• De Haan 2015 compared a compensatory scanning training pro-
gramme with a control;• Rowe 2010 compared paper-based visual scanning training with
a control (and with a substitutive intervention);• Keller 2010 compared two types of compensatory training - au-
diovisual exploratory training and visual exploration training;• Schuett 2012 compared two types of compensatory training - vi-
sual exploration training and reading training;
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• Modden 2012 compared computerised scanning training, an oc-
cupational therapy compensatory training program, and a com-
puterised restitutive therapy;• Roth 2009 compared computer-based scanning training with
restitutive training.
Substitutive interventions
Five studies (227 randomised participants) investigated the effect
of substitutive interventions. In all five studies, the substitutive in-
tervention studied was a type of prism:
• Rossi 1990 compared 15 diopter Fresnel prisms with no prisms;• Rowe 2010 compared 40 diopter Fresnel prisms with no treat-
ment, and with a compensatory intervention;• Bowers 2014 compared 57 diopter oblique prism glasses and
horizontal prism glasses with five diopter sham prism glasses;• Bainbridge 1994 compared full-field 15 diopter Fresnel prisms
with hemi-field 15 diopter Fresnel prisms;• Szlyk 2005 compared 20 diopter Fresnel prisms with 18.5 dioptre
Gottlieb VFAS (Visual Field Awareness System) prisms.
Assessment and screening interventions
One study (64 randomised participants) investigated the effective-
ness of an assessment and screening intervention on relevant out-
comes:
• Jarvis 2012 compared the effect of providing therapy staJ with
information from an orthoptic assessment with no intervention.
Populations studied
The reported diagnoses of the participants within the 20 included
studies were as follows:
• 14 studies recruited participants with mixed diagnoses includ-
ing stroke, trauma, surgery, and infections;• five studies included participants with stroke only; and• one study - the cause of the lesion was unclear.
(See details in Characteristics of included studies and Table 2). De-
spite the high number of studies including participants with mixed
diagnoses, the majority of participants in the studies in this review
did have stroke (across all studies, 85% (520/611) of participants
with data reported had a diagnosis of stroke).
Fourteen of the 20 included studies included participants with vi-
sual field defects only (no visual neglect); seven of 14 studies clear-
ly stated the method of diagnosis of visual neglect (Bowers 2014;
De Haan 2015; Elshout 2016; Keller 2010; Roth 2009; Rowe 2010;
Schuett 2012), four of the 14 studies stated that participants with
neglect were excluded but did not state the method of diagnosis
of visual neglect (Kasten 1998; Kasten 2007; Modden 2012; Poggel
2004), and in the three remaining studies it was assumed (but not
clearly stated) that participants with visual field defects only were
included (Jobke 2009; Spitzyna 2007; Szlyk 2005). Four of the in-
cluded studies included participants who had visual neglect in ad-
dition to, or instead of, visual field defects (Aimola 2011; Bain-
bridge 1994; Jarvis 2012; Rossi 1990). In two studies, it was unclear
whether the participants had visual neglect or not (Gall 2013; Plow
2010). See Table 3.
Visual field measurement
All 20 included studies reported a measurement of the visual field
in order to inform participant inclusion or provide baseline infor-
mation relating to visual field defect, or both. Seven reported one
visual field measure (De Haan 2015; Gall 2013; Jarvis 2012; Mod-
den 2012; Plow 2010; Schuett 2012; Szlyk 2005), 11 reported two vi-
sual field measures (Aimola 2011; Bainbridge 1994; Bowers 2014;
Elshout 2016; Jobke 2009; Kasten 1998; Keller 2010; Rossi 1990;
Roth 2009; Rowe 2010; Spitzyna 2007), and two reported three vi-
sual field measures (Kasten 2007; Poggel 2004). Spitzyna 2007 re-
ported a second measure only where the first perimetric results had
poor reliability.
In three studies, the perimetry equipment was unclear (Aimola
2011; Gall 2013; Jobke 2009), and in Rowe 2010, either of two types
of perimetry was reported (Esterman static programme or Gold-
mann kinetic).
Visual field measurements were categorised as:
• gross visual screening: five studies reported gross visual screen-
ing; two using the Harrington Flocks visual screener (Bainbridge
1994; Rossi 1990), two using a confrontation method (Bain-
bridge 1994; Jarvis 2012), one reporting the visual field assess-
ment from the Test Battery of Attentional Performance (Modden
2012), and one a subjective topographic measure of perceived
visual field defect (Plow 2010);• kinetic perimetry: 10 studies reported measures of kinetic
perimetry; seven used Goldmann perimetry (Bowers 2014; De
Haan 2015; Elshout 2016; Keller 2010; Rowe 2010; Spitzyna
2007; Szlyk 2005), one used Tubingen kinetic perimetry (Schuett
2012), one used tangent screen measures (Rossi 1990), and one
used an unspecified kinetic perimeter (Aimola 2011);• static threshold perimetry: eight studies reported static perime-
try measures; two used standard automated perimetry (Gall
2013; Jobke 2009), four used Tubinger automated perimetry
(TAP) (Kasten 1998; Kasten 2007; Poggel 2004; Roth 2009),
and two used Humphrey automated perimetry (Elshout 2016;
Spitzyna 2007);• static suprathreshold (inclusive of full field 120, Esterman,
campimetry, tangent screen): five studies reported static
suprathreshold measures; two reported Esterman measures
(Aimola 2011; Rowe 2010), one reported Humphrey full field 120
(Bowers 2014), one reported suprathreshold checks on a Gold-
mann perimeter (Keller 2010), and one reported high resolution
campimetry (Poggel 2004);• resolution perimetry: six studies reported resolution perime-
try measures; five used high resolution perimetry (HRP) (Jobke
2009; Kasten 1998; Kasten 2007; Plow 2010; Poggel 2004), and
one used scanning laser ophthalmoscopy (Roth 2009).
Sample size
On average, included studies randomised 36 participants (stan-
dard deviation, 22 participants) into the trial prior to attrition. This
ranged from just 10 participants (Szlyk 2005), to 87 participants
(Rowe 2010). Only five of 19 studies recruited more than 50 partici-
pants: Aimola 2011 (n = 70), Bowers 2014 (n = 73), De Haan 2015 (n =
54), Jarvis 2012 (n = 64), and Rowe 2010 (n = 87). A total of 732 par-
ticipants were recruited across the 20 included studies, with data
available for 638 participants, of whom 547 were stroke patients.
See Table 2 for recruitment numbers across all included studies.
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Outcome measures
Table 4 summarises the outcome measures within the included
studies, and highlights which studies had data which was suitable
for inclusion in meta-analyses within this review.
Primary outcome• Functional ability in activities of daily living. Three studies in-
cluded a measure of functional ability: Rossi 1990 reported the
Barthel Index, Jarvis 2012 reported the FIM, and Modden 2012
reported the extended Barthel Index (German version).
Secondary outcomes• Visual field. As reported above, all 20 included studies used at
least one measure of visual field at inclusion/baseline. Howev-
er, two of the studies did not measure visual field as an out-
come (i.e. measured following treatment) (Bowers 2014; Jarvis
2012); in one cross-over study, while it was measured as an out-
come, no measurement was taken immediately after the cross-
over (Schuett 2012); while in Aimola 2011 it was unclear whether
this was measured as an outcome or just at baseline. The meth-
ods of assessing visual field as a study outcome are summarised
in Table 4. Visual field outcomes of potential relevance to our
meta-analyses included measures of: 1) gross visual screening:
four studies (Bainbridge 1994; Rossi 1990, Modden 2012, Plow
2010); 2) kinetic perimetry: seven studies (Aimola 2011; De Haan
2015; Elshout 2016; Keller 2010; Rowe 2010; Spitzyna 2007; Szlyk
2005); 3) static threshold perimetry: eight studies (Jobke 2009;
Kasten 1998; Kasten 2007; Elshout 2016; Gall 2013; Poggel 2004,
Roth 2009, Spitzyna 2007); 4) static superthreshold perimetry:
four studies (Keller 2010; Poggel 2004; Rossi 1990; Rowe 2010);
and 5) resolution perimetry; six studies (Jobke 2009; Kasten
1998; Kasten 2007; Plow 2010; Poggel 2004; Roth 2009).• Extended activities of daily living. Three studies reported a mea-
sure of extended activities of daily living (other than a measure
of reading ability). Two were measures of functional mobility:
Bowers 2014 quantified "Perceived difficulties with mobility"
using "a 5-point rating scale (no difficulty to extreme difficul-
ty) for seven situations (items) relevant to homonymous hemi-
anopia, including at home, in stores, outdoors, in unfamiliar ar-
eas, in familiar areas, in crowded areas, and noticing objects oJ
to the side when walking"; and De Haan 2015 used an indepen-
dent mobility questionnaire. Rowe 2010 reported the Notting-
ham Extended Activities of Daily Living index.• Reading. Ten studies reported measures of reading ability
(Aimola 2011; De Haan 2015; Elshout 2016; Jobke 2009; Keller
2010; Modden 2012; Roth 2009; Rowe 2010; Schuett 2012; Spitzy-
na 2007). The measures used were the Radner reading test in
three studies (De Haan 2015; Jobke 2009; Rowe 2010), tests of
reading speed in seven studies (Aimola 2011; De Haan 2015;
Elshout 2016; Keller 2010; Roth 2009; Schuett 2012; Spitzyna
2007), and measures linked to the correctness of reading in four
studies (De Haan 2015; Jobke 2009; Modden 2012; Schuett 2012).
Text reading time data were displayed graphically by Spitzyna
2007 but actual data were confirmed by correspondence with
the author.• Falls. One trial reported the number of falls (Rossi 1990).• Quality of life. Ten trials reported measures of quality of life
(Aimola 2011; De Haan 2015; Gall 2013; Jobke 2009; Kasten 1998;
Kasten 2007; Keller 2010; Plow 2010; Roth 2009; Rowe 2010),
with several reporting more than one type of measure. The Na-
tional Eye Institute Visual Functioning Questionnaire (NEI-VFQ)
was used by five studies (Aimola 2011; De Haan 2015; Gall 2013;
Jobke 2009; Rowe 2010), the Short-Form 12 (SF-12) by two stud-
ies (Gall 2013; Rowe 2010), the World Health Organization Qual-
ity of Life Bref (WHOQOL-Bref) by one (Roth 2009), the Impact
of Visual Impairment profile (IVI) and Veterans Affairs Low Vi-
sion Visual Function Quaestion (LV-LFQ) by one (Plow 2010), and
the EQ-5D (standardised EuroQol health-related quality of life
instrument) by one (Rowe 2010). A number of different, often
self-designed, questionnaires of satisfaction, improvement and
visual ability levels were also used (see Table 4). The quality of
life data from Kasten 1998 were included as a dichotomous vari-
able as the data presented in the published paper were a per-
centage of those who reported subjective improvements of vi-
sion; the results were for both the pre- and post-chiasmal group,
with 30 of the 38 participants responding.• Visual scanning. Eight trials reported measures of visual scan-
ning as assessed by a range of scanning and cancellation tech-
niques (Aimola 2011; Bainbridge 1994; De Haan 2015; Keller
2010; Modden 2012; Rossi 1990; Roth 2009; Schuett 2012). In ad-
dition, one reported the visual scan test from the Test Battery
of Attentional Performance (Modden 2012), and one also used
a video eye tracker (Roth 2009). Reported data included scan-
ning/search time and number of errors or omissions (see Ta-
ble 4). Where a study reported a range of scanning outcomes,
we prioritised measures of scanning time for meta-analyses. De
Haan 2015 used three different visual scanning tests, and report-
ed a range of different data; we used the results of the "parallel
search test" for all trials (target present and target absent), but
explored the impact of using alternative data.
Excluded studies
We excluded 158 papers after assessment of the full paper (see Fig-
ure 1). Sixty-two of the 158 clearly did not meet the inclusion cri-
teria, and 30 of the 158 were duplicate publications of excluded
studies. FiMy-seven of the 158 papers required more in-depth ap-
praisal prior to exclusion; we have provided our reasons for exclu-
sion of these studies in the Characteristics of excluded studies ta-
ble. We excluded the majority of these because the intervention
was not specifically targeted at the ability of the participant to cope
with visual field loss (32/57), or because the study was not ran-
domised (22/57). We found one study did not include participants
with stroke, one was focused on central alexia, and one was explor-
ing agreement using a visual screening tool.
We included three studies in the previous (2011) version of this re-
view (Carter 1983, Weinberg 1977 and Weinberg 1979), but they
have been excluded in this update: in the 2011 version, we includ-
ed studies that investigated the effectiveness of visual scanning
training and techniques even if the population of participants had
not been clearly defined as having visual field defects. Carter 1983,
Weinberg 1977 and Weinberg 1979 included populations of partic-
ipants with 'visual scanning' problems, who may have had either
visual field defects or visual neglect, or both. For this latest up-
date, we reconsidered and reversed this decision: we have exclud-
ed populations of participants with 'visual scanning problems', but
no confirmed visual field defect, to ensure that all included studies
are focused on stroke survivors with confirmed visual field defects.
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Studies awaiting classification
Two studies are awaiting classification (Ghandehari 2011; Sand
2017). Ghandehari 2011 compared two different pharmacological
interventions (Neuroaid and Piracetam) without a control group.
The selection criteria, which were prestated for this review, did not
clearly state whether pharmacological interventions were relevant
for inclusion, but discussion amongst review authors supports the
conclusion that it would be appropriate to include any trials of
pharmacological interventions if they are specifically focused on
improving outcomes in participants with visual field defects. How-
ever, it remains unclear whether this study is a randomised con-
trolled trial or not, as there is inconsistent reporting of the study
design, and we await clarification from the study authors. Prior to
any future updates of this review, we will clarify the selection crite-
ria and methods to ensure that the inclusion (or exclusion) of phar-
macological interventions is addressed. Sand 2017 is an ongoing
study; however, it was not possible to determine from available in-
formation whether this was a randomised controlled trial or not.
Ongoing studies
Seven studies are listed as ongoing studies. Two ongoing studies
compare a form of visual restitutive training with control (Feldon
2017; NCT02886663); one is comparing a form of transcranial elec-
trical stimulation with control (Gall 2015); one is comparing a phar-
macological intervention focused on restitution of the visual field
with a placebo (NCT02737930); and one is comparing two different
modes of delivery of computer-based compensatory scanning in-
terventions with a control (ISRCTN16023965). Two of these stud-
ies, listed as ongoing in the previous version of this review, are now
complete (Hayes 2010; Komm 2009), but we have been unable to
obtain results from the authors. If results are not available at the
time of the next update, we will exclude these studies.
Risk of bias in included studies
We have described the assessment of risk of bias for individual stud-
ies in the 'Risk of bias' tables in Characteristics of included studies,
summarised in Figure 2.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
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Figure 2.   (Continued)
 
Interventions for visual field defects in people with stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
25
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Allocation
Although all 20 included studies were described as randomised
controlled trials, only 10 of them reported sufficient information
on the method of randomisation to assess whether the randomi-
sation and allocation concealment methods were adequate, and,
in two of these studies, we judged them to be at high risk of bias:
in Keller 2010 some of the allocation appeared to have been alter-
nate, rather than random, and, in Modden 2012, randomisation was
through throwing of a dice, with no allocation concealment.
Blinding
In the majority of included studies, the nature of the intervention
meant that it was not possible to mask (blind) participants or peo-
ple involved in their care. We judged blinding as low risk of bias if
there was evidence that the outcome assessor was masked to the
treatment allocation of the participants - six of the 20 studies clear-
ly reported having a masked outcome assessor. In eight of the 20
studies this information was unclear, and in six of the 20 studies we
judged that there was a high risk of bias as the outcome assessor
was not masked.
Incomplete outcome data
Lack of information about the management of incomplete out-
come data, and whether or not there had been dropouts or par-
ticipants excluded from the studies, made it difficult to assess risk
of bias relating to incomplete outcome data for all the studies. In
four of the 20 studies, we considered that adequate reasons for
dropouts were provided, numbers of dropouts were even between
groups, or intention-to-treat analysis was carried out. However, in
five of the 20 studies where we felt that incomplete outcome data
were not adequately addressed, and that dropouts were either un-
balanced or might be related to the intervention studied (e.g. be-
cause people dropped out or were excluded because of low compli-
ance), we judged risk of bias to be high. For the remaining 11 stud-
ies, we were unclear as to whether or not incomplete outcome data
were adequately addressed.
Other potential sources of bias
Lack of information and details of methodology within the includ-
ed studies generally made it difficult for us to assess the poten-
tial risk due to other biases. However, four of the studies of visual
restitution therapy were carried out by researchers who have ac-
knowledged a financial interest in this intervention (as stated in
Poggel 2004) (Jobke 2009; Kasten 1998; Kasten 2007; Poggel 2004),
and Bowers 2014 declared a financial conflict of interest relating
to the prisms that were being investigated. We assessed this to po-
tentially introduce a source of bias. We identified concerns that the
increased attention given to the treatment group, as opposed to
the control group, in De Haan 2015 may create a high risk of bias.
For two of the studies, only abstracts were available and there was
insufficient information on which to assess bias (Bainbridge 1994;
Gall 2013). We judged the remaining 12 studies as unlikely to be at
risk of other potential sources of bias, but based this assessment
on the absence of information suggesting bias rather than the pres-
ence of information indicating that the study was free from bias.
Studies included in meta-analyses within this review
From the 20 studies included in this review, there are only eight
studies included in meta-analyses within this review (Aimola 2011;
Bowers 2014; De Haan 2015; Jarvis 2012; Kasten 1998; Rossi 1990;
Rowe 2010; Spitzyna 2007). These eight studies randomised 428
participants. The studies relevant to our prestated comparisons
(see Objectives), and included within the planned meta-analyses
are:
1. Restitutive interventions versus no treatment, placebo, or control• Kasten 1998 (visual restitution therapy versus placebo, n = 19).
We have included data from this study in relevant analyses.
2. Compensatory interventions versus no treatment, placebo, or
control• Aimola 2011 (n = 52), De Haan 2015 (n = 49), Rowe 2010 (n = 70),
and Spitzyna 2007 (n = 22) are all relevant and have data includ-
ed in relevant analyses.
3. Substitutive interventions versus no treatment, placebo, or control• Rossi 1990 (prisms versus no treatment, n = 39) and Rowe 2010
(prisms versus control, n = 59). We have included data from these
studies in relevant analyses.• Bowers 2014 (prisms versus placebo, n = 67). This is a cross-over
study and data were principally presented after the cross-over;
however, there were data for one outcome (extended activities
of daily living) presented before the cross-over, with data suit-
able for inclusion in analysis.
4. Assessment or screening versus no treatment, placebo, or control• Jarvis 2012 (assessment versus control, n = 39). We have includ-
ed data from this study in relevant analyses.
Studies not included in meta-analyses
Ten of the studies included in this review did not have a control
group and are therefore not included in meta-analyses.
These 10 studies each compared one active intervention with an-
other active intervention:
• Jobke 2009, Kasten 2007, Modden 2012, Plow 2010, Poggel 2004,
and Roth 2009 all investigated restitutive interventions, and did
not include a no-treatment, placebo, or control group.• Keller 2010, Modden 2012, Roth 2009, and Schuett 2012 all inves-
tigated compensatory interventions, and did not include a no-
treatment, placebo, or control group.• Bainbridge 1994 and Szlyk 2005 both investigated substitutive
interventions, and did not include a no-treatment, placebo, or
control group.
The results from relevant outcomes from these studies are sum-
marised in Table 5 and Table 6 and in a narrative synthesis below.
One study did have a relevant control group (alternating current
stimulation versus placebo, n = 39) but was published as an ab-
stract only and we have been unable to identify data suitable for
inclusion (Gall 2013).
One study did have a relevant control group (visual restitution
training versus placebo, n = 30) but was a randomised cross-over
trial and we have been unable to obtain data from the first phase
only, in order to include data in meta-analyses (Elshout 2016).
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E:ects of interventions
See: Summary of findings for the main comparison Summary
of findings: Restitutive interventions versus control; Summary of
findings 2 Summary of findings: Compensative interventions ver-
sus control; Summary of findings 3 Summary of findings: Substitu-
tive interventions versus control; Summary of findings 4 Summa-
ry of findings: Assessment/screening interventions versus control
Restitutive interventions versus no treatment, placebo, or
control
There was one included study: Kasten 1998 (see Summary of find-
ings for the main comparison). Data were available for visual field
and quality of life outcomes, but not for any other outcomes of in-
terest to this review. Stroke survivors with visual neglect were not
included in Kasten 1998, therefore these analyses relate to partici-
pants with visual field defects only (no co-existing visual neglect).
Visual field
See Analysis 1.1. Data from Kasten 1998 (19 participants) showed
that there was no statistically significant effect of a restitutive inter-
vention as compared to control (MD 1.02, 95% CI -1.37 to 3.41) for
the visual field outcome (confrontation). We judged this evidence
to be of very low quality.
Quality of life
See Analysis 1.2. Data from Kasten 1998 showed that there was a
statistically significant effect of a restitutive intervention as com-
pared to control (OR 13.00, 95% CI 2.07 to 81.48). The data used in
this analysis were derived from 30 randomised participants, and in-
cluded data from participants with optic nerve injury who had also
received the same interventions in a separate (but parallel) trial. A
total of 38 participants were randomised, of whom 19 had stroke
and 19 had optic nerve injury; data were only available for 30 of
38 of these participants for this outcome. Separate data were not
available for participants with stroke only. We judged this evidence
to be of very low quality.
Compensatory interventions versus no treatment, placebo, or
control
Included studies: Aimola 2011; De Haan 2015; Rowe 2010; Spitzyna
2007 (see Summary of findings 2). Stroke survivors with visual ne-
glect were not included in De Haan 2015; Rowe 2010; Spitzyna 2007,
while participants in Aimola 2011 could have co-existing neglect:
data are presented in subgroups relating to the inclusion of partic-
ipants with neglect.
Visual field
See Analysis 2.1. Data from two studies (95 participants) showed
that there was no statistically significant effect of compensatory in-
terventions compared with control (SMD -0.11, 95% CI -0.92 to 0.70,
heterogeneity: I2 = 75%) (De Haan 2015; Rowe 2010). We judged
this evidence to be of very low quality. Several factors could con-
tribute to the substantial heterogeneity, including different inclu-
sion criteria (e.g. participants had to be < 26 weeks post stroke in
Rowe 2010) and very different interventions (see Characteristics of
included studies). However a key factor to note, which limits confi-
dence in these findings, is that there was a significant difference in
baseline assessment between groups in De Haan 2015).
Extended activities of daily living
See Analysis 2.2. Data from two studies (97 participants) showed
that there was no statistically significant benefit in favour of com-
pensatory interventions compared with control (SMD 0.49, 95% CI
-0.01 to 0.99, heterogeneity: I2 = 25%) (De Haan 2015, Rowe 2010).
We judged this evidence be of very low quality.
Reading
See Analysis 2.3. Data from four studies (162 participants) showed
that there was no statistical significant effect of compensatory in-
terventions compared with control (SMD 0.26, 95% CI -0.05 to 0.58,
heterogeneity: I2 = 0%) (Aimola 2011; De Haan 2015; Rowe 2010;
Spitzyna 2007). We judged this evidence to be of low quality. Al-
though some of the participants in Aimola 2011 may have had
neglect, there was no downgrade for indirectness as the test for
subgroup differences demonstrated no significant differences be-
tween the studies including or not including participants with ne-
glect (P = 0.43).
Quality of life
See Analysis 2.4. Data from two studies (96 participants) showed
that there was a statistically significant effect of compensatory in-
terventions compared with control (MD 9.36, 95% CI 3.10 to 15.62),
with minimal heterogeneity (I2 = 0%), based on the results for the
total score for the VFQ-25 assessment (De Haan 2015; Rowe 2010).
We judged this evidence to be of low quality.
Scanning - cancellation
See Analysis 2.5. Data from two studies (97 participants) showed
that there was no statistically significant effect of compensatory
interventions compared with control (SMD -0.01, 95% CI -0.40 to
0.39), with minimal heterogeneity ( I2 = 0%) (Aimola 2011; De Haan
2015). We judged this evidence to be of low quality. Although some
of the participants in Aimola 2011 may have had neglect, there was
no downgrade for indirectness as the test for subgroup differences
demonstrated no significant differences between the studies in-
cluding or not including participants with neglect (P = 0.55). Substi-
tuting the De Haan 2015 'parallel search test' data for 'all trials' with
other presented data, including the 'serial search test' data and 'dot
counting test', or substituting the 'target present' data for the 'all
trials' data, did not change the non-significant result.
Adverse events
See Analysis 2.6. Rowe 2010 collected and reported data relating
to adverse events, stating that: "Two patients (6.7%) in the visual
search training arm experienced seven adverse events (six fatigue
and one headache). No adverse events were recorded for the stan-
dard care arm". De Haan 2015 did not report adverse events as an
outcome measure, but stated that: "No important harms caused by
the training or the assessments were encountered, nor reported by
the participants". Data from Rowe 2010 (see Analysis 2.6), showed
that there was no difference in the odds of a participant having
an adverse event with compensatory scanning training, when com-
pared to control (OR 15.18, 95% CI 0.24 to 112.57). We judged this
evidence to be of low quality.
Substitutive interventions versus no treatment, placebo, or
control
Included studies: Bowers 2014; Rossi 1990; Rowe 2010 (see Sum-
mary of findings 3). Stroke survivors with visual neglect were not
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included in Bowers 2014 and Rowe 2010, while participants in Rossi
1990 could have co-existing neglect. Substitutive prisms were worn
during the outcome assessment by participants in Bowers 2014 and
Rossi 1990, but were not worn during outcome assessment by par-
ticipants in Rowe 2010. As the wearing of the substitutive inter-
vention during outcome assessment should theoretically expand
the size of the visual field, the data arising from these different ap-
proaches (wearing or not wearing prisms) were presented as sub-
groups, and no pooled total was calculated.
Functional activities of daily living (primary outcome)
See Analysis 3.1. Data from one study (39 participants, wearing
prisms during assessment; participants may have co-existing ne-
glect) showed that there was no statistically significant effect of
a substitutive intervention compared with control for the prima-
ry outcome of functional activities of daily living (MD -4.00, 95% CI
-17.86 to 9.86) (Rossi 1990). We judged this evidence to be of very
low quality.
Visual field
See Analysis 3.2. Data from one study (46 participants; no neglect)
showed that there was no statistically significant effect of a sub-
stitutive intervention compared with control when the substitutive
intervention (prism) was not being worn (SMD 0.12, 95% CI -0.46 to
0.70) (Rowe 2010). Data from one study (39 participants; possibly
co-existing neglect) showed that there was a statistically significant
effect of a substitutive intervention compared with control when
the substitutive intervention (prism) was being worn (SMD 1.12,
95% CI 0.44 to 1.80) (Rossi 1990). There was a statistically signifi-
cant difference between the subgroups in which participants did
and did not wear prisms during assessment (P = 0.03). We judged
this evidence to be of very low quality.
Extended activities of daily living.
See Analysis 3.3. Data from one study (48 participants, no neglect)
showed that there was no statistically significant effect of a sub-
stitutive intervention compared with control when the substitutive
intervention (prism) was not being worn (SMD 0.20, 95% CI -0.44 to
0.85) (Rowe 2010). Data from one study (61 participants, no neglect)
showed that there was no statistically significant effect of a substi-
tutive intervention compared with control for measures of extend-
ed activities of daily living, using a mobility score (SMD 0.24, 95% CI
-0.26 to 0.75) (Bowers 2014). There was no statistically significant
difference between the subgroups that did and did not wear prisms
during assessment (P = 0.92). We judged this evidence to be of very
low quality.
Reading
See Analysis 3.4. Data from one study (45 participants, no neglect)
showed that there was no statistically significant effect of a sub-
stitutive intervention compared with control when the substitutive
intervention (prism) was not being worn (MD 2.80, 95% CI -7.13 to
12.73) (Rowe 2010). We judged this evidence to be of low quality.
Falls
See Analysis 3.5. Data from one study (39 participants, possible co-
existing neglect) showed that there was no statistically significant
effect of a substitutive intervention compared with control for the
risk of falls (OR 1.21, 95% CI 0.26 to 5.76) (Rossi 1990). We judged
this evidence to be of very low quality.
Quality of Life
See Analysis 3.6. Data from one study (43 participants, assessed not
wearing prisms; no neglect) showed that there was no statistically
significant effect of a substitutive intervention compared with con-
trol for a measure of quality of life (MD 8.40, 95% CI -4.18 to 20.98)
(Rowe 2010). We judged this evidence to be of low quality.
Scanning (cancellation)
See Analysis 3.7. Data from one study (39 participants, assessed
wearing prisms; possibly co-existing neglect) showed that there
was a statistically significant effect of a substitutive intervention
compared with control for measures of scanning (MD 9.80, 95% CI
1.91 to 17.69) (Rossi 1990). We judged this evidence to be of very
low quality.
Adverse events
Rowe 2010 collected and reported data relating to adverse events,
stating that "Eighteen patients (69.2%) in the Fresnel prisms arm
experienced a total of 42 adverse events of which 28 were classi-
fied as headache. No adverse events were recorded in the standard
care arm". The reported adverse events in the group wearing prisms
were: headache (28 events in six participants); diplopia (five events
in five participants); visual confusion (four events in three partici-
pants); difficulty with navigation (two events in two participants);
dizziness (two events in one participant); optical glare/aberrations
(one event in one participant). Analysis 3.8 shows that there was
an increased odds of a participant having an adverse event if they
were wearing prisms (OR 87.32, 95% CI 4.87 to 1564.66). We judged
this evidence to be of low quality.
Assessment or screening interventions versus no treatment,
placebo, or control
Included study - Jarvis 2012 (see Summary of findings 4).
Functional activities of daily living (primary outcome)
See Analysis 4.1. Data from Jarvis 2012 (37 participants) showed
that there was no statistically significant effect of an assessment
intervention compared with control for measures of functional ac-
tivities of daily living (MD -6.97, 95% CI -23.78 to 9.84). We judged
this evidence to be of very low quality.
Subgroup and sensitivity analyses
As there were no more than six trials in any single meta-analysis,
as prestated in our protocol, we did not carry out the planned sub-
group or sensitivity analyses. There were two exceptions to this:
• we carried out subgroup analysis to explore the effect of includ-
ing studies in which participants may have had neglect in addi-
tion to visual field defects. This decision was made as there was
one study in which some of the participants may have had ne-
glect (Aimola 2011), and we considered the implications for in-
cluding this group of participants of key clinical importance. Re-
sults of these analyses are reported above;• we carried out subgroup analyses to explore different ways of
doing assessment in studies investigating the use of prisms (i.e.
assessment wearing or not wearing prisms). This was consid-
ered central to the clinical relevance of the pooled result. Results
of these analyses are reported above.
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One active intervention versus another active intervention
(narrative synthesis)
As planned, no meta-analyses have been carried out to pool data
from studies that compared one active intervention with another
active intervention. A summary of results for relevant outcomes for
these comparisons is provided in Table 5 and Table 6, and a brief
narrative summary below.
Studies comparing two similar active interventions
(See Table 5)
One restitutive intervention versus another restitutive intervention
We found two studies that compared the effectiveness of two (or
more) types of visual restitution therapy (Jobke 2009; Kasten 2007).
Jobke 2009 compared extrastriate visual restitution therapy with
conventional visual restitution therapy in a cross-over study includ-
ing 18 participants. After the first phase of the study, the extrastriate
visual restitution therapy group had improved in measures of visu-
al field (detection performance in HRP) by 5.9% and the conven-
tional visual restitution therapy group had improved by 2.9%. No
significant changes were found for either group for Radner reading
scores. Kasten 2007 compared three treatment groups: 1) standard
visual restitution therapy with single stimulation, 2) visual restitu-
tion therapy with parallel co-stimulation, and 3) visual restitution
therapy with moving co-stimulation. We found no statistically sig-
nificant differences between groups for measures of the visual field
(perimetry).
We found two studies that investigated the addition of another in-
tervention to visual restitution therapy (Plow 2010; Poggel 2004).
Plow 2010 investigated the effect of adding transcranial direct cur-
rent stimulation (tDCS) to visual restitution therapy and reported a
greater increase in detection accuracy (perimetry) in the group re-
ceiving tDCS (9.37% increase compared to 5.55% increase in con-
trol group). Poggel 2004 compared standard visual restitution ther-
apy with visual restitution therapy plus attentional cueing in 19
participants; results were primarily presented graphically and as
whole-group data: the authors concluded that the visual field bor-
der increased significantly more in the participants in the attention-
al cueing group.
One compensative intervention versus another compensative
intervention
We found three studies that compared different compensative in-
terventions (Keller 2010; Modden 2012; Schuett 2012). Keller 2010
compared audiovisual training and visual exploration training in
10 participants, reporting that audiovisual training was better than
visual exploration training for outcomes of activities of daily liv-
ing, reading, and visual scanning. Schuett 2012 compared reading
training and visual exploration training in 36 participants within
a cross-over study. We used data reported from before the cross-
over period to calculate effect sizes for Schuett 2012 (see Figure 3);
this demonstrated that visual exploration training was significant-
ly more beneficial than reading training at improving scanning out-
comes, and there was a trend towards reading training improving
reading outcomes more significantly than visual exploration train-
ing. Modden 2012 compared 45 participants within three groups;
one receiving computer-based restitution therapy, one comput-
er-based compensation therapy, and one standard occupational
therapy. We judged the occupational therapy intervention to be a
compensatory intervention. We found no differences between the
groups receiving the computer-based compensatory therapy and
occupational therapy interventions for measures of visual field en-
largement, reading, or visual scanning.
 
Figure 3.   One compensatory intervention versus another compensatory intervention. E:ect sizes for Schuett 2012
(see Table 5)
 
One substitutive intervention versus another substitutive
intervention
We found two studies that compared the effectiveness of two types
of prism (Bainbridge 1994; Szlyk 2005). Bainbridge 1994 compared
the effect of full-field and hemi-field prisms in 18 participants, and
reported a significant effect in favour of full-field prisms for the can-
cellation test and Harrington Flocks Visual Field score. Szlyk 2005
compared Fresnel prisms and the Gottlieb Visual Field Awareness
System in 10 participants and found no statically significant differ-
ences in outcomes between the two groups, although this was a
cross-over study with no data presented for the period of time be-
fore the cross-over.
Studies comparing two di,erent types of active intervention
(see Table 6)
Compensation intervention versus restitutive intervention
Two studies compared the effectiveness of a compensation inter-
vention and a restitutive intervention (Modden 2012; Roth 2009).
Roth 2009 compared explorative scanning training (a compensa-
tion intervention) with flicker stimulation training (a restitution in-
tervention) in 29 participants, finding no significant differences be-
tween groups for key outcomes (although there were differences
between groups at baseline for some outcomes). Modden 2012
compared 45 participants within three groups; one receiving com-
puter-based restitution therapy, one computer-based compensa-
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tion therapy, and one standard occupational therapy. In Table 6,
we compared the results of the groups receiving computer-based
training. There were no significant differences reported for these
groups for measures of visual field enlargement, activities of daily
living, reading, or visual scanning.
Compensation intervention versus substitution intervention
One study compared the effectiveness of a compensative inter-
vention (paper-based visual search training) and a substitutive in-
tervention (Fresnel prisms) (Rowe 2010). This was a three-armed
study, with a control (standard care) treatment; data from the ac-
tive treatment arms compared to the control treatment have been
included in meta-analyses within this review. We found no signifi-
cant differences between the compensative and substitutive inter-
vention for measures of visual field, extended activities of daily liv-
ing, and reading. We found a statistically significant difference in
favour of the compensative intervention for the measure of quality
of life (using the VFQ-25).
D I S C U S S I O N
Summary of main results
We found 20 studies (732 randomised participants, with data for
638 participants, 547 of whom were participants with stroke) that
investigated interventions for visual field defects in people with
stroke. However, only 10 of these studies compared the effect of an
intervention with a placebo, control, or no treatment group, which
were the comparisons of interest to the review question, and on-
ly eight had data suitable for inclusion within meta-analyses. Only
two of these eight studies presented data relating to our primary
outcome of functional abilities in activities of daily living, and there
was a lack of consistency in outcome measures used across stud-
ies, which limited our ability to draw generalised conclusions.
E:ect of restitutive interventions
Three studies (88 participants) compared a restitutive intervention
with a control, but data were only available for one (19 partici-
pants). There was very low-quality evidence that visual restitution
therapy had no effect on visual field outcomes, and a statistically
significant positive effect on quality of life. However, the data re-
lating to the quality of life outcome must be interpreted with cau-
tion as the data used for analysis combined the population of inter-
est with an additional 19 participants with optic nerve injury who
had been included in a separate (but parallel) trial. These partic-
ipants had damage to the anterior visual pathway, a population
which was specifically excluded from this review, and in none of the
participants was the optic nerve damage due to stroke. We, there-
fore, do not believe that the findings based on data from this popu-
lation are applicable to the population of patients with visual field
loss due to post-chiasmal stroke. There is, therefore, insufficient ev-
idence to draw any conclusions about the effectiveness of visual
restitution therapy as compared to placebo, control, or no treat-
ment. There was also some very limited evidence from two small
studies which compared different types of restitutive interventions
that there may be some benefits to adding either attentional cue-
ing or tDCS to visual restitutive therapy, while a further two small
studies found no difference in different modes of delivering visual
restitution therapy.
E:ect of compensatory interventions
Four studies (193 participants) compared a compensatory inter-
vention with a control. There was low-quality evidence of a ben-
eficial effect on measures of quality of life. However, there was
low- or very low-quality evidence of no effect on measures of visual
field, extended activities of daily living, reading, and scanning abil-
ity. Findings from a small study comparing two different types of
compensatory therapy conflicts with the evidence of no effect on
scanning outcome, demonstrating a beneficial effect of visual ex-
ploration therapy on scanning outcomes when compared to read-
ing training. There is, therefore, some limited low-quality evidence
that compensatory scanning training may improve an important
outcome (quality of life) in people with visual field defects follow-
ing stroke, but further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate. Studies comparing different active interven-
tions provide some very limited evidence that there may be bene-
fits associated with audiovisual training, rather than visual explo-
ration training alone, and suggest that compensatory training, as
delivered during standard clinical practice, may be as effective as
computer-based training interventions.
E:ect of substitutive interventions
Three studies (166 participants) compared a substitutive interven-
tion (a type of prism) with a control. There was low- or very low-
quality evidence that prisms did not have an effect on measures of
activities of daily living, extended activities of daily living reading,
falls, or quality of life, but that they may have an effect on scanning
ability. Evidence from one study indicates that people using prisms
may have a higher odds of adverse events, particularly headache.
However, it is important to note a fundamental difference between
these studies in that, in two of the studies, participants in the treat-
ment group wore prisms during the outcome assessments (Bowers
2014; Rossi 1990), while in one study none of the participants wore
prisms during outcome assessment by participants (Rowe 2010).
Evidence relating to measures of visual field demonstrated a sig-
nificant difference between studies that measured outcome whilst
wearing or not wearing the substitutive device, with a beneficial
effect when the prisms were worn during testing but not without.
However, due to the quality and quantity of evidence, we remain
uncertain about the benefits of prisms.
E:ect of screening/assessment interventions
One study (39 participants) compared the effect of assessment by
an orthoptist to standard care (no assessment) and found very low-
quality evidence that there was no effect on measures of activities
of daily living. However, due to the quality and quantity of evidence,
we remain uncertain about the benefits of assessment interven-
tions.
Ten studies compared the effect of two of more different active in-
terventions and did not include a control group.
In summary, this review has identified:
• a lack of evidence relating to the effect of interventions on our
primary outcome (functional ability in activities of daily living);• low-quality evidence that compensatory scanning training is
more beneficial than placebo or control at improving quality of
life, but not other outcomes;
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• insufficient evidence to reach any generalised conclusions
about the effect of restitutive interventions, substitutive in-
terventions (prisms), or screening/assessment interventions as
compared to placebo, control or no treatment;• low-quality evidence that prisms may result in an increase in
the number of people experiencing adverse events (particularly
headache).
Overall completeness and applicability of evidence
Studies with control, placebo, or no treatment group
Although we identified 20 studies that investigated the effect of
interventions for visual field defects after stroke, only 10 of these
studies (and only eight with data) compared the effect of an in-
tervention with a control, placebo, or no treatment group, which
was the question of interest to this review. The remaining 10 stud-
ies compared different types of interventions, with nine of these
studies comparing interventions of the same 'type' (i.e. compar-
ing two substitutive interventions or two restitutive interventions);
arguably, comparisons of different active interventions have little
merit until such time as the benefits (and harms) of active interven-
tions, as compared to control, placebo, or no treatment have been
established. Three studies did compare the relative effects of two
different types of intervention (i.e. compensatory versus restitu-
tive, or compensative versus substitutive). Thus, although we made
the decision to include all the studies which investigated the effec-
tiveness of interventions for visual field defects, in fact only nine
of these studies included comparisons that were directly relevant
to the review question, focusing on a comparison with a control,
placebo, or no treatment group. Five of the 20 included studies, in-
cluding two of the 10 studies with a control/placebo comparison,
were cross-over studies. The reporting of data from after the cross-
over in studies with this design limited our ability to incorporate da-
ta within meta-analyses in this review, and there is a risk that out-
comes from after the cross-over are affected by the treatments ad-
ministered prior to the cross-over.
Restitutive interventions versus no treatment, placebo, or
control
Kasten 1998 was the one study comparing a restitutive interven-
tion with a control or placebo, with data suitable for inclusion in
our meta-analyses. This study included 19 participants, only 10 of
whom had stroke. The study did not measure our primary outcome
of interest (functional ability in activities of daily living). There was
an uneven distribution of stroke patients between the two groups
(with two stroke patients out of the nine participants in the treat-
ment group and eight stroke patients out of 10 participants in the
control group). This uneven distribution means that only two pa-
tients with stroke received an active intervention, providing evi-
dence from which it would be inappropriate to generalise. Further-
more, for quality of life outcome data, the 19 participants in this
study had been combined with the results of 19 participants in an-
other similar study. However, the additional 19 participants all had
optic nerve injury rather than post-chiasmal injury. Due to the na-
ture of the participants included in this study, it would not be ap-
propriate to make generalisations from this evidence to the popu-
lation of stroke patients with visual field defects after stroke. Our
confidence in the findings from this evidence is very low.
Compensatory interventions versus no treatment, placebo, or
control
We were able to combine data from four studies (162 participants)
comparing compensatory (scanning) interventions with control or
placebo in meta-analysis. None of these studies measured our pri-
mary outcome of interest (functional ability in activities of daily liv-
ing). Visual field defects in the participants included in these stud-
ies were confirmed using perimetry (see Table 3). Three of the stud-
ies included participants with visual field defects and no co-existing
visual neglect; two of these studies excluded participants with ne-
glect based on clinical testing (De Haan 2015; Rowe 2010), while one
only included participants with a leM-sided cerebrovascular acci-
dent where patients rarely experience persistent neglect (Spitzyna
2007). One study included participants who had visual field defects
but possibly also co-existing visual neglect (Aimola 2011); clinical
testing confirmed that only three of the 52 participants had con-
firmed neglect. Participants included those from a mixed popula-
tion (i.e. stroke and other neurological conditions) for three of the
four studies; 41 of the 49 participants had stroke in De Haan 2015,
39 of 52 had stroke in Aimola 2011, and 13 of 22 had stroke in Spitzy-
na 2007. All participants had stroke in Rowe 2010. The majority of
participants in these studies, therefore, had visual field defects fol-
lowing stroke and did not have co-existing neglect (as confirmed
by clinical testing); therefore, it would be appropriate to generalise
from these results to the population of stroke survivors with visual
field defects and no neglect.
The nature of the scanning training in the four studies com-
bined within the meta-analyses varied considerably; two investi-
gated computer-based scanning training, one focused on visual
exploration training (Aimola 2011), one on reading training using
scrolling horizontal text (Spitzyna 2007), one was a training pro-
gramme, primarily delivered face-to-face by an occupational ther-
apist (De Haan 2015), and one was a self-delivered paper-based
scanning exercise (Rowe 2010). It is likely that the nature of these
interventions will result in varied scanning movements of the eye.
As well as differences in the mode of delivery of the scanning train-
ing, there were also differences in the amount of training. These
differences in the compensatory interventions reduce confidence
in any findings, and limit ability to generalise from these findings.
During the GRADE assessment of quality of evidence, we applied a
downgrade to each comparison combining results from these stud-
ies due to the variations in the interventions studied. We, therefore,
have low- to very-low confidence in the findings from this evidence.
Substitutive interventions versus no treatment, placebo, or
control
Two studies compared a substitutive intervention (prisms) with a
no treatment control (Rossi 1990; Rowe 2010). Rossi 1990 measured
our primary outcome of interest (functional ability in activities of
daily living). Both studies only included participants with stroke,
but Rossi 1990 included participants with visual neglect in addi-
tional to visual field defect. The studies both investigated the ef-
fect of Fresnel prisms. There was a fundamental difference between
these studies relating to the assessment of outcome: Rossi 1990
measured outcomes whilst participants in the intervention group
wore the assigned prisms, whilst Rowe 2010 measured outcomes
while participants were not wearing any assigned prisms. It has
been argued that the rationale for prisms is that they provide visu-
al field expansion when in use, and that consequently outcomes
from clinical trials exploring the effectiveness of prisms should be
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measured with participants wearing the prisms (Bowers 2014). In
contrast, Rowe 2010 measured outcomes without use of assigned
prisms in order to preserve blinding of outcome assessor and en-
able direct comparison of study treatment groups. It was, there-
fore, not appropriate to pool data from these different studies of
prisms, as the wearing of prisms during assessment in one study
but not the other makes the results incomparable. This is an impor-
tant issue which must be appropriately considered in future trials.
Due to the methodological limitations of these studies, and the in-
ability to combine results, we have low to very low confidence re-
lating to this evidence.
Assessment/screening intervention versus control
One study explored the effect of implementing a full visual assess-
ment by an orthoptist and sharing the results with hospital staJ
(Jarvis 2012). This study measured our primary outcome of inter-
est (functional ability in activities of daily living). The evidence was
judged to be very low quality, limiting our confidence in the find-
ings from this study.
Quality of the evidence
For this updated review, we judged the quality of evidence using
the GRADE approach. We judged all evidence included within meta-
analyses to be of low or very low quality. Key factors contributing to
downgrading of the evidence within these comparisons included:
Risk of bias
We identified concerns about the methodology for the majority of
included studies, and there were often insufficient details available
from incomplete reporting of methodological details. We judged
only eight of the 20 studies to be at low risk of bias for allocation
concealment, six of the 20 for blinding of outcome assessment,
and four of the 20 for incomplete outcome assessment. Further-
more, five of the studies were carried out by researchers who have
acknowledged a financial interest in intervention (Bowers 2014;
Jobke 2009; Kasten 1998; Kasten 2007; Poggel 2004); we assessed
this as potentially introducing a source of bias.
Imprecision
The number of participants within the included studies was small,
ranging from 10 to 87 participants, with only five of the 20 studies
including more than 50 participants. While there were a total of 732
randomised participants, variations in studies made it inappropri-
ate for the majority of study data to be combined within analyses,
and the maximum number of participants with data combined in
a single analysis was 162 (Analysis 2.3). The small number of par-
ticipants within the included studies and suitable for combination
within meta-analyses limits the conclusions that can be drawn from
this evidence.
Indirectness
A number of factors contributed to indirectness of the data includ-
ed within meta-analyses. In particular:
• population: there was considerable heterogeneity between
the populations recruited to individual studies. In addition to
stroke-related differences, such as time post-stroke, initial im-
pairment, and the presence of other stroke-related impairments
(e.g. communication, mobility), this was confounded by the in-
clusion of participants with conditions other than stroke, and in
opposing the decision to either include or exclude participants
with visual neglect. The variations in populations contributed to
decisions to downgrade the quality of evidence, as this reduced
our certainty in the reported findings;• interventions: this review aimed to synthesise evidence relat-
ing to a wide range of different interventions for visual field
defects following stroke and preplanned categories to support
appropriate combination of evidence. However, we found sub-
stantial variations in the interventions within these different
categories in relation to the details of the delivered interven-
tions. In particular, the compensative interventions had consid-
erable variation in the mode of delivery, with interventions vary-
ing from computer-based scanning training and reading train-
ing, paper-based scanning training, to face-to-face scanning and
mobility training. What is being delivered in terms of the eye
movements being trained with these different interventions is
likely to vary considerably, and - while data from these 'scan-
ning' interventions have been combined - the variations in inter-
ventions limit our ability to be confident about the pooled result;• outcomes: as is highlighted in Table 4, there was a lack of consis-
tency in the outcomes assessed by individual studies, and in the
assessment tools used to do this. While there is an argument that
outcome measures should be carefully selected according to
the anticipated action of, or scientific rationale for, the interven-
tion (Bowers 2017), the variations in interventions do not fully
explain the lack of consistency between the outcome measures.
Within the studies of prisms, the difference in choice of outcome
measure was further confounded by opposing decisions relating
to whether outcomes were assessed wearing or not wearing the
prisms. The variations in outcome measures limited the ability
to pool data from individual studies in a meaningful way, and
where measures have been pooled, limited our certainty in the
result.
In summary, we judged the quality of the evidence synthesised
within this review to be low to very low, and this limits our confi-
dence in the results. Future research needs to address the factors
which contribute to this level of evidence, in order to produce re-
sults which are useful and meaningful.
Potential biases in the review process
Publication bias
Through a thorough searching process we are quite confident that
we should have identified all relevant published studies. However,
at the peer review stage of this review update, we were alerted to
the fact that we had erroneously excluded a relevant study (Elshout
2016): while this was corrected prior to publication, it does high-
light the potential for human error in our process of screening titles.
A limitation of our search strategy for this update is that we have
not searched a number of trials databases beyond March 2015 (Cur-
rent Controlled Trials, Health Service Research Projects in Progress,
National Eye Institute Clinical Studies Database, Stroke Trials Reg-
istry); this may have limited our ability to identify ongoing trials, but
ought not to have impacted on our identification of completed tri-
als. It must be acknowledged that there is a small possibility that
there are additional studies (published and unpublished) that we
did not identify. We had planned to explore the effect of publication
type using sensitivity analyses; however, all data included in meta-
analyses were from peer-reviewed journals.
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Categorisation of interventions
Although we anticipated that we may experience difficulty in cat-
egorising the interventions studied into our predefined categories
of restitutive, compensative, and substitutive interventions, this
was not the case and the categorisation process was a clear and
unambiguous process. This was because the studies we identified
were primarily visual restitution therapy (restitutive), compensato-
ry scanning training (compensative), or prisms (substitutive). We
are, therefore, confident that our categorisation of interventions
has not introduced bias into the review process. However, we did
find substantial differences between the interventions within each
category (see discussion above), and decisions to combine data
from varied interventions may reduce applicability of these results.
Future updates of this review should, therefore, consider and pre-
plan which interventions it is clinically relevant to combine. In-
volvement of key stakeholders to inform this decision making for
future updates would be an advantage.
Inclusion criteria: participants
In the previous version of this review, we reported that the inclusion
criterion that was judged as most difficult to assess by the indepen-
dent review authors was the participants. The particular difficulty
encountered was with studies that did not appear to include the di-
agnosis of visual field defects as an inclusion criterion. In the previ-
ous version, we identified and included several studies that either
used a clinical assessment of 'scanning' as an inclusion criterion
without formally assessing or diagnosing either visual field defects
or visual neglect, or which included participants with a right-sided
cerebrovascular accident, making the assumption that these par-
ticipants would have visual neglect (and possibly also visual field
defects). For this update of the review, we addressed this difficulty
by only including studies that reported a method for diagnosing vi-
sual field defects at the recruitment stage. This led to the exclusion
of a number of studies that had previously been included, but in
which the participants did not have confirmed visual field defects
(Carter 1983; Weinberg 1977; Weinberg 1979). We made this change
between the previous version and this updated version of the re-
view in order to reduce potential bias in the review process; howev-
er, we acknowledge that this may have led to the exclusion of stud-
ies in which some participants had visual field defects that were not
confirmed through clinical diagnosis (e.g. instead manifesting as a
scanning problem).
Outcomes
Categorisation of some reported outcome assessments into our
predefined outcomes of interest was difficult in some cases. For this
update of the review, we added a table to report our categorisa-
tion of outcomes to ensure transparency in this process (Table 4).
We also reconsidered categorisation of all outcomes from trials in-
cluded in the previous version of the review, and made a number of
changes through a process of consensus. For example, Plow 2010
reported the Veterans Affairs Low Vision-Visual Functional Ques-
tionnaire (LV-VFQ) which "assesses an individual's visual ability to
perform ADLs across 4 domains, including reading, mobility, visual
motor function, and visual processing". This measure arguably re-
lates to both extended activities of daily living and quality of life. In
the first version of this review, this was listed as a measure of EADL:
however, this was changed to being listed as a measure of QoL out-
come for subsequent updates, following consensus discussion be-
tween review authors.
The primary outcome for this review was functional ability in ac-
tivities of daily living, measured using standardised scales. It has
been argued that measurement of effectiveness in rehabilitation
ought to take into account patients' individual goals (Turner-Stokes
2009). There is growing evidence that goal attainment scaling (a
standardised method of scoring performance of patient-specific
tasks) may provide a valid, reliable, sensitive method of evaluat-
ing outcomes that are of greatest importance to individual patients
(Krasny-Pacini 2016). This scale was not considered for inclusion
within this review, and could be considered for future updates.
As has been discussed under Quality of the evidence, variations in
outcomes and outcomes assessment tools between included stud-
ies created challenges for the synthesis of evidence within this re-
view. The need to make judgements and decisions relating to cate-
gorisation and pooling of outcomes created potential for the intro-
duction of bias into the review process. We have aimed for trans-
parency in our decision making and reporting in an attempt to
avoid the introduction of bias. However, to support the creation of
meaningful evidence syntheses and meta-analyses, there is a need
for consensus between stroke survivors, their families and carers,
health professionals, and researchers in relation to core outcomes
for trials relating to interventions for visual field defects after stroke
as recommended by the COMET Initiative.
Agreements and disagreements with other studies or
reviews
Agreements and disagreements between this updated version
and previous version
In the previous 2011 version of this review, we stated the key con-
clusions and implications for practice arising from the evidence as
follows.
• There is limited evidence which supports the use of compen-
satory scanning training for patients with visual field defects
(and possibly co-existing visual neglect) to improve visual field,
scanning, and reading outcomes.• There is insufficient evidence to reach a conclusion about the
impact of compensatory scanning training on functional activi-
ties of daily living.• There is also insufficient evidence to reach generalised conclu-
sions about the benefits of visual restitution therapy (restitutive
intervention) or prisms (substitutive intervention) for patients
with visual field defects after stroke.
Key changes in the methods between different versions of this re-
view include:
• updated searches in this updated version, increasing the num-
ber of included studies;• amended inclusion criteria, leading to the exclusion of studies in
which participants did not have confirmed visual field defects;• the use of the GRADE approach to systematically assess quality
of evidence in this updated version.
These changes have highlighted further uncertainty around previ-
ous limited evidence supporting the use of compensatory interven-
tions and have introduced evidence relating to adverse events as-
sociated with substitutive interventions, but have not resulted in
any changes in conclusions relating to restitutive or substitutive in-
terventions.
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• There is limited low-quality evidence that compensatory scan-
ning training may improve an important outcome (quality of
life) in patients with visual field defects following stroke, but fur-
ther research is very likely to have an important impact on our
confidence in the estimate of effect and is likely to change the
estimate. There is insufficient evidence to reach a conclusion
about the impact of compensatory scanning training on other
outcomes.• There remains insufficient evidence to reach generalised con-
clusions about the benefits of visual restitution therapy (resti-
tutive intervention) or prisms (substitutive intervention), and
there is insufficient evidence to reach conclusions about the ef-
fect of screening or assessment interventions for patients with
visual field defects after stroke.• There is now some low-quality evidence from one study that
prisms may result in an increased number of adverse events,
particularly headache.
Agreements and disagreements with other published reviews
The Royal College of Physicians updated the evidence included in
the earlier version of this review, concluding that there is "insuffi-
cient evidence regarding the effectiveness of interventions aimed
at improving function in people with visual field defects" (ISWP
2016). This updated review is in agreement with the conclusions
drawn from the evidence in the guideline.
The Scottish Intercollegiate Guideline Network (SIGN) guidelines
for stroke rehabilitation state that there is "limited poor quality
evidence suggesting that visual scanning compensatory training
techniques may be effective in improving functional outcomes af-
ter stroke" (SIGN 2011). This SIGN guideline (updated in 2010) is
based on a number of other reviews (Barrett 2009; Bouwmeester
2007; Jones 2006). While the previous version of our review was
in agreement with the recommendations made by the Royal Col-
lege of Physicians and SIGN guidelines, our updated review has
highlighted further uncertainty relating to the effect of compen-
satory interventions. The National Institute for Clinical Excellence
(NICE) stroke guidelines recommends that "eye movement thera-
py" is provided to "people who have persisting hemianopia after
stroke and who are aware of the condition" (NICE 2013): our updat-
ed review does not directly support this recommendation.
Our review is in agreement with the conclusions in other reviews
that the evidence relating to the effectiveness of visual restora-
tion therapy is inconsistent and of poor quality (Barrett 2009;
Bouwmeester 2007), and that few studies have assessed functional
ability in activities of daily living as an outcome.
Our review is in agreement with narrative reviews of evidence for
interventions for visual problems after stroke (Lane 2008, Hanna
2017), which have concluded that there is a need for high-quality
studies of the effectiveness of interventions for visual field defects.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is limited low-quality evidence that compensatory scanning
training may improve an important outcome (quality of life) in pa-
tients with visual field defects following stroke, but further research
is very likely to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate. There is in-
sufficient evidence to reach a conclusion about the impact of com-
pensatory scanning training on other outcomes.
There is insufficient evidence to reach generalised conclusions
about the benefits of visual restitution therapy (restitutive in-
tervention), prisms (substitutive intervention), or assessment or
screening interventions for patients with visual field defects after
stroke. Prisms may cause a range of adverse events, particularly
headache.
Implications for research
Specific implications for research, based on the findings of this re-
view, are outlined below.
Are further randomised controlled trials (RCTs) required?
RCTs are required to determine the effect of:
• compensatory scanning training compared to no treatment,
placebo, or usual care;• restitutive interventions compared to no treatment, control, or
placebo;• substitutive interventions compared to no treatment, control,
or placebo;• assessment or screening interventions compared to standard
care.
Such RCTs must:
• have adequate power (i.e. with an appropriate power calcula-
tion undertaken based on existing trial evidence);• have adequate allocation concealment, blinding of outcome as-
sessor, and intention-to-treat analysis;• clearly define trial participants, with particular care relating to
the diagnosis and inclusion of patients with visual field defects
or visual neglect, or both;• consider the severity of the visual field defect and plan subgroup
analyses, where appropriate;• include measures of functional ability in activities of daily living;• collect and report data relating to adverse events;• report clear and usable data.
We recommend that future RCTs concentrate on answering the spe-
cific question relating to the effectiveness of interventions com-
pared to control, placebo, no treatment, or usual care rather than
comparisons with variations of the same 'type' or category of inter-
vention, or comparisons of different doses, adjuncts to treatment,
or modes of delivery. We believe that until such time as the ben-
efits of interventions for visual field defects compared to control,
placebo, no treatment, or usual care have been established (or re-
futed), it is not beneficial to compare the relative effects of different
interventions. We recommend that future RCTs should include out-
comes that are of importance to people affected by this problem,
such as quality of life, confidence, and participation in social activ-
ities and relationships. We recommend that consensus is reached
relating to the important outcome measures which all future trials
of interventions for visual field defects in people with stroke should
assess (i.e. a core outcome set), and that stroke survivors, carers,
health professionals, and researchers are involved in developing
this core outcome set.
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A number of RCTs are currently ongoing. Once they are completed it
will be important to update this review and to re-evaluate the need
for further RCTs of interventions for visual field defects.
Are other primary research studies required?
We do not recommend other study designs aimed at investigating
the effects of visual restitution therapy or prisms, although devel-
opment or pilot studies may be justified to support the design of a
full trial if such work has not previously been completed. Given the
variation in compensatory interventions included in this review, we
do recommend that other primary research studies are considered
to explore an optimal scanning training intervention. Such studies
may consider the evaluation of computerised as well as non-com-
puterised interventions, the effective dosage, and the role of read-
ing-specific training. However, this work ought to be done as a pre-
quel to a well-designed RCT of the scanning intervention. Studies
evaluating different types of scanning training should provide clear
details of the treatment parameters, including the eye movements
which are being trained by the intervention.
There is a need for further research to identify optimal outcome
measures for use within future RCTs in this area. Such research may
consider the relationship between functional measures of activities
of daily living (ADL), measures of vision-related extended ADL (such
as reading, driving, navigating within an environment), and labora-
tory measures of the visual field.
Are further systematic reviews required?
We do not recommend any further systematic reviews aimed at ad-
dressing the effectiveness of interventions for visual field defects
after stroke. We do recommend that this review is updated when
the ongoing RCTs are completed.
Summary of findings• The quality of evidence summarised in this review is judged to
be low to very low.• Methodological quality of studies is, in general, poor or poorly
reported, providing insufficient high-quality evidence on which
to reach generalisable conclusions.
• Limited low-quality evidence suggests compensatory interven-
tions may improve an important outcome (quality of life) in pa-
tients with visual field defects following stroke, but further re-
search is very likely to have an important impact on our confi-
dence in the estimate of effect and is likely to change the esti-
mate. There is insufficient evidence to reach a conclusion about
the impact of compensatory scanning training on functional ac-
tivities of daily living, or other outcomes.• There is insufficient evidence to reach generalised conclusions
about the benefits of vision restoration therapy for patients with
visual field defects after stroke.• There is insufficient evidence to reach generalised conclusions
about the benefits of prisms for patients with visual field defects
after stroke; there is some low-quality evidence that prisms may
cause adverse events.• High-quality RCTs are needed to compare compensatory, resti-
tutive, substitutive, and assessment interventions with placebo,
control, no treatment, or usual care.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Compensative intervention versus control, placebo, or no intervention
Design: "A randomized, controlled, parallel-group design was used."
Stratification: no
Randomisation sequence: "participants were randomized equally to 2 groups ... using parallel trial al-
location software"
Comparisons: 2 groups: intervention versus control
Allocation concealment: "Participants were informed about the training types but did not know to
which group they were assigned."
Blinding: not stated if outcome assessor was blinded
Power calculation: no (feasibility study)
Intention-to-treat analysis: no
Other recruitment details: "recruited from local hospitals or as self-referrals"
Patient and public involvement: not stated
Participants Total study population: randomised 70; "final sample included in analyses consisted of 52 partici-
pants; 28 intervention and 24 control"
Withdrawals: 18 "dropped out during the intervention period because of health problems (n = 7),
death (n = 2), or low motivation (n = 9)".
Method of diagnosing VFD: monocular automatic perimetry
Characteristics of population: "chronic hemi-VFDs resulted from any post-chiastmatic lesion." Partici-
pant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: at least 18 years old, no previous access to any formal hemi-VFD rehabilitation
(restoration, substitution or compensation)
Exclusion criteria: "medical instability, inability to provide informed consent, visual loss as a conse-
quence of prechiasmatic damage or a progressive condition, photosensitive epilepsy, oculomotor dis-
orders, and severe cognitive impairment. Participants were not enrolled until at least 3 months after
onset to minimize confounding by spontaneous recovery (range = 3-276 months)".
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Baseline comparison of treatment groups: no differences noted at baseline
This study included participants with diagnoses other than stroke.
This study included participants with visual field defects and co-existing visual neglect.
Method of diagnosing visual perceptual problems: Bells test
Interventions Group 1: home-based compensatory training (n = 28)
Intervention: "the experimental training consisted of reading and exploration components; patients
completed components sequentially with order randomized."
Intervention type: compensation. Materials: computer-based: Where can materials be accessed?
not stated. Procedures: "In the visual exploration tasks patients had to find a target defined by a spe-
cific feature (color, shape, size) among an array containing distractors (i.e. a red letter among blue
ones). In the reading task, patients had to detect a nonword target (ie, vowels) among a varying num-
ber of words (i.e. accent), presented in a single central horizontal line. In both task types participants
responded to target presence using an appropriate computer-mouse press. Computer feedback on
speed and accuracy of responses, and overall progress to date (i.e. difficulty level achieved and num-
ber of training sessions completed), was provided at the end of each block of trials." Provided by: "at
the start of the intervention period the experimenter demonstrated the training, during which the com-
puter was set up ... Participants were encouraged to train in a similar manner, though adherence can-
not be guaranteed" .Delivery: home-based (Table 1). Regimen: "Patients could perform a maximum
of 14 blocks per day. Each block contained 120 trials. They completed 294 exploration and 196 read-
ing blocks." Tailoring: "For both training components difficulty level was dynamically adjusted based
on both accuracy and speed of previous performance. If patients were ≥ 90% accurate then difficulty
would increase to the next level, whereas with accuracy < 75% difficulty would drop to an easier level.
In exploration tasks difficulty was increased by enlarging the spatial zone within which a target could
appear and by making targets and distractors more similar. For the reading task the word length and
number of distractor words increased (up to a maximum of 7). For both tasks, presentation time was di-
rectly related to previous response times, that is, the faster the participant, the shorter the successive
presentation time". Modification: see tailoring. Adherence: "There were 18 withdrawals, 9 due to low
motivation. A total of 89% of the low-motivation withdrawals were in the control group. Recommend-
ed training duration was 5 weeks. However, only 3 patients met this requirement; the mean completion
time for the experimental training was 9.3 weeks (SD = 6.0)."
Group 2: control (n = 24)
Intervention: "This training consisted of a number of tasks requiring visual attention but no systemat-
ic exploration or large horizontal eye movements." Intervention type: placebo/attention control. Ma-
terials: computer-based. Where can materials be accessed? not stated. Procedures: "The random-
ly presented tasks included a Go/No-Go task, centrally presented sequential search, Sternberg task,
and a "rabbit hunting" task." Provided by: "at the start of the intervention period the experimenter
demonstrated the training, during which the computer was set up ... Participants were encouraged to
train in a similar manner, though adherence cannot be guaranteed".Delivery: home-based (Table 1).
Regimen: "Patients were instructed to complete 10 blocks per day in approximately 1 hour, with a to-
tal of 350 blocks." Tailoring: "Difficulty was adjusted dynamically depending on performance by reduc-
ing presentation time or increasing attentional load." Modification: see tailoring. Adherence: "There
were 18 withdrawals, 9 due to low motivation. A total of 89% of the low-motivation withdrawals were in
the control group. Recommended training duration was 5 weeks. However, only 3 patients met this re-
quirement; the mean completion time for the experimental training was 9.3 weeks (SD = 6.0)."
Outcomes See Table 4
Perimetry (Esterman)
Visual search (find the number)
Reading (corrected reading speed)
Tasks simulating ADL: 1) driving hazard perception (mean score per hazard), 2) obstacle avoidance
(completion time), 3) visuomotor search (time)
Aimola 2011  (Continued)
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Attention tasks: 1) sustained attention to response (mean percentage error score), 2) test of everyday
attention
Subjective questionnaires: Visual Functioning Questionnaire (VFQ-25), Subjective Reasons Question-
naire
Time points when outcomes were assessed: before and after intervention
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk Stated "using parallel trial allocation software"
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk "Participants were informed about the training types but did not know to
which group they were assigned." Not stated if outcome assessor was blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk "There were 18 withdrawals, 9 due to low motivation."
Other bias Low risk No other issues noted
Aimola 2011  (Continued)
 
 
Methods Substitutive intervention versus substitutive intervention
Design: parallel RCT
Stratification: not stated
Randomisation sequence: not stated
Comparisons: Full Field plastic press-on 15-diopter Fresnel prisms (base towards the deficit) versus
Half Field prisms cut to cover the respective homonymous field
Allocation concealment: not stated
Blinding: not stated
Power calculation: not stated
Intention-to-treat analysis: not stated
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 18 (stroke only) participants who had hemianopsia or visual neglect, or both
Withdrawals: none
Method of diagnosing VFD: confrontation; method of diagnosing visual perceptual problems: con-
frontation
Characteristics of population: participant details are listed in Table 2
Bainbridge 1994 
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Type and severity of visual problems: participant details are listed in Table 3
Inclusion criteria: not stated
Exclusion criteria: not stated
Baseline comparison of treatment groups: not stated
Interventions Group 1: Full field prism (n = 10)
Intervention type: substitution. Materials: Full field prism. Where can materials be accessed? not
stated. Procedures: 15 dioptre full-field plastic press-on Fresnel prisms (base towards the deficit). Pro-
vided by: not stated. Delivery: face-to-face, individual, location not stated (Table 1). Regimen: used
the prisms while awake for 4 weeks. Tailoring: not stated. Modification: not stated. Adherence: not
stated
Group 2: Hemi-field prism (n = 8)
Intervention type: substitution. Materials: Hemi-field 15 diopter Fresnel prism. Where can materials
be accessed? not stated. Procedures: Hemi-field prisms cut to cover the respective field. Provided by:
not stated. Delivery: face-to-face, individual, location not stated (Table 1). Regimen: used the prisms
while awake for 4 weeks. Tailoring: not stated. Modification: not stated. Adherence: not stated
Outcomes See Table 4
Motor visual perception score
Line Bisection Test
Line Cancellation test
Harrington-Flocks Visual Field score
Time points when outcomes were assessed: baseline and at 4 weeks
Adverse events? not stated
Notes Insufficient information to assess for any confounding variables (abstract)
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Quote "patients were randomized". Insufficient information available in the
abstract
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Insufficient information available in the abstract
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information available in the abstract
Other bias Unclear risk Insufficient information available in the abstract
Bainbridge 1994  (Continued)
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Design: RCT (cross-over, with a "counterbalanced AB/BA design (AB = real first, BA = sham first)". The
"real" prisms could be either "oblique" or "horizontal" peripheral prism glasses, meaning that there
were 4 possible treatment allocations for each participant).
Stratification: see below (minimisation)
Randomisation sequence: participants were assigned using minimisation. "The first participant was
assigned randomly, with each subsequent participant assigned in such a way as to minimize imbal-
ances among the 4 treatment allocations. We could realistically balance for only 2 factors. Study site
was the primary factor (because continuation rates varied significantly across sites in our first multicen-
ter study) and side of hemianopia (right or leM) was the second factor (because the side of the lesion
could potentially affect performance with the prism glasses). We did not balance for age because it was
not a significant factor affecting continuation rates in our previous study."
Comparisons: oblique peripheral prism glasses, horizontal peripheral prism glasses, sham prism glass-
es
Allocation concealment: yes
Blinding: "Double-masking was used, with participants and data collectors being masked as far as pos-
sible. In addition, the principal investigator who conducted data analyses was masked. However, it was
impossible to mask all study personnel; there was an unmasked practitioner at each site who fitted the
prism glasses and dealt with clinical aspects of patient care."
Power calculation: yes (data from previous trial used to calculate minimum sample size; led to "plan
to enrol at least 68 participants")
Intention-to-treat analysis: no
Other recruitment details: "Data were collected at 13 study sites, including the Peli laboratory at
Schepens, 11 vision rehabilitation clinics in the United States, and 1 in the United Kingdom. The clinics
included university, hospital, and private practice clinics. Each site recruited a median of 7 participants
(range, 3-12). Participants were recruited by practitioners at each study site."
Patient and public involvement: not stated
Participants Total study population: 73 randomised
Withdrawals: 6 (before the start of the cross-over)
Method of diagnosing VFD: visual field mapping extended to at least 50° from fixation in all directions
and was performed using Goldmann perimetry (V4e target), a Humphrey Field Analyzer 120-point full-
field screening test, or similar tests, depending on the equipment available at each clinic.
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3
Inclusion criteria: "Complete homonymous hemianopia of greater than 3 months' duration, no visu-
al neglect (Bells test and Schenkenberg Line Bisection test), and no history of having worn peripher-
al prism glasses. In addition, participants had corrected monocular visual acuity of at least 20/50 in
each eye, refractive error within the −5 diopter (D) to +5 D range, no strabismus, no significant cognitive
decline (Short Portable Mental Status Questionnaire), and no balance problems or other deficits that
could impair ability to walk or use the prism glasses. To ensure that study inclusion criteria were uni-
formly applied, screening data were sent to the principal investigator (A.R.B.), who determined eligibili-
ty".
Exclusion criteria: none listed
Baseline comparison of treatment groups: yes (mobility questionnaire)
Interventions Group 1: Prism glasses (total n = 37)
Group 1a. Real oblique prism glasses (n = 19)
Bowers 2014  (Continued)
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Group 1b. Real horizontal prism glasses (n = 18)
Intervention type: substitution. Materials: peripheral prism glasses of 57 prism dioptres (interven-
tion) versus 5 prism dioptres (sham). Where can materials be accessed? From vision specialists; for
the study these were manufactured by "Chadwick Optical, Inc. (White River Junction, Vermont)". Pro-
cedures: participant fitted and provided with prism glasses to be worn for the following 4 weeks.
"Training in how to use the prism glasses was conducted by the practitioner." "Participants were
taught to view through the central prism-free area of the spectacle lens at all times and to turn the
head and eyes to fixate objects of interest that were initially detected from the prism image in peripher-
al vision. A simple "reach and touch" training exercise was used to familiarize participants with the re-
lationship between the apparent and real positions of objects detected from the prism image; this ex-
ercise was also encouraged for home-training. Participants were given verbal and written instructions
about how to use the prism glasses and were encouraged to wear them as much as possible each day.
They were advised not to use the peripheral prism glasses for driving or prolonged reading." Provided
by: "practitioner". Delivery: face-to-face, individual, clinic appointment to be provided with the glass-
es, then to be worn by participant (Table 1). Regimen: first pair of prisms glasses 4 weeks; then cross-
over and use of second pair of prism glasses for another 4 weeks (see procedures). Tailoring: not stat-
ed. Modification: not stated. Adherence: not stated
Group 2: Sham prism glasses (total n = 36)
2a. Sham oblique prism glasses (n = 17)
2b. Sham horizontal prism glasses (n = 19)
Intervention: control. Intervention type: placebo control. Materials: sham prism glasses.Where can
materials be accessed? For the study these were manufactured by "Chadwick Optical, Inc. (White Riv-
er Junction, Vermont)". Procedures: as for real prisms. Provided by: "practitioner".Delivery: face-to-
face, individual, clinic appointment to be provided with the glasses, then to be worn by participant (Ta-
ble 1). Regimen: first pair of prisms glasses 4 weeks; then cross-over and use of second pair of prism
glasses for another 4 weeks (see procedures). Tailoring: not stated. Modification: not stated. Adher-
ence: not stated
Outcomes See Table 4
The proportion of participants fitted with each type of prism glasses for whom the decision is to contin-
ue using the glasses
Difference in perceived mobility (i.e. rating of how helpful each type of prism glasses are in avoidance
of obstacles when walking)
Time points when outcomes were assessed: at the end of each cross-over period
Notes Data presented for the first phase (i.e. before the cross-over) is presented for "real" versus "sham"
prisms, i.e. with data from the oblique and horizontal groups combined: "there were no statistically
significant differences between the oblique and horizontal groups for any of the outcome measures ...
therefore, data were pooled across the 2 groups for the main analyses".
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk "The clinical coordinator at Schepens assigned participants to 1 of 4 possible
treatment allocations (real oblique AB/BA and real horizontal AB/BA) using
minimization". Allocation was done by central clinical co-ordinator.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Outcome assessor was blinded. The personnel fitting the prism were not blind-
ed: "Double-masking was used,with participants and data collectors being
masked as far as possible. In addition, the principal investigator who conduct-
ed data analyses was masked. However, it was impossible to mask all study
personnel; there was an unmasked practitioner at each site who fitted the
prism glasses and dealt with clinical aspects of patient care". In the debriefing,
Bowers 2014  (Continued)
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61% (37/61) of participants reported that they thought that one pair of glasses
might have been a sham; of these, 92% (34/37) correctly identified the sham.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reasons for dropouts were reported and were balanced across the groups.
Other bias High risk Authors have disclosed conflicts of interest: "Dr Peli has financial interest in a
patent related to the peripheral prism glasses (assigned to Schepens Eye Re-
search Institute). Ms Keeney has licensed that patent for Chadwick Optical,
Inc. Chadwick Optical, Inc funded the study in part from National Institutes
of Health (NIH) grant EY014723 through a subcontract with Schepens Eye Re-
search Institute. Dr Peli was a paid consultant to Chadwick Optical, Inc on the
design of the permanent prisms. No other financial interests were reported."
Bowers 2014  (Continued)
 
 
Methods Compensative intervention versus control, placebo or no intervention
Design: RCT
Stratification: minimisation ("minimised regarding gender, side of field defect (leM or right), side of
field defect (hemianopia versus quadrantanopia), age (younger versus older than 55), and time since
onset (shorter versus longer than 12 months - because time since onset was assumed less important
than the other variables, this variable was weighted less heavily than the others)
Randomisation sequence: randomisation software
Comparisons: 2 groups, training group and control group
Allocation concealment: no, "author GH entered the characteristics of the patient into the randomisa-
tion software ... which resulted in allocation to the training group or the waiting list control group"
Blinding: "Assessors were blinded to participants' group allocation".
Power calculation: yes
Intention-to-treat analysis: no; some participant data excluded from analysis due to deviations from
study protocol ("too low compliance with training protocol", "time period between T1 and T2 longer
than acceptable")
Other recruitment details: patients were recruited at Royal Dutch Visio and Bartiméus, the two cen-
ters of expertise for blind and partially sighted people in the Netherlands.
Patient and public involvement: not described
Participants Total study population: 54 randomised; training group (n = 30), control group (n = 24)
Withdrawals: at follow-up immediately after training; training group (n = 28), control group (n = 24).
Additional participants excluded from analysis, so in analysis: training group (n = 26), control group (n =
23).
Method of diagnosing VFD: specific method not clear: "patients underwent extensive and standard-
ized ophthalmological and neuropsychological assessments at the centers mentioned above prior to
participation in the study."
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
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Inclusion criteria: "The main inclusion criterion was presence of a hemi-VFD, at least a quadran-
tanopia, restricted to one half of the visual field, due to acquired postchiasmatic brain injury ... To be in-
cluded, patients required a minimum binocular visual acuity of Snellen 0.5 (6/12 or 20/40, LogMAR 0.3),
a stable neurological and ophthalmological condition, non-disturbed eye and head motility, ability to
walk at least 50 meters, and a Mini Mental State Examination (MMSE) score 24 out of 30."
Exclusion criteria: "Exclusion criteria were ocular diseases affecting the visual field or binocular visual
acuity, signs of severe physical impairments or (neuro)psychological disorders. Neglect was excluded
based on the Balloons, Drawings, Line Bisection and Rey Complex Figure Test."
Baseline comparison of treatment groups: yes
Interventions Group 1: InSight-Hemianopia Compensatory Scanning Training (IH-CST) (n = 26)
Intervention type: compensation. Materials: "The full training protocol is available at Visio and Bar-
timeus for occupational therapists trained for applying the protocol". Electronic software was need-
ed: "software was needed in order to implement the exercises ... this software was developed by the
faculty of Behavioural and Social Science at the University of Groningen".Procedures: "The aim of the
IH-CST is to teach patients with HVFD to compensate for their visual field defect during a wide range
of mobility-related activities ... The compensation strategy taught in the IH-CST is to apply a scanning
rhythm consisting of a triad of saccades. First a large saccade towards the blind side is made in order to
receive information from the periphery. This is followed by a second saccade back towards the seeing
side to prevent overcompensation. Third, a small saccade is made back to the starting point of look-
ing straight forward ... The training program consists of exercises for improving awareness of the visu-
al field defect and its consequences for daily life, exercises to learn the scanning rhythm, and practice
of the scanning rhythm in daily life mobility situations".Provided by: occupational therapists: "Thir-
ty occupational therapists ... experienced in working with brain injured patients were schooled in pro-
viding the IH-CST ... ". Delivery: "Training according to the protocol was provided in Dutch at nine lo-
cations of Royal Dutch Visio and one location of Bartimeus in the Netherlands." "Homework assign-
ments are included in the training protocol". (Table 1). Regimen: 15 individual sessions of 60 to 90 min-
utes each, 18.5 hours of face-to-face training in total during a period of 10 weeks. Tailoring: yes (stated
"not applicable" in author's checklist, but stated that "... the patient proceeds to the next exercise once
the predefined targets or an exercise are accomplished. This creates flexibility for individual needs and
progress and can cause the training to take more or less than 15 sessions"). Modification: no. Adher-
ence: "patients are asked to keep a diary of their practice at home and the therapist asks about the
progress of the homework assignment at the beginning of every training session".
Group 2: Wait-list control (n = 23)
Intervention type: control. Materials: none. Where can materials be accessed? NA. Procedures: NA.
Provided by: NA. Delivery: NA. (Table 1) Regimen: NA. Tailoring: NA. Modification: NA. Adherence:
NA.
Outcomes See Table 4
Tests for visual functions (Goldman perimetry)
Reading tests
Basic scanning tests
Hazard perception test
Tracking task
Obstacle course
Questionnaires for activity and participation
Time points when outcomes were assessed: participants in the training group were assessed the
week before training (T1) and the week after training (T2); participants in the control group were as-
sessed at the same time points (T1 and T2).
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Notes Trial registration details: ISRCTN Registry (ID ISRCTN16833414); Central Committee on Research In-
volving Human Subjects (CCMO; registration number NL31718.042.10)
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk Random allocation, using randomisation software. Researcher (GH) was aware
of allocation, but was not involved in providing treatment or assessment
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Outcome assessors were blinded. Personnel providing training and partici-
pants could not be blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk No intention-to-treat analysis. Final analysis completed only on those who
completed training, and who complied with the training programme.
Other bias High risk Control group received no treatment or contact with personnel. Therefore,
high risk of bias due to attention received by training group.
De Haan 2015  (Continued)
 
 
Methods Restitutive intervention versus control, placebo or no intervention
Design: randomised cross-over trial
Stratification: not stated
Randomisation sequence: "For each cohort of 10 patients, numbers (J01–J40), the training stimuli
(FloworPoint), and the order of training rounds [Test (defect) round first or Control (intact) round first]
were randomly assigned to a patient number ... The patients were included in order of registration
on our website. Thus, the assignment of a patient to a patient number (with corresponding training
scheme: stimulus type and the training order) was determined prior to the first inclusion, completely
random and not based on selection."
Comparisons: 2 groups: "(1) test (high contrast training of the affected field) and (2) control (low-con-
trast training of the intact visual field)"
Allocation concealment: see randomisation sequence
Blinding: "We applied both Humphrey (blinded) and Goldmann perimetry (not blinded, because of in-
sufficient staJing)." Not stated for reading tests
Power calculation: not stated
Intention-to-treat analysis: no. "Three patients dropped out during the first training round for person-
al reasons and were excluded from analyses".
Other recruitment details: "This study was part of a larger project ... Forty stroke patients with visual
field defects due to post-chiasmatic stroke were included following written informed consent. Patients
throughout the Netherlands could signup for our study voluntarily by filling in a form on our website."
However after 3 cohorts of 10 patients, the training procedure was modified "because in some patients
the control training reversed the increase of the visual field of the preceding defect training". This study
therefore only reported the first 3 cohorts of participants.
Patient and public involvement: not stated
Participants Total study population: 30 patients with post-chiasmatic lesions
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Withdrawals: 3 patients dropped out "for personal reasons". They were excluded from analyses.
Method of diagnosing VFD: Goldmann perimetry measurement
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: "Patients in the chronic phase of stroke (> 10 months post CVA) were included if they
showed no signs of visual neglect (line bisection test). Patient age was between 18 and 75 years, and
they were able to undergo (f)MRI scanning."
Exclusion criteria: visual neglect (see above)
Baseline comparison of treatment groups: not stated
Interventions Group 1: defect training (high contrast stimuli offered within the field defect along its border) (n = 15
for first phase, before cross-over)
Intervention type: restitution - high-contrast stimuli in affected hemifield. Materials: "Each patient re-
ceived a training unit at home to create a controlled training environment.This unit consists of a con-
tainer, to be placed on a table, with a top cover and side covers to present a dark visual surround for
the training stimuli with the exclusion of stray light. Mini Mac computer, keyboard, and mouse, a sup-
port with 24" LED monitor, webcam, and chin/headrest were positioned inside the matte black con-
tainer". Where can materials be accessed? not stated. Procedures: "Viewing distance was fixed at 40
cm. The subject’s face was indirectly lighted with a TL light for eyetracking with the webcam. The com-
puter was prepared with eyetracking software, and training programs that were adjusted to the partic-
ular visual field defect of the patient." "For both stimuli, the patient maintained fixation binocularly on
a ring (diameter = 0.5°) at the center of the screen. During stimulus presentation (7s),patients shifted
attention covertly (i.e. without shifting eye fixation) toward the stimulus and responded using the key-
board. Only the fixation point was shown during the intertrial interval of 2s". "To cue the stimulated tar-
get location and to perform a discrimination task, a line was presented simultaneously with the point
extending from the fixation target into the trained hemifield.The meridional angle of the line differed
by 10° from the training point.The patient made a forced-choice response whether the point stimulus
was presented clockwise or counterclockwise relative to the presented line". Provided by: Not stat-
ed. Delivery: In patients home. (Table 1). Regimen: "1h a day, 5 days a week during 8 weeks to com-
plete at least 40h of training per hemifield". "The length of one training session was on average 12min
(depending on the number of trials set per session and amount of fixation errors). The number of tri-
als in a session ranged between 60 and 100, depending on the shape and quality of the visual field de-
fect. The stimuli were randomly presented for each session". Tailoring: The number of trials depended
on the shape and quality of the visual field defect. "Point size was at least 0.2° in diameter (at 1° eccen-
tricity) and was scaled with eccentricity: scale (E) = (0:0006E∧2 + 0:0448 E + 0:092) = 0:1374". Mod-
ification: not stated. Adherence: was monitored: "Throughout the training, fixation was monitored
via a low-cost commercial webcam and eyetracking software available in the public domain (www.in-
ference.phy.cam.ac.uk/opengazer/) that was adapted to supply eye position data to the training pro-
gram".
Group 2. Control (intact training) (stimuli presented in the intact field about the same eccentricities as
for defect training) (n = 15 for first phase, before cross-over)
Intervention type: placebo/control. Although paper stated: "Following three cohorts of 10 patients,
we modified the training procedure, because in some patients the control training reversed the in-
crease of the visual field of the preceding defect training". Materials: as above.Where can materials
be accessed? not stated. Procedures: similar to above defect training: "During intact training, stimuli
were presented within the intact field at about the same eccentricities as for the patient’s defect train-
ing ... To offer a challenging training during the intact training, the stimulus contrast was reduced (C <
0.15)". "Within the entire visual field, a pattern of flow was shown that contracted on to a training loca-
tion within the visual field (white points on a dark screen). The stimulus to be discriminated was placed
on a black disk that covered the center of the contraction pattern, the diameter of which was eccentric-
ity scaled with the same factor as for the point target. We used a minimal disk size of 1.7° at 1° eccen-
tricity. The origin of the contraction pattern was the location cue for the flow discontinuity that had to
be detected. The discontinuity stimulus (on the disk) was a flow pattern rotating clockwise or counter-
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clockwise about the training location. The patient had to indicate the direction of rotation".Provided
by: not stated.Delivery: in participant's home (Table 1). Regimen: as above. Tailoring: stimuli were
presented at the same eccentricities as for the defect training, which depended on the shape and quali-
ty of the visual field defect. Modification: not stated. Adherence: as above
Outcomes See Table 4
Perimetry: Humphrey (blinded) and Goldmann perimetry (not blinded because of insufficient staJing)
Reading tests: reading speed
Notes Supplementary material referred to within published paper, but not accessible via weblink. Requested
from authors February 2019
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk Patients were included in the order in which they registered on the website.
Order of treatment phases was randomly assigned, and allocated to patient
number prior to patient registrations.
Blinding (performance
bias and detection bias) 
All outcomes
High risk No blinding for Goldmann Perimetry ("because of insufficient staJing").
Humphrey perimetry was blinded. Not stated for reading tests. Unclear who
delivered the intervention and whether they were blind to the treatment
phase.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No intention-to-treat analysis. 3 dropouts during first phase "for personal rea-
sons", but unclear which treatment group they were in.
Other bias Low risk No other issues noted
Elshout 2016  (Continued)
 
 
Methods Restitutive intervention versus control, placebo or no intervention
Design: RCT
Stratification: not stated
Randomisation sequence: not stated
Comparisons: 2 groups
Allocation concealment: not stated
Blinding: stated "blinded"
Power calculation: not stated
Intention-to-treat analysis: not stated
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 29 patients with post-chiasmatic lesions
Withdrawals: not stated
Gall 2013 
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Method of diagnosing VFD: not stated
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: not stated
Exclusion criteria: not stated
Baseline comparison of treatment groups: not stated
Interventions Group 1: non-invasive brain stimulation using alternating current stimulation (ACS) (n = 15)
Intervention type: restitution - alternating current stimulation. Materials: not stated. Where can ma-
terials be accessed? not stated. Procedures: not stated. Provided by: not stated. Delivery: face-to-
face, individual, location unclear (Table 1). Regimen: 10 days. No other details reported. Tailoring: not
stated. Modification: not stated. Adherence: not stated
Group 2: sham stimulation (n = 14)
Intervention type: placebo/control. Materials: not stated.Where can materials be accessed? not
stated. Procedures: not stated.Provided by: not stated.Delivery: face-to-face, individual, location un-
clear (Table 1). Regimen: 10 days. No other details reported. Tailoring: not stated. Modification: not
stated. Adherence: not stated
Outcomes See Table 4
Perimetric thresholds within areas of residual vision
Subjectively perceived visual functioning/vision-related quality of life (composite score of National Eye
Institute Visual Function Questionnaire 39)
Health-related quality of life (Short Form Health Survey SF-12)
Time points when outcomes were assessed: baseline and post-intervention (time point not stated)
Notes Insufficient information to assess for any confounding variables (abstract)
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information available in the abstract
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Insufficient information available in the abstract
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information available in the abstract
Other bias Unclear risk Insufficient information available in the abstract
Gall 2013  (Continued)
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Design: pilot RCT
Stratification: none
Randomisation sequence: "randomized into one of two groups using a computer-generated random-
ization table"
Comparisons: 2 groups: Group A (control) and Group B (experimental)
Allocation concealment: not stated ("randomization process was administered by a researcher at
the University of Liverpool, who was not involved in data collection but was involved in the later data
analysis")
Blinding: participants were blinded ("participants were masked to group allocation"), "assessors were
not masked" ("findings from the visual assessment were withheld from the therapy staJ in group A
(control group). In comparison the visual assessment details were made available to the therapy staJ
for participants in group B (experimental group)".
Power calculation: feasibility study ("prospective observation cohort study in the UK suggested that
of all stroke patients referred with suspected visual impairment, 85% were found to have an identi-
fiable visual impairment (Rowe 2007). On the basis of this preliminary data, this pilot study aimed to
screen 100 patients in order to recruit a minimum of 70 participants").
Intention-to-treat analysis: no ("All data analysis was conducted based on the recruited patients to
each group with full FIM data collection for both baseline and 6-week follow-up assessment").
Other recruitment details: "Participants were prospectively recruited between February 2008 and Ju-
ly 2009". "Specified members of the health care team (nurses, stroke physicians, physiotherapists and
occupational therapists) on the stroke unit were required to screen patients against these criteria to
identify potential participants. StaJ used a screening form with questions to identify visual signs (head
turning, strabismus, ptosis) and symptoms (diplopia, loss of vision, field loss). This was adapted from
the screening form used in the Visual In Stroke (VIS) study (Rowe 2010)"."If visual impairment was not-
ed, the screening form was sent to the orthoptist and hence, it doubled as a referral form". "Where nec-
essary, for example when a potential participant had communication difficulties, adaptations were
made to the consent process".
Patient and public involvement: not stated
Participants Total study population: 64
Withdrawals: 13 died before full baseline assessment (Group A: 4; Group B: 9). Another 10 cases
( Group A: 6, Group B: 4) withdrew (death, early discharge, no follow-up or DNA follow-up) at follow-up
assessment.
Method of diagnosing VFD: full visual assessment undertaken by orthoptist. Battery of routine tests
used as part of a previous study (Rowe 2009). It comprised tests of visual acuity - logMAR (Bailey 1976),
ocular alignment - cover test (Pediatric Eye Disease Investigator Group 2009), ocular motility - saccadic,
smooth pursuit and vergence assessment (Holmes 2001), stereopsis - Frisby test (Rosner 1984), visual
field - confrontation (Cassidy 2001) and visual inattention - line bisection, star cancellation, and clock
drawing. "The orthoptist did not suggest possible adaptive strategies to be undertaken, the focus was
on alterations made by the therapists based only on the visual assessment information".
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: "stroke within 2–6 weeks of being recruited, had a decreased functional ability com-
pared to pre-stroke functioning, had a post-stroke visual impairment, and were able to understand the
research process"
Exclusion criteria: "unable to consent due to cognitive impairment or communication difficulties, or if
they had a visual field impairment pre-existing their stroke"
Jarvis 2012  (Continued)
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Baseline comparison of treatment groups: "no significant difference in the composition of both
groups (x2 test) for gender (P = 0.846), age (P = 0.113), stroke type (P = 0.564), stroke area (P = 0.499),
stroke laterality (P = 0.396) and handedness (P = 0.268)"
Interventions Group 1: experimental (n = 24 full baseline assessment; n = 20 at follow-up assessment)
Intervention type: assessment or screening. Materials: modified screening form. Where can materi-
als be accessed? Screening form (modified) available from the Visual In Stroke (VIS) study (Rowe 2010).
Procedures: "all participants underwent a full visual assessment by an orthoptist. The findings from
the visual assessment were ... made available to the therapy staJ for participants in group B (experi-
mental group)". "participants in both groups received occupational therapy and physiotherapy". "Ther-
apy routinely included working to regain motor activity and increase ability to achieve valued function-
al tasks. The therapists used strategies such as visual scanning and cueing to the affected side as part
of their practice". Treatment in the experimental group was informed by the results of the visual as-
sessment. Provided by: orthoptists. No details provided about their training. Delivery: face-to-face, lo-
cation Inpatient, stroke unit (Table 1). Regimen: not stated. Tailoring: yes. Details not supplied. Modi-
fication: not stated. Adherence: not stated
Group 2: control (n = 27 full baseline assessment; n = 19 at follow-up assessment)
Intervention type: control/standard care. Materials: NA.Where can materials be accessed? NA. Pro-
cedures: described above. Treatment in the control group was not informed by results of the visual as-
sessment ("all participants underwent a full visual assessment by an orthoptist. The findings from the
visual assessment were withheld from the therapy staJ in group A (control group)"). Provided by: OT,
physiotherapy. No details provided about their training. Delivery: face-to-face, individual, location in-
patient (Table 1). Regimen: NA. Tailoring: NA. Modification: NA Adherence: NA
Outcomes See Table 4
Functional independence measure (FIM)
Timed 10 m walk
Non-validated questionnaire ("Therapist with the most contact with each participant was asked to
complete a non-validated questionnaire giving qualitative information about their treatment ap-
proach." "Two versions of this questionnaire. The group A questionnaire asked the therapist to justify
their treatment approach. The group B questionnaire required the therapist to comment on whether
their treatment approach had been influenced by the visual assessment").
Time points when outcomes were assessed: "baseline and at 6 weeks after baseline (or on discharge
if this occurred earlier)"
Notes Review author Fiona Rowe was involved in this trial.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk "computer generated randomization table. The randomization process was
administered by a researcher at the University of Liverpool, who was not in-
volved in data collection but was involved in the later data analysis. Partici-
pants were masked to group allocation, but the assessors were not masked in
this trial".
Blinding (performance
bias and detection bias) 
All outcomes
High risk "Participants were masked to group allocation, but the assessors were not
masked in this trial."
"The qualitative study indicated an inherent bias had been introduced to this
trial, due to the inability to blind carers, and assessors to group allocation. The
health care team perceived that the presence of a full baseline vision assess-
ment enhanced their awareness of the effect of visual deficits following stroke.
Jarvis 2012  (Continued)
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This was regardless of whether or not the full visual assessment details were
available."
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No intention-to-treat analysis. Dropouts were clearly reported, but reason for
not attending was not clear and could be related to the intervention.
Other bias Low risk No other concerns noted
Jarvis 2012  (Continued)
 
 
Methods Restitutive intervention versus restitutive intervention
Design: RCT (cross-over)
Stratification: no
Randomisation sequence: no details reported ("randomly assigned them into 2 groups")
Comparisons: 2 groups, extrastriate vision restoration therapy versus conventional vision restoration
therapy
Allocation concealment: not stated
Blinding: "double-blind"
Power calculation: no
Intention-to-treat analysis: no
Other recruitment details: none
Patient and public involvement: no
Participants Total study population: 21 (mixed population) participants, with visual field defects, lesions over 1
year old
Group 1: 8 participants, Group 2: 10 participants. The study included a mixed population.
Withdrawals: "Three patients had to be excluded from the analysis. One male patient (patient 19) used
another vision therapy program not included in this study. Another patient (patient 20) was excluded
because he discontinued the training for more than 4 weeks during the trial and a female patient (pa-
tient 21) showed poor fixation performance (70% rather than the minimally required 90%)."
Method of diagnosing VFD: high-resolution perimetry and "common static perimetry diagnosis at
their own ophthalmologists office". Method of diagnosing visual perceptual problems: not stated
Characteristics of population: participant details are listed in Table 2
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: at least 6 months prior experience of vision restoration therapy
Exclusion criteria: none listed
Baseline comparison of treatment groups: yes
Interventions Group 1: extrastriate vision restoration therapy (VRT) (n = 8)
Intervention type: restitution. Materials: extrastriate vision restoration therapy - not stated where
this could be accessed/acquired
Jobke 2009 
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Procedures: stimulation of the "entire blind area with a massive moving spiral", plus standard VRT
in areas of residual vision. "The spiral consisted of concentric circles which moved with a frequency
of 2.5 Hz, and increased in width to generate the perception of motion". "Additionally, areas of resid-
ual vision (relative defects) were stimulated by standard VRT, i.e. the common single-point stimulation
paradigm. Just like in standard VRT, the patient had to respond to the white target stimuli presented
at random locations in areas of residual vision." Provided by: not stated. Delivery: training carried
out at home by participants (Table 1). Regimen: extrastriate VRT, 1/2 hour daily for 90 days Tailoring:
Yes. "The size of the training area varied from patient to patient according to the size of the visual field
defect". Modification: Yes: "Every week the patients completed a self-administered diagnostic test
at home and sent their data to the institute for updating the training region if necessary. Adherence:
"Training breaks of longer than 2 weeks led to exclusion of the patient."
Group 2: conventional vision restoration therapy (VRT) (n = 10)
Intervention type: restitution. Materials: standard visual restoration therapy - not stated where this
could be accessed/acquired. Procedures: standard vision restoration therapy consisted of single white
target stimuli, presented at random in areas of residual vision. The participant had to respond to the
white target stimuli presented at random locations in areas of residual vision. Provided by: not stated.
Delivery: training carried out at home by participants (Table 1). Regimen: conventional vision restora-
tion therapy, 1/2 hour daily for 90 days. Tailoring: see above. Modification: see above. Adherence: see
above
Outcomes See Table 4
High-resolution perimetry
Perimetry: common static perimetric diagnosis at own ophthalmologist
Near visual acuity: Radner reading test
NEI-VFQ
Zahlen-Verbindungs test: speed of connecting numbers in a paper-pencil test
Time points when outcomes were assessed: before and after each cross-over period
Notes 1. "All patients had used VRT for at least 6 months (range from 6-36 months) prior to study entry and
were therefore experienced participants. We were aware that this might reduce the power of the ther-
apy because of a possible 'ceiling effect'. To eliminate training bias, no patient carried out VRT during
the 6 months preceding the study". But this also means that this was potentially a very selective group
of patients, i.e. those who were motivated to continue using VRT after an initial experience. Therefore,
it may be inappropriate to generalise from this study to the general population of patients with visual
function defects. There was no data on the type or length of each participant's previous VRT (just the
range of 6 to 36 months), and if there were previous changes in the functions measured in this test. In
his previous paper on VRT, (Kasten 2001) concluded that patients can be split into 3 main types after
scanning training: 1) those whose field increases both during and after training, 2) those whose field in-
creases during training, but decrease afterwards, and 3) those who show no change at all. If true, this
would impact on the results of this study, as types 1) and 3) do not benefit from further training.
2. Participants did not use their glasses for treatment and measurements. Measurements included a
measure of near visual acuity; given the age of patients, most will be presbyopes, so will struggle with
this task, dependent on age and prescription.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Quote "random assignment", no further details given
Blinding (performance
bias and detection bias) 
Unclear risk "Double-blind" was in the title, but no further information appeared in the pa-
per
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 3 participants excluded from analysis and not included in demographic de-
tails. "One patient used another vision therapy program not included in this
study. Another patient was excluded because he discontinued the training
for more than 4 weeks during the trial and a patient showed poor fixation
performance (70% rather than the minimally required 90%)." Some of these
dropouts may have occurred because of an issue directly associated with the
intervention studied
Also, missing data for standard perimetry measures
Other bias High risk Researchers may have had financial interest in intervention being investi-
gated. Poggel 2004 stated "BA Sabel and E Kasten are inventors. BA Sabel is
a consultant and shareholder of NovaVision Inc, and has equity in excess of
$10,000."
Jobke 2009  (Continued)
 
 
Methods Restitutive intervention versus control, placebo or no intervention
Design: RCT
Stratification: not stated
Randomisation sequence: not stated; correspondence with author did not provide any further detail
Comparisons: visual restitution training (computer-based training) versus placebo (fixation training
program)
Allocation concealment: stated "randomly assigned (double-blind)"; no further details
Blinding: "double-blind"
Power calculation: no
Intention-to-treat analysis: no (1 dropout from placebo group)
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 19
Withdrawals: 1 ("one patient from the placebo group failed to meet the requirement to train for 150 h.
This patient dropped out of the study").
Method of diagnosing VFD: high-resolution perimetry and Tubinger automated perimetry
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: "patients had to have both a visual-field defect and post-chiasmatic or optic nerve
damage as shown by CT, MRI, surgical records or ophthalmoscopic documentation of optic nerve atro-
phy".
Exclusion criteria: insufficient fixation ability, neglect, non-optic nerve heteronymous visual field de-
fect, disorders of the eye, no residual vision, no visual deficit, age > 75 years, age < 18 years, died, lesion
age < 12 months, epilepsy or photosensitivity, cognitive deficits, not willing to participate in trial, no
shows after initial screening
Kasten 1998 
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Baseline comparison of treatment groups: baseline comparison was presented for combined groups
of 19 post-chiasmatic injury participants and 19 participants with optic nerve injury (see notes below).
Interventions Group 1: visual restitution therapy (n = 9)
Intervention type: restitution. Materials: computer-based training. Procedures: during vision
restoration therapy, the participant maintained fixation on a central fixation spot, with their "visual
border zone" stimulated by repetitive stationary stimuli of varying luminance presented in a random
location within this border zone. Provided by: not stated. Delivery: training was carried out on a per-
sonal computer placed in a darkened room at home. (Table 1). Regimen: 1 hour per day, 6 days per
week for 6 months (a total of 150 hours required). Tailoring: yes "compliance checks and adjustments
of training difficulty level were done monthy". Modification: yes "we used an individually adapted
training protocol, which was determined by the characteristics of the transition zone". Adherence: a
total of 150 hours was required (compliance checks done monthly).
Group 2: placebo (fixation training) (n = 10)
Intervention type: placebo.Materials: computer-based training.Procedures: the fixation training pro-
gram required "eye movements to stimuli near the foveal region for a comparable amount of time".
Provided by: not stated.Delivery: training was carried out on a personal computer placed in a dark-
ened room at home. (Table 1). Regimen: 1 hour per day, 6 days per week for 6 months (a total of 150
hours required).Tailoring: not stated. Modification: not stated. Adherence: a total of 150 hours was
required (compliance checks done monthly).
Outcomes See Table 4
Visual field: high-resolution perimetry
Visual field: Tubinger automated perimetry
Visual acuity: Landolt ring to give minimum angle of resolution
Quality of life questionnaire
Notes 1. Reports of this trial combined data from the trial of 19 post-chiasmatic injury participants with data
from a trial of 19 participants with optic nerve injury. However, within the paper it did state "The data
reported here are from two independent clinical trials each with an experimental and a control group.
In the first trial, two groups of optic nerve injury patients ... In the second trial, patients with post chias-
matic injury were randomly assigned ...". It is the second trial which is included in this review. However,
baseline characteristics (age, gender, size of visual field deficit) were only available for the 2 trials com-
bined ... i.e. from 38 participants, 19 of whom had optic nerve injuries and who were not relevant to this
trial/review.
2. This study included a mixed population of patients and there was no separate data for stroke. There
was an uneven distribution of stroke patients between the groups, with only 2/9 in Group 1 and 8/10 in
Group 2.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Stated that participants were randomly assigned (double-blind). No further
details of method of randomisation. Correspondence with the author gave
the further detail that while participating in the study the participants did not
know which of the treatments were expected to produce effects.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Stated "(double-blind)", but no further information provided in the paper. Cor-
respondence with the author stated that it was a different person performing
the tests than the person who gave the training
Kasten 1998  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk "One patient who failed to meet the requirement to training for a total of 150
hours. This patient dropped out from the study". Data for this participant ap-
peared to be included in baseline data but did not say if included in final as-
sessment data; the implication was no. Visual acuity reported to be performed
but no data were presented.
Other bias High risk Researchers may have financial interest in intervention being investigated.
Poggel 2004 stated "BA Sabel and E Kasten are inventors. BA Sabel is a consul-
tant and shareholder of NovaVision Inc, and has equity in excess of $10,000".
Kasten 1998  (Continued)
 
 
Methods Restitutive intervention versus restitutive intervention
Design: RCT
Stratification: not stated
Randomisation sequence: "Patients were assigned randomly to one of 3 groups", method of randomi-
sation not stated. Correspondence with author did not provide any further detail.
Comparisons: "Three experimental groups: Group I: parallel co-stimulation (n = 7); Group II: moving
co-stimulation (n = 7); and Group III: single stimulation (n = 9)".
Allocation concealment: not stated: ("Patients were informed that the effectiveness of three different
programs for visual field training was being studied and that there was no placebo group".
Blinding: not clear: Correspondence with the author stated that it was a different person performing
the tests than the person who gave the training.
Power calculation: no
Intention-to-treat analysis: no ("A total of 5 patients had to be excluded after baseline examinations
for one or more of the following reasons: fixation deficits, noncompliance to the training procedure,
other treatments that may have had influenced their training, or illness during the trial.")
Other recruitment details: not stated
Patient and public involvement: no
Participants Total study population: 28 considered; data available for 23
Withdrawals: "A total of 5 patients had to be excluded after baseline examinations for one or more of
the following reasons: fixation deficits, noncompliance to the training procedure, other treatments that
may have had influenced their training, or illness during the trial."
Method of diagnosing VFD: high-resolution perimetry and Tubinger automated perimetry
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3
Inclusion criteria: patients aged 18 to 75 years with a stable homonymous visual field defect resulting
from CNS lesion, of greater than 6 months. Visual fields had to have matching deficits of both eyes on
monocular perimetry plus structural damage of post-chiasmic visual system as documented by MRI/CT
or medical reports.
Exclusion criteria: total blindness, central scotomata, lesions of the optic nerve or chiasma, insuffi-
cient fixation, other visual diseases, visual neglect, motor disturbances, cognitive deficits, psychotic
episodes, or epilepsy. Method of diagnosing visual perceptual problems: "Zahlen-Verbbinbungd test"
and "alters-Konzentrationstest"
Kasten 2007 
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Baseline comparison of treatment groups: 23 causes of lesions were: 14 with vascular disease,
stroke, cerebral haemorrhage or ischaemia; 8 with trauma; 1 with inflammation.
Interventions Group 1: parallel co-stimulation (n = 7)
Intervention type: restitution (2 stimuli presented simultaneously). Materials: training programs ran
on commercially available personal computers. Procedures: "visual field training was completed at
home after initial examinations and instruction sessions were carried out in our laboratory". Provid-
ed by: not stated. Delivery: "All three training conditions had the following features in common: While
the patient had to watch a fixation control, a target stimulus (adjustable between about 0.5°and 1.5°
diameter, 100 cd/m2) was presented repeatedly in a predetermined intact part of the border region of
the dark screen (adjustable between < 1 cd/m2 up to 50 cd/m2). Upon detection of the target stimulus,
the patient was required to respond as soon as possible by pressing the spacebar of the computer key-
board. Then the stimulus moved some degrees towards the blind area. If the patient still perceived the
stimulus, this had to be acknowledged by pressing the spacebar again; the stimulus then moved again
some degrees into the direction of the blind area and so forth. This procedure was repeated until the
patient was unable to see the stimulus in the absolute blind field. At this “blind” position the stimulus
was then presented 10 times. Thereafter, stimulation started at another predetermined position of the
border region (see also “transition zone”, Kasten 1998b), and the stepwise stimulation process moving
from intact to blind visual field regions was repeated. Standardized variables throughout training pro-
cedures in all patients were size and luminance of stimuli and background luminance." (Table 1). Reg-
imen: 30 minutes twice per day for three months. Tailoring: yes. "the trained area was individually ad-
justed to the patient’s visual field border". "Other variables were adjusted individually according to the
visual defect — for example, the location of fixation control, the location to start stimulation, the direc-
tion of stimulation, the frequency of fixation controls, and whether feedback upon responding was ac-
companied by a tone. Accordingly, training parameters were adjusted to the individual pattern of resid-
ual vision."
Modification: yes "Each month (if necessary even more often), results stored on the disc were ana-
lyzed, and the training area was readjusted, based on the progress of the patients". Adherence: "After
each session, data were saved automatically on a disk to control compliance".
Group 2: moving co-stimulation (n = 7)
Intervention: restitution (2 stimuli presented, with 1 nearer the blind area "running" continually be-
tween intact and lost field). All other intervention details as Group 1
Group 3: single stimulus (n = 9)
Intervention: Restitution (only a single stimulus was presented). All other intervention details as
Group 1
Outcomes See Table 4
Visual field: high-resolution perimetry (number of hits, learning effects, fixation ability, false hits)
Visual field: Tubinger automated perimetry at 30 and 90 degrees (no of hits, fixation ability)
Eye movements: "Chronos Vision Eye Tracker"
Visual acuity
Subjective visual ability questionnaire
Attention: "Zahlen-Verbindungs Test" of visuo-spatial attention
"Alters-Konzentrationstest" attention test for older people
"testbatterie zur Aufmerksamkeitspruefung" ability to improve attention
Notes 1. This study included a mixed population of patients and there was no separate data for stroke.
2. Visual acuity at 40 cm was measured without glasses.
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Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Quote "participants were randomly assigned to one of three experimental
groups", no further information on method given. Correspondence with the
author gave the further detail that participating the patients did not know
which of the treatments were expected to produce effects.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Correspondence with the author stated that it was a different person perform-
ing the tests than the person who gave the training.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk "A total of 5 patients had to be excluded after baseline examinations for one or
more of the following reasons: fixation deficits, non-compliance to the training
procedure, other treatments that may influence training, illness during the tri-
al". No data were provided for these participants.
Other bias High risk Researchers may have had financial interests in intervention being investi-
gated. Poggel 2004 stated " BA Sabel and E Kasten are inventors. BA Sabel is
a consultant and shareholder of NovaVision Inc, and has equity in excess of
$10,000".
Kasten 2007  (Continued)
 
 
Methods Compensative intervention versus compensative intervention
Design: parallel-group RCT
Stratification: "To achieve a nearly balanced number of patients with quadrantanopia in each group,
the assignment of quadrantanopic patients between treatment groups was alternated, resulting in 3
patients in the AVT group and 4 patients in the VST group".
Randomisation sequence: random number algorithm
Comparisons: 2 groups, audiovisual stimulation training (AVT) versus visual stimulation training (VST)
Allocation concealment: not stated
Blinding: no detail provided about blinding of patients, caregivers or assessors
Power calculation: not stated
Intention-to-treat analysis: not stated
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 20 with unilateral lesions of the occipital lobe confirmed by MRI. Not all par-
ticipants had VFD as a result of stroke. 18/20 stroke; 1/20 tumour and 1/20 TBI
Withdrawals: none
Method of diagnosing VFD: Goldmann perimeter examination. Visual field assessment was done using
the kinetic method with suprathreshold checks. Measured before and after training. "Pre–post compar-
isons of visual field defects were classified as stable in all patients".
Characteristics of population: participant details are listed in Table 2.
Keller 2010 
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Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: "leM- or right-sided visual field deficits primarily caused by stroke" (as confirmed by
MRI). Normal bilateral hearing measured by audiometry with no asymmetry between ears, normal or
corrected binocular visual acuity.
Exclusion criteria: visual neglect or signs of aphasia ("Patients were initially tested with 3 different ne-
glect tests (line bisection, Mesulam test, draw a clock face test) and the token test")
Baseline comparison of treatment groups: "Both groups were comparable with regard to demo-
graphic and clinical variables before treatment".
Interventions Group 1: audiovisual exploration training (AVT) (n = 10)
Intervention type: compensation. Materials: red light-emitting diodes (LEDs), piezoelectric loud-
speakers, white-noise generator, laptop computer using a custom-made software for this purpose.
Where can materials be accessed? not stated.Procedures: "training sessions were conducted in a
dimly illuminated room. The patients sat in chairs 60 cm in front of the apparatus, with their eyes ad-
justed to the center of the apparatus. Stimuli to the blind visual field and intact visual field were pre-
sented in random sequence. Patients were instructed to detect the presence of visual targets by press-
ing a response button as fast as possible. To prevent patients from reacting to false positives, 20%
catch trials with solely acoustic stimulation were implemented in each training session. Whenever pa-
tients responded to a catch trial, a computer-generated 'nickering' of a horse sounded. Patients were
explicitly instructed to execute eye movements with their head held straight forward. Training was car-
ried out under binocular conditions". Provided by: not stated. Delivery: face-to-face, individual, loca-
tion inpatient (Table 1). Regimen: 20 therapy sessions (each session lasting 30 minutes) over 3 weeks.
Tailoring: yes. Based on type of VFD ("For patients with homonymous hemianopia, 70% of all stim-
uli were presented in the blind visual field. For patients with quadrantanopia, 70% of the stimuli were
presented in the 2 upper or 2 lower rows of the affected side"). Modification: yes, "whenever a patient
complained of tiredness, the training was interrupted for 1 minute". Adherence: not stated
Group 2: visual exploration training (VET) (n = 10)
Intervention type: compensation. Materials: as described for AVT. Where can materials be accessed?
not stated. Procedures: "settings of stimuli presentation were identical as for the AVT, with the excep-
tion that the sound was turned oJ during all training sessions and catch trials were not needed". Pro-
vided by: not stated. Delivery: face-to-face, individual, location inpatient (Table 1). Regimen: 20 ther-
apy sessions (each session lasting 30 minutes) over 3 weeks. Tailoring: yes. Based on type of VFD ("For
patients with homonymous hemianopia, 70% of all stimuli were presented in the blind visual field. For
patients with quadrantanopia, 70% of the stimuli were presented in the 2 upper or 2 lower rows of the
affected side"). Modification: yes, "whenever a patient complained of tiredness, the training was inter-
rupted for 1 minute". Adherence: not stated
Outcomes See Table 4
Visual field: Perimetry - Goldmann kinetic and suprathreshold
Visual exploration test
Reading test
Search task
Evaluation of ADL
Electro-oculography
Time points when outcomes were assessed: before and after treatment
Definitions relevant to outcomes: "Changes in visual fields defects were established by comparing
the pretraining visual field with the post-training visual field. Changes were classified as better, stable,
or worse. Better or worse were defined by differences of more than 5° horizontally or vertically".
Keller 2010  (Continued)
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
High risk Random number algorithm used to assign participants. However, it was also
stated that "To achieve a nearly balanced number of patients with quadran-
tanopia in each group, the assignment of quadrantanopic patients between
treatment groups was alternated, resulting in 3 patients in the AVT group and
4 patients in the VT group". This suggests that allocation was not concealed for
these participants.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No information was given on blinding of participants, or outcome assessors. It
is unlikely that personnel could be blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No mention of any dropouts
Other bias Low risk No other concerns noted
Keller 2010  (Continued)
 
 
Methods Restitutive intervention versus compensative intervention
Design: prospective randomised controlled, single-blind, single-center treatment study
Stratification: no
Randomisation sequence: "Patients were randomly assigned to receive either CT, RT, or OT. Random-
ization by throwing dice and allocation took place before starting with the initial assessment of neu-
ropsychological tests".
Comparisons: compensatory therapy (CT) versus restorative computerised training (RT) versus stan-
dard occupational therapy (OT)
Allocation concealment: no
Blinding: no ("All patients were recruited and assigned to treatment groups by a neuropsychologist.
The same neuropsychologist also tested the patients before (time point T1) and after (time point T2)
the treatment and was not blinded to the type of training. The training itself was performed by a psy-
chological assistant or by the occupational therapists not involved in the study, and they provided the
test results at T1 and T2."
Power calculation: yes
Intention-to-treat analysis: no dropouts
Patient and public involvement: not stated
Participants Total study population: 45 patients randomised
Withdrawals: 0
Method of diagnosing VFD: "a perimetry test from the Test Battery of Attentional Performance, the lat-
ter having a sensitivity and specificity for visual field defects similar to the Goldmann perimetry."
Modden 2012 
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Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: homonymous hemianopia with a posterior cerebral artery stroke
Exclusion criteria: visual neglect, eye-movement disorders, neuropsychological disorders like apha-
sia, dysexecutive syndromes, memory deficits, or higher order motor impairments like apraxia
Baseline comparison of treatment groups: "At baseline, the 3 groups did not differ in demographic
and neuropsychological measures".
Interventions Group 1: restitution therapy (RT) (n = 15)
Intervention: RT - computer-based stimulation of visual field
Intervention type: restitutive. Materials: computer-based restitution therapy: "A therapy-integrated
perimeter program (provided by Teltra company)". Procedures: "A therapy-integrated perimeter pro-
gram (provided by Teltra company) created the exact measurement of the individual visual field bor-
der. Using that measurement, a series of colored targets appeared on a blue screen anywhere at 1 of
10 positions on the border line. A randomly presented first fixation target (a rotating arrow) announced
the second stimulus target in the hemianopic border zone (basic principle of covert attention shiM).
The patients were instructed to respond (by pressing a key) to each stimulus target (colored and flick-
ering frames, beams, and spots) as soon it was perceived. The program contained no adaptive difficul-
ty levels. Eye movements were not allowed, and this was controlled by the assistant". Provided by:
"The training itself was performed by a psychological assistant or by the occupational therapists not in-
volved in the study". Delivery: face-to-face, individual, location rehabilitation centre: "The participants
in both PC-based therapy groups were seated 60 cm away from the screen (19-inch monitor) and had to
perform the tasks binocularly. As during testing, the head was fixed by a chin rest, the sessions were al-
ways controlled by the assistant to make sure that the instructions were followed." (Table 1). Regimen:
30 minutes/day for 15 sessions. Tailoring: no: "The program contained no adaptive difficulty levels."
Modification: no. Adherence: stated "no-one dropped out because of problems with compliance".
Group 2: compensatory therapy (CT) (n = 15)
Intervention: CT - computer-based stimulation of visual field
Intervention type: compensatory. Materials: computer-based: "The 'Exploration' task (from Re-
haCom, provided by HASOMED GmbH, Magdeburg, Germany)". Procedures: "The “Exploration”
task . . . . . . . . . . . was adapted individually according to the side of the hemianopia. On a dark back-
ground, different bright stimuli arranged in rows and columns were presented. A ring (diameter of 2
cm) moved line by line (interlaced) on a matrix unit over the field. The participant was instructed to fol-
low the ring (starting point to an outmost fixation in the blind side) by eye movements and to identi-
fy a critical targeted icon. The targets were not always distributed homogeneously but were clustered
in the blind side. Thus, the exploration in the hemianopic field was further promoted. The patients
had to respond (by pressing a key) when the targeted icon was perceived in the circle. Provided by:
"The training itself was performed by a psychological assistant or by the occupational therapists not in-
volved in the study". Delivery: face-to-face, individual, location rehabilitation centre: "The participants
in both PC-based therapy groups were seated 60 cm away from the screen (19-inch monitor) and had to
perform the tasks binocularly. As during testing, the head was fixed by a chin rest. The sessions were al-
ways controlled by the assistant to make sure that the instructions were followed." (Table 1). Regimen:
30 minutes/day for 15 sessions. Tailoring: yes: "The program contained several difficulty levels. In lev-
els 1 to 20, all lines were completely filled with symbols, whereas there were omissions in the rows of
symbols in levels 21 to 30 to increase the difficulty." Modification: not clear. Adherence: stated "no-
one dropped out because of problems with compliance".
Group 3. occupation therapy (OT) (n = 15)
Intervention: OT - standard occupational therapy
Intervention type: compensatory. Procedures: "After a standardized assessment of daily living activ-
ities, the therapy consisted of individually adapted stimulation of daily activity tasks to compensate
via eye-, head-, and body movements. These compensation strategies included aspects of spatial and
Modden 2012  (Continued)
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body perception, searching or arranging objects, pen and paper searching task, reading maps or news-
papers, and self-care activities. The participant was instructed to perform systematic eye movements
toward the lost visual field. The interventions were carried out in the treatment rooms, on the wards,
in a kitchen or a bathroom, outside in the park, or in a supermarket." Provided by: occupational ther-
apist. Delivery: face-to-face, individual, location rehabilitation centre: (Table 1). Regimen: 30 min-
utes/day for 15 sessions. Tailoring: yes: "After a standardized assessment of daily living activities, the
therapy consisted of individually adapted stimulation of daily activity tasks". Modification: not clear.
Adherence: stated "no-one dropped out because of problems with compliance".
Note: "Patients receiving RT and CT did not receive OT in the context of their standard rehabilitation
treatment."
Outcomes See Table 4
Visual field expansion - test battery of attentional performance visual field assessment
Visual search performance - cancellation
Reading performance - Weschler memory tests
ADL - Extended Barthel Index
Time points when outcomes were assessed: after completion of training
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
High risk Randomisation was by throwing a dice: no allocation concealment.
Blinding (performance
bias and detection bias) 
All outcomes
High risk No blinding: "All patients were recruited and assigned to treatment groups by
a neuropsychologist. The same neuropsychologist also tested the patients be-
fore (time point t1) and after (time point t2) the treatment and was not blind-
ed to the type of training. The training itself was performed by a psychological
assistant or by the occupational therapists not involved in the study, and they
provided the test results at t1 and t2."
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No dropouts
Other bias Low risk No other concerns noted
Modden 2012  (Continued)
 
 
Methods Restitutive intervention versus restitutive intervention
Design: "Randomised controlled, double-blind pilot trial"
Stratification: no
Randomisation sequence: "Participants were randomly assigned using a predetermined enrollment
sequence to 1 of 2 arms". Method of randomisation not stated. Correspondence with the author provid-
ed the information that "as subjects were admitted, they were randomly assigned to one of two groups
based on an a priori generated randomization strategy."
Plow 2010 
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Comparisons: 2 groups: vision restoration therapy with active transcranial direct current stimulation
(VRT + tDCS) and vision restoration therapy with sham transcranial direct current stimulation (VRT +
sham)
Allocation concealment: yes: "Participants and investigators analyzing visual field outcomes were
blinded to the tDCS mode (active versus sham)."
Blinding: yes: "Participants and investigators analyzing visual field outcomes were blinded to the tDCS
mode (active versus sham)."
Power calculation: not stated
Intention-to-treat analysis: no
Other recruitment details: "A total of 150 potential participants were screened. Following compre-
hensive neurological and ophthalmological screening, 12 patients ... were enrolled".
Patient and public involvement: not stated
Participants Total study population: 12
Withdrawals: 4
Method of diagnosing VFD: high-resolution perimetry
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: "Patients with unilateral postchiasmal visual field loss following stroke or brain
damage, who were in the chronic phase of recovery (> 3 months post-lesion)". Participants were "aged
over 18, with deep hemianopic field loss as defined and confirmed by monocular perimetry along with
established structural damage of the post-charismatic visual system as documented by standard neu-
roimaging techniques (CT or MRI), medical reports, or a combination of these. Participants also had
cognitive, language and motor function sufficient to understand the experiments and follow instruc-
tions, had given informed written consent to participate in the study and had motivation to participate
in the VRT program."
Exclusion criteria: "Any ocular visual pathology or contraindication to noninvasive brain stimulation
and tDCS. Specific criteria drawn from safety guidelines pertaining to the use of noninvasive cortical
stimulation include 1) the presence of any metallic, mechanical, or magnetic implant in the head or im-
plantable device (e.g. cardiac pacemaker); 2) prior history of seizure or familial history of seizure disor-
der in a first degree relative, and 3) chronic use of neuroactive medication (e.g. neurostimulants, anti-
convulsants, or antidepressants)."
Baseline comparison of treatment groups: not stated. Baseline data were provided, but no statistical
comparison. Time since stroke did not appear to be comparable, with the VRT + tDCS group mean, 20.8
months (SD 26.6, range 3 to 72 months), and VRT + sham group mean, 58.7 months (SD 72.9, range 10 to
192 months).
This study appeared to include participants with visual field defects only (no visual neglect), although
the method of ensuring no visual neglect was unclear
Method of diagnosing visual field defect: "monocular perimetry", no further details of method
Method of diagnosing visual perceptual problems: not stated
Interventions Group 1: visual restoration therapy + transcranial Direct Current Stimulation (VRT + tDCS) (n = 6; data
available for n = 4)
Intervention: computer-based stimulation of the visual field with active transcranial direct current
stimulation, 30-minute sessions twice per day, 3 times per week for 3 months of vision restoration ther-
apy and concurrent transcranial direct current stimulation of 2 mA/minute
Plow 2010  (Continued)
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Intervention type: restorative. Materials: computer-based restitution therapy: "Vision Restoration
Therapy (VRT; Novavision Inc, Boca Raton, Florida)", transcranial Direct Current Stimulation: "tDCS was
applied using two 5 × 7 cm2 saline-soaked sponge electrodes connected to a 9-V battery-driven stimu-
lator (IOMED Inc. Salt Lake City, Utah)". Procedures: vision restoration therapy: "Briefly, participants
were seated in front of a computer screen at a constant viewing distance and instructed to detect (sig-
naled by a key press) the presence of a flashed light stimulus while maintaining fixation on a central
target. Built-in fixation monitoring required patients to respond to a color change of the central fixa-
tion target occurring at random intervals. Target stimuli were presented primarily in the region of the
transition zone (identified by a prior visual field test; see details on high-resolution perimetry), and the
spatial parameters of customized therapy were determined based on weekly progress and results of
monthly tests." Transcranial direct current stimulation: "tDCS was applied using two 5 × 7 cm2 saline-
soaked sponge electrodes connected to a 9-V battery-driven stimulator delivering a constant current
of 2 mA for the entire duration of the training procedure. Following the 10-20 International EEG co-ordi-
nate system, the anode was placed at the occipital pole and the cathode (reference) was positioned at
the vertex. Electrodes were then secured using nonlatex rubber straps, and an identical montage was
worn by all patients throughout training." Provided by: University eye clinic. Delivery: face-to-face, in-
dividual, location University eye clinic (Table 1). Regimen: "We used a contracted VRT regimen lasting
3 months (2 half-hour sessions, separated by a 30-minute rest interval, for 3 d/wk)." Tailoring: not stat-
ed. Modification: not stated. Adherence: not stated
Group 2: visual restoration therapy + sham transcranial Direct Current Stimulation (VRT + sham) (n = 6;
data available for n = 4)
Intervention: computer-based stimulation of the visual field with sham transcranial direct current
stimulation, 30-minute sessions twice per day, 3 times per week for 3 months of vision restoration ther-
apy, transcranial direct current stimulation turned on for 30 seconds then ramped down to zero and
turned oJ. Intervention type: restorative. Materials: see above. "Experimental blinding with respect
to active or sham transcranial direct current stimulation was implemented according to standard pro-
tocol guidelines described previously". Procedures: see above. Provided by: see above. Delivery: see
above (Table 1). Regimen: see above. Tailoring: not stated. Modification: not stated. Adherence: not
stated
Outcomes See Table 4
Visual field - high-resolution perimetry: position of visual field border and stimulus detection accuracy
Visual field - subjective topograhic measure of perceived visual field deficit
Extended ADL - Veterans Affairs Low Vision-Visual Functional Questionnaire (LV-VFQ)
QoL - Vision Impairment (IVI) profile
Other - independent measure of fixation performance during training and HRP testing
Time points when outcomes were assessed: baseline and at completion of training (3 months)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk "Participants were randomly assigned using a predetermined enrollment se-
quence to 1 of 2 arms". Method of randomisation not stated. Correspondence
with the author provided the information that "as subjects were admitted,
they were randomly assigned to one of two groups based on an a priori gener-
ated randomization strategy."
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Correspondence with the author stated "the investigators assessing the visu-
al field results (primary outcome) were also blinded to patient group assign-
Plow 2010  (Continued)
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ment. Once visual field assessment was complete, they were provided with an
encrypted copy of the data without any identifying information".
Correspondence with the author stated "Blinding to stimulation (i.e. sham)
was maintained by exploiting the inherent properties of tDCS. All patients
wore the electrode montage regardless of the group they were relegated to.
When the tDCS unit is turned on, current is slowly ramped up until the target
current level is reached. During this time, patients will typically report a tin-
gling or itching sensation beneath the surface of the anode electrode (overly-
ing the occipital cortex). This sensation subsides shortly after a couple of min-
utes of habituation. Thus, in the experimental group, the current remains on
but in the sham control group, the current is turned oJ. In either case, the pa-
tient is not aware of this happening. This fact is exploited for the purposes of
experimental blinding since patients in the VRT + tDCS group can not perceive
sensation of stimulation and neither can those patients who are in the VRT +
sham tDCS group."
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There were 4 dropouts who were not included in data analysis. Reasons for
dropouts were provided, and were even between the groups. The author sup-
plied the following information: "Out of 12 patients who were enrolled into
the study, 4 (i.e. 2 from each group), were excluded or could not complete the
study. Here are the reasons: VRT + tDCS group: Patient 1 - excluded soon af-
ter randomization as she had an unrelated adverse event that excluded her
from participation; Patient 2 - excluded from analysis due to technical issues
that could not allow us to ascertain whether sufficient tDCS current was being
delivered throughout the training period. VRT + sham tDCS group: Patient 1:
did not receive allocated intervention due to onset of medication use that was
contraindicated with tDCS; Patient 2 - discontinued due to onset of a medical
condition that precluded her from further participation."
Other bias Low risk No other concerns noted
Plow 2010  (Continued)
 
 
Methods Restitutive intervention versus restitutive intervention
Design: prospective RCT
Stratification: no
Randomisation sequence: stated participants were "assigned randomly" but no details given. Corre-
spondence with author did provide any further detail.
Comparisons: 2 groups - visual restoration therapy (VRT) with attentional cueing, VRT without atten-
tional cueing
Allocation concealment: no - "Patients were not told which type of training they received; a dou-
ble-blind control was not possible owing to staJ limitations."
Blinding: no
Power calculation: no
Intention-to-treat analysis: no. 1 dropout, for whom no data was presented. Stated: "Patient 5 did not
participate in the training procedure owing to time constraints and is not listed here."
Other recruitment details: not stated
Patient and public involvement: not stated
Poggel 2004 
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Participants Total study population: 20 recruited (data available for 19)
Withdrawals: 1 ("Patient 5 did not participate in the training procedure owing to time constraints and
is not listed here.")
Method of diagnosing VFD: high-resolution perimetry and standard Tübingen Automated Perimetry
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: homonymous visual field defects after postgenicular lesions, age 18 to 75 years. Vi-
sual field size, assessed by high-resolution campimetry, had to be stable; that is, patients were includ-
ed only if visual field size increased or decreased by < 2% over at least 4 weeks before the study start-
ed".
Exclusion criteria: optic nerve, retinal or other ophthalmic disorders; mental deficits; impaired atten-
tion and neglect; psychiatric disorders; epilepsy and diseases with obvious visual or cognitive effect
Baseline comparison of treatment groups: not stated
This study included patients with visual field defects only (no visual neglect).
Method of diagnosing visual perceptual problems: not stated
Interventions Group 1: visual restitution therapy (VRT) with attentional cueing (n = 10)
Intervention: computer-based stimulation of visual field, with cueing
Intervention type: restitution
Materials: computer-based vision restoration therapy (Nova Vision, Magdeburg, Germany). Proce-
dures: a high-resolution computer-based campimetric test (high-resolution perimetry [HRP]; Nova Vi-
sion, Magdeburg, Germany) was used to assess visual field size and to determine ARVs.Training stim-
uli appeared on a dark computer screen, each target increasing in brightness in four steps from dark
gray (30 cd/m2) to bright white (96 cd/m2) over 2000 milliseconds. Stimulus size, fixation control, mode
of response, and viewing distance were identical to those used for HRP. For vision restoration therapy
with attentional cueing, the training stimulus was preceded by a large (12° x 12° visual angle) dim gray
cue frame enclosing a predetermined segment in the upper visual field that included parts of the intact
and blind fields as well as ARVs. The frame appeared for 200 milliseconds and was followed at a ran-
domised interval (mean stimulus onset asynchrony: 1000 milliseconds, range 750 to 1250 milliseconds)
by a training stimulus presented in the area that had been stimulated by the cue frame (the attention
field). In each training session, patients received 500 training stimuli. In the experimental group, ap-
proximately one-third of the trials, that is, those where the target was to be presented in the attention
field, were preceded by a cue. Targets were presented at random locations within the upper and the
lower visual fields. Depending on the percentage of stimuli detected, the duration of each training ses-
sion was approximately 30 to 35 minutes." Provided by: not stated.Delivery: training completed at
home using computer (Table 1). Regimen: "Patients performed the training in six training units, each
lasting approximately 1 month. A unit consisted of 56 sessions, with two sessions per day." Tailoring:
yes: "Each patient's ARV was determined based on five HRP tests. The training area was then adjusted
to the visual field border of that individual." Modification: not stated. Adherence: not stated ("Data
from each session were saved on a disk")
Group 2: visual restitution therapy (VRT) with no attentional cueing (n = 9)
Intervention: computer-based stimulation of visual field
Intervention type: restitution
Materials: see above. Procedures: see above.Provided by: see above. Delivery: see above. (Table 1).
Regimen: see above. Tailoring: see above. Modification: see above. Adherence: see above
Outcomes See Table 4
Poggel 2004  (Continued)
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Change in size of visual field:
Tubinger automated perimetry (TAP)
High resolution perimetry (HRP)
Time points when outcomes were assessed: at the end of each training unit (HRP), and after the 6th
training unit (HRP and TAP)
Notes Training and measurement were essentially the same thing.
Authors referred to Kasten 2001 as proof that control was not needed. They did not address his conclu-
sions on effects of training when recruiting from an already trained group - see Jobke 2009 above.
Outcome data was largely presented for all patients combined (control and experimental groups com-
bined)
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk "Patients were not told which type of training they received; a double-blind
control was not possible owing to staJ limitations" - the paper did not state
what methods (if any) were used to conceal the allocation from those enrolling
and assigning participants and correspondence with the author did not pro-
vide any further information.
Blinding (performance
bias and detection bias) 
All outcomes
High risk "Patients were not told which type of training they received; a double-blind
control was not possible owing to staJ limitations".
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 1 participant did not participate, none of his data were included in final analy-
sis. The co-author was not totally clear on the reason for non-participation, but
believed it to be another stroke.
Other bias High risk Researchers had financial interest in intervention being investigated: "BA Sa-
bel and E Kasten are inventors. BA Sabel is a consultant and shareholder of
NovaVision Inc, and has equity in excess of USD 10,000".
Poggel 2004  (Continued)
 
 
Methods Substitutive intervention versus control, placebo or no intervention
Design: RCT
Stratification: no
Randomisation sequence: "randomly assigned". Method of randomisation not stated
Comparisons: 2 groups; 15 diopter Fresnel prisms and control (no prisms)
Allocation concealment: no
Blinding: no, as the prism group wore their prisms during testing
Power calculation: no
Intention-to-treat analysis: not stated (not clear if any dropouts)
Rossi 1990 
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Other recruitment details: "39 patients with either homonymous heminaopia or unilateral visual ne-
glect were recruited from an inpatient stroke rehabilitation unit".
Patient and public involvement: not stated
Participants Total study population: 39
Withdrawals: none
Method of diagnosing VFD: tangent screen (inability to reliably detect a 1 cm red target on tangent
screen examination in a homonymous field pattern) and Harrington Flocks visual field screener
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: homonymous hemianopia or unilateral visual neglect and a diagnosis of stroke
based on clinical history, neurological exam and neuroimaging
Exclusion criteria: visual acuity worse than 20/200, unable to comprehend and co-operate with visual
field assessment, disabling cardiac, pulmonary or rheumatologic problems
Baseline comparison of treatment groups: yes
The study included only stroke patients.
This study included patients with visual field defects and/or visual neglect.
Method of diagnosing visual perceptual problems: neglect was confirmed by inability to reliably de-
tect bilateral tachistoscopically presented targets using the Harrington Flocks Visual Screener.
Interventions Group 1: 15 diopter Fresnel prisms (n = 18)
Intervention: prisms
Intervention type: substitution
Materials: plastic, press-on Fresnel prisms (stated these are "commercially available"). Procedures:
"Plastic press-on Fresnel prisms were trimmed to fit on the inside of the patients's spectacle lenses.
Each prism was cut to the shape of a half circle overlaying only the affected hemifield, with the base of
the prims toward the affected field". Provided by: not stated (university neurology department), De-
livery: face-to-face, individual, location inpatient (Table 1). Regimen: "Patients wore the prisms for all
daytime activities. Prism position and cleanliness were checked daily by study personnel. Patients were
restricted to ambulation 'with assessance only' for at least 1 day after the fitty of the prisms". Also "par-
ticipated in a routine stroke rehabilitation program including physical, occupational, and speech ther-
apy ... ADL training and table-top visual perception retraining tasks". Tailoring: no. Modification: no.
Adherence: not stated (stated "In practice, most patients tolerated the Fresnel prisms well after a day
or two")
Group 2: control (n = 21)
Intervention: no prisms
Intervention type: control
Materials: NA. Procedures: NA.Provided by: NA.Delivery: NA. Regimen: "participated in a routine
stroke rehabilitation program including physical, occupational, and speech therapy ... ADL training and
table-top visual perception retraining tasks". Tailoring: NA. Modification: NA. Adherence: NA
Outcomes See Table 4
Modified Mini Mental Status Examination
Motor free visual perception test
Rossi 1990  (Continued)
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Line bisection task
Line cancellation task
Harrington Flocks Visual Screener
Tangent Screen Examination
Barthel ADL score
Frequency of falls
Time points when outcomes were assessed: baseline, 2 weeks and 4 weeks
Notes 1. The length of time that the prisms were worn may vary considerably for different patients, as this
was for "all day time activities"
2. States that diagnosis of homonymous hemianopia precludes diagnosis of neglect - this is not current
thinking so must question diagnostic criteria especially with respect to neglect
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Patients were "randomly assigned" but methodology not stated.
Blinding (performance
bias and detection bias) 
All outcomes
High risk "the study was not performed in a blinded fashion", however for Tangent
Screen Examination "results were plotted onto templates and judged by ob-
server unaware of the patient’s group assignment ..."
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No incomplete data mentioned
Other bias Low risk No other sources of bias noted
Rossi 1990  (Continued)
 
 
Methods Compensative intervention versus restitutive intervention
Design: RCT
Stratification: no
Randomisation sequence: paper stated "an equal number of patients assigned randomly to either the
EST or the FT group"; and correspondence with the author stated that "the patients were randomized
according to a pre-existing list".
Comparisons: 2 groups; compensatory "exploratory saccadic training (EST)" and control ("flicker-stim-
ulation training (FT), which is unlikely to affect visual-search behaviour")
Allocation concealment: no
Blinding: not stated
Power calculation: no
Intention-to-treat analysis: no
Roth 2009 
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Other recruitment details: participants, aged 18 to 80 years, with post-chiasmatic lesions of greater
than 6 months duration and visual field defects that are isolated homonymous hemianopias or quad-
rantanopias. The study included a mixed population (mainly stroke).
Patient and public involvement: not stated
Participants Total study population: 30 participants recruited (data analysed for 28)
Withdrawals: "Two FT patients droppped out because of illness and insufficient compliance".
Method of diagnosing VFD: not stated.
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: visual field defects must not cross the vertical midline, but reach within 5 degrees of
it and there must be no other visual field defects, or visual acuity deficit.
Exclusion criteria: other visual field defects, visual acuity less than 0.6 (20/33), other diseases of eye or
brain, motor impairments hampering computer use, other neurologic impairments (particularly epilep-
sy or hemineglect)
Baseline comparison of treatment groups: "The groups did not differ regarding age, diagnoses or du-
ration of disease".
This study included a mixed population (mainly stroke). Group 1: 15 participants (12 stroke or haemor-
rhage, 3 other), Group 2: 15 participants (14 stroke or haemorrhage, 1 other)
This study included patients with visual field defects only (no visual neglect).
Method of diagnosing visual perceptual problems: clock drawing and line bisection test
Interventions Group 1: explorative scanning training (n = 15)
Intervention: computer-based scanning training
Intervention type: compensation
Materials: laptop. Where can materials be accessed? "A custom software program (Borland Delphi
7.0) was used to generate a random array of digits....". Procedures: random digits were presented with
equal distribution in blind and seeing fields: patients had to find these digits with positive feedback
provided for a correctly found number. Provided by: not stated. Delivery: face-to-face, individual, lo-
cation home-based training (Table 1). Regimen: training was performed for 30 minutes, twice per day,
5 days per week for 6 weeks at home, on a laptop set at 30 cm. Tailoring: no. Modification: no. Adher-
ence: protocols were used to attempt to ensure standardisation and patients were instructed to avoid
head movements. However, it is not know whether this standardisation and instructions were adhered
to. There may, therefore, be some inconsistencies in the delivery of the intervention. Errors in aspects
such as laptop position, etc. could impact on the position of the stimuli viewed and subsequently the
explorative eye movements.
Group 2: flicker-stimulation training (n = 15)
Intervention: computer-based training, "designed to stimulate the blind hemifield"
Intervention type: restitution (note - author stated this is 'potential' restitution training)
Materials: laptop. Where can materials be accessed? "Borland Delphi 7.0 was used to generate the
flicker stimulus". Procedures: letters flickering at 10 Hz were presented at 21.8 degrees eccentricity,
with proportion 3:1 blind:seeing field. Participant to maintain central fixation but identify peripheral
letter: positive feedback given of correctly identified letter. Provided by: not stated. Delivery: "The pa-
tients trained at home, using our laboratory’s laptops to ensure standard training conditions (screens,
fixed viewing distance, and visual-field area trained)" (Table 1). Regimen: training was performed for
30 minutes, twice per day, 5 days per week for 6 weeks at home, on a laptop set at 30 cm. Tailoring:
Roth 2009  (Continued)
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no. Modification: no. Adherence: patients were instructed to fixate. There appears to have been no at-
tempt to control or measure fixation.
Outcomes See Table 4
Digit search task (response time)
Natural search task (response time)
Natural scene exploration and fixation stability (video eye tracker)
Perimetry (Tubinger automated perimeter)
Reading speed
QoL - World Health Organisation questionnaire WHOQOL-BREF
Time points when outcomes were assessed: baseline, post-treatment, follow-up
Notes Inclusion criteria stated visual field defect with "duration exceeding 6 months". However, 1 patient in
group 2 was reported to have a 4-month-old homonymous hemianopia. Possibility of spontaneous re-
covery. Furthermore, this discrepancy casts doubt on the application of the selection criteria.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Correspondence with the author stated that "the patients were informed
that probably each method could be effective, one by eye movement training
(EST), the other by visual field stimulation (FT). FT was supposed to be a po-
tential restitution training. Therefore, the patients of both groups performed a
potentially effective training - but with quite different approaches".
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details in the paper or by contacting the author of whether or how assessor
was blinded
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Stated "two FT (Group 2) patients dropped out because of illness and insuffi-
cient compliance. Finally data from 15 EST and 13 FT patients were included".
Data from these participants were included in baseline characteristics, but not
included in final analyses.
Other bias Low risk No other cause of bias noted
Roth 2009  (Continued)
 
 
Methods Substitutive intervention versus compensative intervention versus control, placebo or no inter-
vention
Design: "Randomized controlled, multicentre pilot trial"
Stratification: "Randomization lists were generated using block randomization stratified by centre
and degree of hemianopia (partial or complete) with treatment allocation ratio of 1:1:1."
Randomisation sequence: "Participants were individually randomized to one of three treatment
groups using a secure (24-hour) web-based randomization programme."
Comparisons: 3 groups: Group 1 - Fresnel prisms; Group 2 - visual search training; Group 3 - control
(standard care/information only)
Rowe 2010 
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Allocation concealment: treatment allocation was disclosed to the patient by the treating clinician:
"The local PI (orthoptist) obtained the treatment allocation and subsequently assigned the participant
to the treatment arm."
Blinding: outcome assessors for visual field assessment and reading speed were blind to treatment al-
location. "due to the nature of the intervention, it is not possible to blind other study personnel or the
participant."
Power calculation: no - pilot trial; designed to enable sample size calculation for future trials
Intention-to-treat analysis: "Outcome data were analysed according to the intention-to-treat princi-
ple."
Other recruitment details: "Participants were recruited from stroke units based in 15 United Kingdom
(UK) National Health Service (NHS) trusts. Potentially eligible participants were identified by stroke re-
search nurses, and screened for inclusion by a local principal investigator (a qualified orthoptist reg-
istered with the Health and Care Professions Council, UK). Participants eligible for inclusion, and pro-
viding consent, attended for a baseline assessment, which included assessment and documentation of
patient demographics, visual signs and symptoms, visual acuity measures, any additional ocular prob-
lems, comorbidity, severity of stroke and level of disability".
Patient and public involvement: protocol stated: "This trial has involved a stroke survivor directly in
the development of this protocol (JR) and will liase closely with her for advice and direction throughout
the conduct of the trial and in the dissemination process. Involvement of stroke survivors in oversight
committees is also planned for this trial".
Participants Total study population: 87 participants randomised. 71 participants at 26-week follow-up
Withdrawals: 2 "complete withdrawal" ("patients withdrawn from all data analysis and follow-up"). 9
"partial withdrawal" ("patients withdrawn from follow-up"). 5 loss to follow-up
Method of diagnosing VFD: "Stable homonymous hemianopia (partial or complete) induced by recent
stroke, defined following WHO guidelines". "The visual field assessment will be conducted by a quali-
fied Orthoptist at baseline and at the 6-week, 12-week and 26-week follow-up visits. An Esterman strat-
egy is to be used for quantitative visual field assessment. This can be performed using either: The Es-
terman programme on Humphrey or Octopus perimetry; The III4e target on Goldmann with additional
checks of static points in the central visual field."
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: "a. 18 years of age or older; b. best corrected visual acuity of 0.5 or better in each
eye at distance; c. stable homonymous hemianopia (partial or complete) induced by recent stroke, de-
fined following WHO guidelines, present over 2 weeks (to exclude rapid recovery cases) but less than 26
weeks prior to randomization; d. refractive error within ± 5 dioptres; e. willing and able to give consent
for the study; f. prior to stroke able to read and understand English."
Exclusion criteria: "a. unable to consent due to severe cognitive impairment; b. assessed to have oc-
ular motility impairment and/or visual inattention in addition to the visual field impairment; or c. had
pre-existent visual field impairment due to previous stroke."
Baseline comparison of treatment groups: "There were no notable differences at baseline between
three arms."
This study included patients with visual field defects only (no visual neglect).
Method of diagnosing visual perceptual problems: "as assessed by the orthoptist"
Interventions Group 1: prisms (n = 27)
Intervention: Fresnel prisms (40 prism dioptre strength)
Intervention type: substitution
Rowe 2010  (Continued)
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Materials: "Participants were assessed and given sector Fresnel prisms of 40 prism dioptre strength on
their glasses (or plain glasses if not already worn). Separate prism segments were used as a mechan-
ical displacement to expand the upper and lower quadrants." Where can materials be accessed? In
the UK: NHS supplies for Fresnel prisms. Procedures: "The participant will be instructed to maintain
central fixation through their glasses. They will then be instructed to use head movements to explore
their field to the affected side when they become aware of an object of interest through the prism. The
first prism will be placed at the participant’s first visit; if possible the second prism will also be fitted at
this time. However, if the participant is not comfortable with both prisms being fitted at once, the sec-
ond prism can be placed at a second visit (2 weeks later, ± 1 week) if no adaptation difficulties to the
first prism have occurred. If adaption difficulties have occurred the patient can continue with only the
first prism and this will be captured on the case report forms." Provided by: orthoptist. Delivery: face-
to-face, clinic location (patients could be in or outpatients). (Table 1) Regimen: "The prisms should be
worn for a minimum of 2 h daily from prism affixation until 6-week follow-up visit as a minimum, af-
ter this the patient can elect to continue treatment if they wish." Tailoring: no. Modification: no. Ad-
herence: "There were 73 protocol deviations in 58 patients (68.2% overall: 77% in the Fresnel prisms
arm, 93% in the visual search arm and 34.5% in the standard care arm). The majority of deviations (n =
41, 56.2%) related to lack of compliance in the intervention arms (e.g. prism not worn a minimum of 2
hours daily for 6 weeks or visual exercises not carried out for 30 minutes daily for 6 weeks). Compliance
level was similar across the intervention arms. Patients in the Fresnel prisms arm wore the prisms dur-
ing 27 days on average."
Group 2. scanning training (n = 30)
Intervention: "visual search training"
Intervention type: compensatory (scanning) training
Materials: "Comprised an A4 landscape card with horizontal and diagonal numbered circles radiating
out from a central fixation target." Where can materials be accessed? From author. Procedures: "The
participant will be instructed to hold this at a distance of 8 inches from their eyes (to ensure a wide field
of vision is utilised), glasses can be worn as required. Participants will be asked to transfer gaze quick-
ly between printed targets on the A4 card. The targets are printed oJ centre to the right and leM sides
along the horizontal as well as oblique planes to ensure stimulation of a wide area in the blind and see-
ing parts of the visual field." Provided by: instructions provided by orthoptist. Training carried out at
home by patients. "Participants will be instructed on the scanning exercises following randomisation
to ensure their understanding of the procedure of doing this training. In addition, printed instructions
will be provided with the visual training target card". Delivery: home (self-adminstered) (Table 1). Reg-
imen: "Participants will be instructed to continually scan between the various targets for 30 min dai-
ly from baseline until their 6-week follow-up, after which they can elect to continue treatment if they
wish." Tailoring: no. Modification: no. Adherence: "There were 73 protocol deviations in 58 patients
(68.2% overall: 77% in the Fresnel prisms arm, 93% in the visual search arm and 34.5% in the standard
care arm). The majority of deviations (n = 41, 56.2%) related to lack of compliance in the intervention
arms (e.g. prism not worn a minimum of 2 hours daily for 6 weeks or visual exercises not carried out for
30 minutes daily for 6 weeks). Compliance level was similar across the intervention arms ... patients in
the visual search training arm followed the visual search exercises 28 days on average."
Group 3: standard care (n = 30)
Intervention: advice only ("all three arms will receive the same information leaflets")
Intervention type: control
Materials: "Participants were given information leaflets from the UK Stroke Association and the UK
Royal National Institute for the Blind about visual impairment following stroke." Where can materi-
als be accessed? UK Stroke Association and the UK Royal National Institute for the Blind. Procedures:
standard care. Provided by: NA. Delivery: NA (Table 1). Regimen: NA. Tailoring: NA. Modification: NA.
Adherence: NA
Outcomes See Table 4
Visual field assessment
Reading ability (Radner reading test)
Rowe 2010  (Continued)
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Visual function questionnaire (VFQ 25-10)
Rivermead mobility index
Nottingham extended activities of daily living assessment
ED-5Q (a standardised instrument for measuring health outcome)
Short Form-12 (SF-12)
Adverse events
Time points when outcomes were assessed: baseline, 6-week, 12-week, and 26-week follow-up
Notes Review authors Fiona Rowe and Alex Pollock were involved in this study.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk "Participants were individually randomized to one of three treatment groups
using a secure (24-hour) web-based randomization programme. Randomiza-
tion lists were generated using block randomization stratified by centre and
degree of hemianopia (partial or complete) with treatment allocation ratio of
1:1:1. The local PI (orthoptist) obtained the treatment allocation and subse-
quently assigned the participant to the treatment arm."
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Participants and clinical personnel unable to be blinded due to the nature of
the intervention. Blinded outcome assessors
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Incomplete data all accounted for. Intention-to-treat analysis (where possible)
Other bias Low risk No other cause of bias noted
Rowe 2010  (Continued)
 
 
Methods Compensative intervention versus compensative intervention
Design: randomised cross-over trial
Stratification: no
Randomisation sequence: "randomly allocated"
Comparisons: 2 groups, Group A (VET followed by RT) and Group B (RT followed by VET)
Allocation concealment: not stated
Blinding: not stated
Power calculation: not stated
Intention-to-treat analysis: not stated
Other recruitment details: not stated
Patient and public involvement: not stated
Schuett 2012 
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Participants Total study population: 36: Group A: 17/18 stroke and Group B: 17/18 stroke. The study included a
mixed population.
Withdrawals: none
Method of diagnosing VFD: not stated
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: not stated (although the authors reported that "none of the patients had visual ne-
glect as assessed by tests in accordance with the Behavioural Inattention Test (line bisection, letter and
star cancellation, figure and shape copying, drawing from memory; Halligan 1991)." and "All patients
were native German speakers and had at least 5 years of education. All patients complained of moder-
ate to severe difficulties in reading and visual exploration and showed impaired performance in both
domains".
Exclusion criteria: cerebral visual disorders, including reduced visual acuity (< 0.90 for near and far
binocular vision), impaired spatial contrast sensitivity (Vistech contrast sensitivity test, 1988), visual
adaptation, disturbances of the anterior visual pathways or of the oculomotor system, macular disease
(according to ophthalmologic examination), aphasia, premorbid reading disorders, pure alexia (vertical
word reading test; Zihl 1995; Zihl 2011), impairments of visual–lexical numerical processing (horizontal
and vertical number reading; Zihl 1995; Zihl 2011), or verbal memory deficits
Baseline comparison of treatment groups: none ("before treatment, there were no differences be-
tween groups either for demographic and clinical variables or for reading and visual exploration perfor-
mance".) However, more participants with hemianopia in Group A compared with Group B (Table 3)
This study included patients with diagnoses other than stroke.
This study included patients with visual field defects only (i.e no neglect).
Method of diagnosing visual perceptual problems: "Behavioural Inattention Test (line bisection, let-
ter and star cancellation, figure and shape copying, drawing from memory; Halligan 1991)."
Interventions Group 1: visual exploration training (VET) (n = 18)
Intervention type: compensation
Intervention: "Visual exploration training: for improving visual exploration, we used standardized ver-
sions of the visual search paradigm (parallel and serial search mode)."
Materials: software-based reading and visual exploration training programmes (developed by Zihl
2011); training material was presented using a LCD monitor with a stimulus display.
Where can materials be accessed? not stated (but references provided). Procedures: "Patients were
systematically trained to use larger saccadic eye movements to gain a quick complete visual overview
as well as to develop and use a more efficient oculomotor visual exploration or scanning strategy that
can be flexibly adapted to the visual–spatial structure of the respective scene or environment. Training
material consisted of visual search displays extending 50° horizontally and 42° vertically. We used dif-
ferent target and distractor letters of varying similarity as stimuli. Stimulus size was 2.5°, and we used
the same colours for the training material and the monitor background as in the reading training. Each
training trial was composed of the presentation of a visual search display. Patients were instructed to
fixate on a cross in the centre of the monitor and to search, after its offset, for a single target letter (e.g.
‘T’) among distractor letters (e.g. ‘O’s) as accurately and quickly as possible. In target-present trials, the
patient was asked to press the leM mouse button, in target-absent trials, the right mouse button. Pre-
sentation and, thus, visual search time was unlimited (exhaustive visual search)." Provided by: treat-
ment was administered and supervised by the experimenter. No details about the training or experi-
ence of the experimenter.Delivery: not clear (Table 1). Regimen: "An individual training session last-
ed ˜45 min consisting of 10–15 practice units (20 trials each) and short or, if required, longer breaks
between units. Training was completed when patients reached a defined criterion (at least 90% cor-
rect responses) for any level of difficulty used. Patients required on average 12 training sessions, which
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were carried out within 2–3 weeks for each patient. . . .Visual exploration training: Group A: 12.3 ses-
sions (SD 3.4)." Tailoring: "In addition to varying letter similarity during the course of training, visual
search difficulty was also systematically increased by increasing the visual display size, i.e. the number
of stimuli, not the display area (15–20-item displays). This training protocol was adjusted to individual
reading performance and training progress. Modification: (see tailoring). Adherence: "Training was
completed when patients reached a defined criterion (at least 90% correct responses) for any level of
difficulty used".
Group 2: reading training (RT) (n = 18)
Intervention type: compensation
Intervention: reading training
Materials: "The treatment was performed using the software-based reading and visual exploration
training programmes as developed by Zihl 2011; training protocol and procedure were similar to our
previous studies (Schuett 2008; Zihl 1995; Zihl 2011). Training material was presented using a LCD mon-
itor with a stimulus display extending 50! horizontally and 42! vertically at a viewing distance of 115
cm." Where can materials be accessed? not stated. Procedures: "single words of different lengths,
ranging from 3 to 12 letters, were used as training material. Letter and digit size was 2.5, and width sub-
tended 1° ; spacing between letters (text material) was 0.4°. We used yellow for the training material
and a dark blue for the background. These size and colour specifications have been shown to allow
for comfortable reading and oculomotor training (Schuett 2008; Zihl 1995; Zihl 2011). Each training tri-
al was composed of the time-limited presentation of one single word in the centre of the screen. Pa-
tients were instructed to perceive each word as a whole before reading it aloud by intentionally shifting
their gaze, as quickly as possible, from the screen’s centre to the beginning (in cases with leM-sided vi-
sual field loss) or to the end (in cases with right-sided visual field loss) of each word. This paradigm al-
lows reading-related eye movements to be trained and reinforced by the patient’s normal internal vi-
sual feedback and feedback given by the experimenter. During the course of training, the length of the
presented words was systematically increased from 3- to 13-letter words. When a patient was able to
read at least 90% of the words of a given length correctly, presentation time was reduced from 1000
ms to 300–400 ms. The final training stage involved the randomized presentation of words of different
lengths. By adopting this procedure, patients were forced to make quicker and more efficient saccades
in order to perceive and read the whole word before its disappearance. In addition, patients learned
to flexibly adjust the size of saccades according to word length". Provided by: treatment was admin-
istered and supervised by the experimenter. No details about the training or experience of the experi-
menter. Delivery: not clear (Table 1). Regimen: "an individual training session lasted ˜45 min; it con-
sisted of 10 practice units (30 trials each) and short or, if required, longer breaks between units. Train-
ing was completed when patients reached a defined criterion (at least 90% correct responses) for any
level of difficulty used. Patients required on average 12 training sessions, which were carried out with-
in 2–3 weeks for each patient ... Group B (12.6 sessions, SD 2.4)." Tailoring: "training protocol was ad-
justed to individual reading performance and training progress". Modification: not stated. Adherence:
"Training was completed when patients reached a defined criterion (at least 90% correct responses) for
any level of difficulty used".
Outcomes See Table 4
Reading test (reading time and errors)
Visual exploration (cancellation task - time and errors)
Visual field assessment (Kinetic perimetry using a standard Tubingen perimeter)
Time points when outcomes were assessed: this was a cross-over trial. Time points before the
cross-over were: T1, initial assessment; T2, before treatment; T3, after the first training component.
(Additional time points - after the cross-over were: T4, after the second training component; T5, after a
follow-up interval). "Visual field assessment was carried out before and after treatment (T2 and T4)."
Notes  
Risk of bias
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Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Stated "randomly allocated". No further details on method of randomisation
or concealment
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk It was unclear whether there was participant and/or outcome assessor blind-
ing. However the "experimenter" delivered the intervention, and may there-
fore have taken the outcome measures.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No flow diagram, and no details of recruitment or retention
Other bias Low risk No other issues noted
Schuett 2012  (Continued)
 
 
Methods Compensative intervention versus control, placebo or no intervention
Design: randomised cross-over trial.
Stratification: "Because of the small number of patients entering the study, we wished to ensure that
the two treatment groups did not become unbalanced on a few key variables so patients were allocat-
ed using a modified minimization technique where cumulative measures of two factors (text reading
speed (≤ 90 or >90 wpm) and degrees of sparing of right foveal/parafoveal (0 or 2 degrees) vision) were
used to minimize the difference between the two groups."
Randomisation sequence: modified minimisation technique: "The weighting used for allocation to the
group with the lowest total was one. We describe the minimisation as modified because the first sub-
ject was not allocated randomly to either group, but deterministically placed in Group 1."
Comparisons: "Two-armed study with two therapy blocks in each arm: one group practiced reading
moving text (MT) that scrolled from right-to-leM, daily for two four week blocks (group 1), while the oth-
er had sham therapy (spot-the-difference) for the first block and then crossed over to MT for the sec-
ond."
Allocation concealment: personal communication with authors: "The allocation was concealed from
the persons recruiting into the study but not from the tester. The recruiter(s) did not know that the first
subject would be placed in group 1 but the tester did".
Blinding: personal communication with authors: "The tester was the first author (a psychologist). She
was not blind to the therapy. It was not possible to blind her to this as it was a behavioural therapy and
she was 'dispensing' this at each time point."
Power calculation: no
Intention-to-treat analysis: no
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 22 participants recruited, data for 18
Withdrawals: "three dropped out before completing therapy".
Method of diagnosing VFD: "Perimetry was performed twice, before and after completion of the thera-
py blocks (B and T4). Static fields were measured using the automated Humphrey field analyser II (Carl
Zeiss Group, California, USA) analysis of the central 10 degrees of vision (central 10-2 threshold test).
Dynamic fields were also measured using a Goldmann perimeter (Haag Streit, Köniz, Switzerland) when
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there were concerns over subject’s performance with the automated procedure (a false positive or false
negative response rate greater than 15%). The procedures for determining the amount of field sparing
were as reported previously. In the event of a discrepancy between the static and dynamic fields or pre-
and post-therapy changes, the opinion of the orthoptist who performed the tests (Ms Bronia Unwin)
was sought. The precision of the static perimerty is two degrees and all the patients fell into one of two
groups, either 0 or 2 degrees spared to the right of fixation."
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: not stated, but described as "participants with fixed homonymous right-sided visu-
al field defect that interfered with reading (hemianopic alexia)." "All the patients had a fixed homony-
mous defect that had been present for at least 3 months".
Exclusion criteria: not stated
Baseline comparison of treatment groups: some discrepancies between baseline characteristics of
groups. Length of time since symptom onset - all participants in Group 1 were over 1 year since onset
of symptoms; 4 participants in Group 2 were less than 1 year since onset (3 are 6 months or less). Aver-
age age at time of symptom onset was 43 years for group 1 (range 5 to 67 years) and 63 years for group
2 (range 39 to 78 years). "There were no differences between the groups on all of the variables" for gen-
eral neuropsychological assessments.
The study included a mixed population.
This study included patients with visual field defect only (no visual neglect).
Method of diagnosing visual perceptual problems: not stated
Interventions Group 1: optokinetic nystagmus inducing reading therapy (n = 11)
Intervention type: compensation
Intervention: horizontal scrolling text from right to leM to "induce small-field optokinetic nystagmus"
Materials: "The tapes were made by animating freely available text from a variety of Sherlock Holmes
stories (www.citsoft.com/holmes3.html) across a computer screen from right-to-leM (i.e. horizontal
motion was from the patients’ blind field into their seeing field), so-called Times Square presentation.
After some minor preparations, such as deleting hyphens and adding a few spaces after each sentence,
custom-written software was used to animate the text across the screen at a variable rate. The output
from the graphics card was connected to the video-input on a VHS video recorder to produce the tapes.
Tape speeds of: 85, 105, 143, 173, 205, 240, and 275 wpm were made with the text presented in Times
New Roman font, 24-point, black on white, scrolling across the middle of the screen." Where can ma-
terials be accessed? not stated. Procedures: participants were instructed to read and try to follow a
line of text scrolling horizontally from right to leM in the middle of a computer screen at speeds of 85 to
275 words per minute. "Patients were instructed to read the story on the tapes and try to follow it, al-
though no tests of comprehension were made to check this." Provided by: not stated. Delivery: not
clear. Patient-led therapy. (Table 1). Regimen: "treatment blocks lasted for 4 weeks each" and partici-
pants were asked to record how long they spent on the tasks each day. "The aim was to achieve a min-
imum of 400 minutes of rehabilitation (20 sessions x 20 minutes) over approximately 4 weeks". Tailor-
ing: "patients contacted one of us (G.A.S.) when they required a new (usually faster) tape." Modifica-
tion: no. Adherence: "There were no differences between the two groups in total time spent on reha-
bilitation tasks across both treatment blocks in minutes (range), 914 (865-955); 901 (840-1000), t-test, t
(10) 0.50, P = 0.628".
Group 2: control (n = 11)
Intervention type: control
Intervention: sham training; "spot the difference"
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Materials: "'Spot-the-difference' tests were taken from a children's puzzle booklet; the original car-
toons were altered to remove text. The number of differences on each page varied between eight and
12."
Where can materials be accessed? not stated. Procedures: "Patients were instructed to look for as
many differences as possible between the two pictures, but were not told how many to expect, com-
pleting at least two cartoons over 20 min. Between 40 to 60 examples were selected randomly for each
patient (out of a total of the 70 prepared tests), depending on their speed." Provided by: not stated.
Delivery: not clear. Patient-led therapy. (Table 1). Regimen: "treatment blocks lasted for 4 weeks
each" and participants were asked to record how long they spent on the tasks each day. "The aim was
to achieve a minimum of 400 minutes of rehabilitation (20 sessions x 20 minutes) over approximately 4
weeks". Tailoring: not stated. Modification: no. Adherence: "There were no differences between the
two groups in total time spent on rehabilitation tasks across both treatment blocks in minutes (range),
914 (865-955); 901 (840-1000), t-test, t (10) 0.50, P = 0.628"
Outcomes See Table 4
Text reading speeds (passages from Neale analysis of reading)
Single word reading speeds (words taken from MRC psycholinguistic battery)
Eye movement characteristics - spatial characteristics of saccadic amplitude, incoming saccade ampli-
tude and landing position
- temporal characteristics
Perimetry - Humphrey field analyser
- Goldmann perimetry
Time points when outcomes were assessed: T1, initial assessment; T2, before treatment; T3, after the
first training component. (Additional time points - after the cross-over were: T4, after the second train-
ing component; T5, after a follow-up interval)
Notes Did not state whether visual correction using glasses was used during training or testing.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk Modified minimisation technique of sequence generation. Personal communi-
cation with authors: "The allocation was concealed from the persons recruit-
ing into the study but not from the tester. The recruiter(s) did not know that
the first subject would be placed in group 1 but the tester did".
Blinding (performance
bias and detection bias) 
All outcomes
High risk Personal communication with authors: "The tester was the first author (a psy-
chologist). She was not blind to the therapy. It was not possible to blind her to
this as it was a behavioural therapy and she was 'dispensing' this at each time
point."
Incomplete outcome data
(attrition bias) 
All outcomes
High risk "Three patients dropped out before completing therapy" (all from group 2)
and "data from these subjects were excluded from analyses"
Other bias Low risk No other potential bias noted
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Design: randomised cross-over design
Stratification: not stated
Randomisation sequence: "randomly assigned" but method not given
Comparisons: participants in Group 1 received Gottlieb prism during the first 3-month phase of the
study, and participants in Group 2 received Fresnel prisms during the first 3-month phase of the study.
Participants then crossed over to receive the other treatment.
Allocation concealment: not stated
Blinding: not stated
Power calculation: not stated
Intention-to-treat analysis: not stated
Other recruitment details: not stated
Patient and public involvement: not stated
Participants Total study population: 10 participants.
Withdrawals: no information (7 participants provided follow-up data at 2 years - 3 could not be con-
tacted)
Method of diagnosing VFD: not stated.
Characteristics of population: participant details are listed in Table 2.
Type and severity of visual problems: participant details are listed in Table 3.
Inclusion criteria: stated "The patients were screened to include patients with only occipital lobe
strokes". Participants described as having "Hemianopsia because of cerebral vascular accidents". All in-
cluded participants were male, but unclear if this was an inclusion criterion.
Exclusion criteria: not stated.
Baseline comparison of treatment groups: yes
The study included a mixed population.
It was assumed that participants did not have neglect (as this is unlikely in occipital lesions).
Method of diagnosing visual perceptual problems: not stated - it was not stated whether the pa-
tients may have had visual neglect (although neglect is unlikely in occipital lesions)
Interventions Group 1: Gottlieb Visual Field Awareness System (VFAS) (n = 5)
Intervention type: substitution
Intervention: Gottlieb VFAS prism
Materials: 18.5 dioptre Gottlieb VFAS prism
Where can materials be accessed? "Rekindle(R), Stone Mountain, GA, USA". Procedures: 18.5 dioptre
Gottlieb VFAS prism drilled into one lens. Positioned just oJ pupil centre - generally on the same eye as
side of field loss, on same side as field loss, base out. Provided by: low-vision specialist for laborato-
ry and outdoor training, kinesiotherapist for on-road training. Delivery: laboratory and out-door train-
ing within university grounds, and on-road (driving) training on a road course within a medical cen-
tre (Table 1). Regimen: training of 4 x 2 to 3-hour sessions indoors with low vision specialist and 8 x 2-
hour outdoor sessions behind the wheel. The lenses were then worn for 3 months. Tailoring: not stat-
ed. Modification: not stated. Adherence: no information (whether prism was still worn at time of fol-
low-up was recorded as never/occasionally/frequently)
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Group 2: Fresnel prisms (n = 5)
Intervention type: substitution
Intervention: Press-OnTM Fresnel 20 Diopter Prisms
Materials: Press-OnTM Fresnel 20 Diopter Prisms. Where can materials be accessed? "3M Health Care,
St. Paul, MN, USA". Procedures: 20 dioptre press-on Fresnel prisms attached to posterior surface of 1
spectacle lens. Positioned just oJ pupil centre - generally on the same eye as side of field loss, on same
side as field loss, base out. Provided by: low-vision specialist for laboratory and outdoor training, kine-
siotherapist for on-road training. Delivery: laboratory and out-door training within university grounds,
and on-road (driving) training on a road course within a medical centre (Table 1). Regimen: training of
4 x 2 to 3 hour sessions indoors with low-vision specialist and 8 x 2-hour outdoor sessions behind the
wheel. The lenses were then worn for 3 months. Tailoring: not stated. Modification: not stated. Adher-
ence: no information (whether prism was still worn at time of follow-up was recorded as never/occa-
sionally/frequently)
Outcomes See Table 4
Goldmann visual field
Visual acuity
Contrast sensitivity
Lab assessment - indoor functional assessment
Outdoor function assessment
Driving skills assessment - indoor and on-road
Pyschophysical assessment
- attentional visual acuity
- attentional motion sensitivity
Self-report (satisfaction)
Time points when outcomes were assessed: before and after each cross-over. Continued use of de-
vices assessed at 2-year follow-up
Notes 1. Data were presented after the cross-over, for both groups combined - no first phase data were avail-
able.
2. Stated: "For each assessment task for each individual in the test-retest period, we computed the
change in score from the initial baseline testing to the repeat baseline testing. We then averaged these
change scores across subjects for each task". For each task If the change from baseline to training ex-
ceeded the test-retest change it was scored as 'improved', if it was less than or equal it was scored as
'no change'. The sum of improved tasks across the test battery was then computed.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Stated "randomly assigned into one of two experimental groups" but no de-
tails of method provided
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details of blinding included
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No incomplete data issues apparent, however, scores have been combined so
it is difficult to tell if there are any missing outcomes.
Other bias Low risk No other cause of bias noted
Szlyk 2005  (Continued)
AB/BA: refers to order of interventions within cross-over trial, where A and B denote different interventions and AB or BA the order of delivery
ACS: alternating current stimulation
ADL: activities of daily living
ARV: area of residual vision
AVT: audiovisual exploration training
cd/m2: candela per square meter (standard unit of luminance)
CNS: central nervous system
CT: computerised tomography
CVA: cerbrovascular accident
EEG: electroencephalogram
EQ-5D:standardised EuroQol health-related quality of life instrument
FIM: Functional Independence Measure
FT: flicker stimulation training
HRP: high resolution perimetry
HVFD: homonymous visual field defect
IH-CST: InSight Hemianopia - Compensatory Scanning Training
IVI: impact of visual impairment
LCD: liquid crystal display (high definition monitor)
LEDs: light emitting diodes
LV-VFQ: Low Vision - Visual Function Questionnaire
MMSE: Mini Mental State Examination
MRC: Medical Research Council
MRI: magnetic resonance imaging
MT: moving text
n: number
NA: not applicable
NEI-VFQ: National Eye Institute Visual Function Questionnaire
OT: occupational therapy
PI: principal investigator
QoL: quality of life
RCT: randomised controlled trial
RT: restitution therapy
SD: standard deviation
SF-12: Short-Form Health Survey
T1/T2/T3/T4/T5: outcome asssessment timepoint 1, 2, 3, 4 or 5
TAP: Tubinger automated perimetry
TBI: traumatic brain injury
tDCS: transcranial direct current stimulation
TL: tube luminescent
VET: visual exploration training
VFAS: visual field awareness system
VFD: visual field defect
VFQ-25: visual functioning questionnaire
VIS: Visual In Stroke (study name)
VRT: vision restoration therapy
VST: visual stimulation training
WHOQOL-BREF:
wpm: words per minute
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Akinwuntan 2005 The protocol for this review was to include "any intervention that is specifically targeted at im-
proving the visual field defect, or improving the ability of the participant to cope with the visu-
al field loss". Although this randomised controlled intervention study did measure visual, neuro-
physical and driving outcomes, the intervention targeted a person's decreased ability to drive, not
specifically due to their visual field defect, but by all the "motor, visual, cognitive, and perceptual
deficits ... experienced after stroke", and thus was ineligible.
Akinwuntan 2010 Not VFD
Akinwuntan 2012 Not VFD
Alber 2015 Not RCT
Balconi 2013 Not VFD
Beasley 2013 Not VFD
Bowers 2012 Not RCT
Braga 2018 Not RCT
Brandt 2009 Not RCT
Brigui 2014 Not RCT
Cameirao 2012 Not vision
Carter 1983 ***Was an included study in 2011 version of Cochrane review***
Excluded from updated version because participants were not confirmed to have visual field de-
fects: this study included 33 participants, all of whom had a diagnosis of stroke. The 2011 version
stated: "this study did not diagnose visual field defects but instead relied on clinical identification
of a 'visual scanning problem'. Visual scanning problems are likely to be due to visual neglect as
well as visual field defects, thus we have to assume that the participants in this study had a com-
bination of problems. However, it could be possible that the participants had visual neglect prob-
lems but not visual field defects, and vice versa."
Carter 1988 The protocol for this review was to include "any intervention that is specifically targeted at improv-
ing the visual field defect, or improving the ability of the participant to cope with the visual field
loss". The intervention in this study was cognitive skills retraining and ADL retraining; it included vi-
sual scanning training within a large battery of training activities, but this was not specifically tar-
geted at visual field loss.
Chen 2013 Not stroke
ChiCTR-OON-15006688 Not RCT
Cho 2015 Not VFD
Courtney-Harris 2015 Aim of study was validation of a vision screening tool; and outcomes were focussed on level of
agreement between tests.
Crotty 2009 Not VFD
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Study Reason for exclusion
Cutfield 2011 Not RCT
Dai 2014 Not RCT
Dargie 2012 Not RCT
Davis 2009 Not vision
Fedorov 2010 Not VFD
Ginsberg 2013 Not VFD
Gordon 1985 The method of sequence generation was described as "patients ... were assigned to either experi-
mental or control condition, depending on the rehabilitation service to which the patient was as-
signed for treatment. All patients were accessed from two comparable inpatient services; exper-
imental and control conditions were alternated every six months between the two services dur-
ing the time which all patients on a given service were assigned to the same treatment condition".
Although this was described as "quasi-random" it did not meet the level of randomisation of se-
quence generation that was needed for inclusion.
Hamel 2012 Not RCT
Hazelton 2013 Not RCT
Hollands 2013 Not VFD
Jo 2012 Visual neglect, not VFD
Kang 2009 Not VFD
Kerkhoff 2013 Visual neglect, not VFD
Kerry 2017 Focussed on central alexia ("an acquired reading disorder co-occuring with a generalised language
deficit (aphasia)")
Ko 2011 Not RCT
Lane 2010 The method of sequence generation in this study of compensation interventions was stated as "
the first 23 were assigned to Group A, and the last 23 to Group B" and thus was non-random.
Lee 2013a Visual neglect, not VFD
Lee 2013b Not RCT
Loverro 1988 The method of sequence generation in this study of bed orientation was stated as "assigned to re-
habilitation hospital beds based on bed availability" and thus was non-random.
Machner 2012 Visual neglect, not VFD
Mancuso 2012 Visual neglect, not VFD
Markowitz 2010 This was a comment on a study: Bergsma DP and Van der Wildt G. British Journal of Ophthalmology
2010; 94:88–96, which was not a randomised controlled trial.
NTR5637 Not RCT
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Study Reason for exclusion
Olma 2013 Not RCT
Opolka 2013 Visual neglect, not VFD
Padula 2009 Not RCT
Park 2013 Not VFD
Rosenberg 2011 Not VFD
Sabel 2009 This study looked at visual restitution in optic nerve disorder. The consensus of the Advisory Group
for this review was that the review should be limited to post-chiasmal visual field loss only, so this
study was not included.
Saposnik 2013 Not VFD
Scholomov 2010 Not RCT
Taylor 2011 Not RCT
Teasell 2011 Visual neglect, not VFD
Thurtell 2010 Not VFD
Van Wyk 2011 Not VFD
Van Wyk 2016 Not VFD (eye movement disorders)
Weinberg 1977 ***Was an included study in 2011 version of Cochrane review***
Excluded from updated version because participants were not confirmed to have visual field de-
fects. Weinberg 1977 and Weinberg 1979 both included participants with the same inclusion crite-
ria. The 2009 version stated: "These studies included only people with right-sided cerebrovascu-
lar accident. However, from the limited information available in the published papers, it does ap-
pear that the diagnosis of visual field defect (or visual neglect) was not an inclusion criterion for en-
try to these studies. The authors appear to assume that this patient group will have visual neglect
as they have right-sided brain damage. It is worth noting that in these two studies the participants
were divided into subgroups of 'mild' and 'severe' based on "presence of visual field defect on con-
frontation and performance on visual cancellation", and that we can therefore be confident that
the 'severe' subgroup contained people with visual field defects, while it is not confirmed whether
all the 'mild' subgroup had a visual field defect. Arguably, therefore, the 'severe' subgroups are
more relevant to our review question than the 'mild' subgroups. There was substantial heterogene-
ity when we included the 'mild' subgroups in the analyses. Exploring this heterogeneity using sub-
group analyses found that the 'severe' subgroup had a greater response to the intervention than
the 'mild' subgroup, for all outcomes ... Arguably it was inappropriate to have included the 'mild'
subgroups within any of the analyses, as it is possible that participants in this group did not have a
visual field defect. However, due to the uncertainty we felt it was appropriate to include the 'mild'
subgroup but to further explore the effect of removing them from the analyses."
Weinberg 1979 ***Was an included study in 2011 version of Cochrane review***
Excluded from updated version because participants were not confirmed to have visual field de-
fects. Weinberg 1977 and Weinberg 1979 both included participants with the same inclusion crite-
ria. The 2009 version stated: "These studies included only people with right-sided cerebrovascu-
lar accident. However, from the limited information available in the published papers, it does ap-
pear that the diagnosis of visual field defect (or visual neglect) was not an inclusion criterion for en-
try to these studies. The authors appear to assume that this patient group will have visual neglect
as they have right-sided brain damage. It is worth noting that in these two studies the participants
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Study Reason for exclusion
were divided into subgroups of 'mild' and 'severe' based on "presence of visual field defect on con-
frontation and performance on visual cancellation", and that we can therefore be confident that
the 'severe' subgroup contained people with visual field defects, while it is not confirmed whether
all the 'mild' subgroup had a visual field defect. Arguably, therefore, the 'severe' subgroups are
more relevant to our review question than the 'mild' subgroups. There was substantial heterogene-
ity when we included the 'mild' subgroups in the analyses. Exploring this heterogeneity using sub-
group analyses found that the 'severe' subgroup had a greater response to the intervention than
the 'mild' subgroup, for all outcomes ... Arguably it was inappropriate to have included the 'mild'
subgroups within any of the analyses, as it is possible that participants in this group did not have a
visual field defect. However, due to the uncertainty we felt it was appropriate to include the 'mild'
subgroup but to further explore the effect of removing them from the analyses."
While we were confident that the 'severe' subgroup from this study contained some participants
with visual field defects, this was not the focus of this trial, which was focused on participants with
right brain damage only. Further, we cannot be certain that all participants in this group had visual
field defects (there is a chance that some had severe visual neglect but no visual field defect).
White 2010 Not VFD
ADL: activities of daily living
RCT: randomised controlled trial
VFD: visual field defect
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Methods described this as a "prospective, observational study".
Results described as a "randomised controlled trial", and included a study flowchart.
No details of randomisation were provided.
Participants 40 participants: "stroke patients with posterior cerebral artery territory infarction" with "pure
homonymous hemianopia without neglect"
Interventions Group 1: Neuroaid (MLC601)
Group 2: Piracetam
Outcomes Visual field (standard perimetry)
Notes Study carried out in Iran during 2009-2010
Authors emailed in 2015, but no reply
Ghandehari 2011 
 
 
Methods Conference abstract: "Patients were randomised ..."
ClinicalTrials.gov: "observational" study
Participants Stroke patients - not clear if VFD was an inclusion criteria
Interventions Experimental: "training with vision teacher with individually adapted training program"
Sand 2017 
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Control: no training
Outcomes Visual field defect
Visual function
Quality of life
National Institute of Health Stroke Scale (NIHSS)
Notes ClinicalTrials.gov Identifier: NCT02307981
Unclear if this was an RCT or not
Sand 2017  (Continued)
NIHSS: National Institute of Health Stroke Scale
RCT: randomised controlled trial
VFD: visual field defect
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Visual restoration for hemianopia
Methods RCT
Participants Adults (21 to 75 years); lesion in the occipital lobe of the brain (18 to 90 days previously); stable
homonymous hemianopia
Interventions Experimental: training in the blind field: A computer software and chin-rest necessary to perform
visual training will be loaned to each participant to use at home. They will perform 1 to 2 daily
training sessions in their home, consisting of 200 to 300 trials each. The visual task performed
repetitively will involve discriminating the direction of motion of a small cloud of dots located at a
predetermined location in the blind field. The computer program will automatically create a record
of participant performance during each home training session. They will train daily (about 40 to 60
minutes total), 5 to 7 days per week, for at least 24 weeks.
Control: training in the intact field (as above)
Outcomes Primary outcome measure: 24-2 Humphrey PMD - Change in the perimetric mean deviation (PMD)
from 24-2 Humphrey perimetry between baseline and post-training
Starting date March 2018
(Estimated completion: May 2019)
Contact information lisa_blanchard@urmc.rochester.edu
Notes ClinicalTrials.gov Identifier: NCT03350919
Feldon 2017 
 
 
Trial name or title Restoration of vision after stroke (REVIS)
Methods "Randomised"
Gall 2015 
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Participants Adults aged 18 to 75 years; > 6 months post stroke; hemianopia or quadrantopia confirmed by stan-
dard automated perimetry
Interventions Experimental: active tDCS (transcranial direct current stimulation)
Control: sham stimulation
Outcomes Primary outcome: improved detection in the visual field, measured using high resolution perimetry
Secondary outcome: change in extent of visual fields using standard automated perimetry
Starting date April 2015
(study completion: April 2017)
Contact information turgut.tatlisumak@hus.fi
Notes ClinicalTrials.gov Identifier: NCT02405143
Gall 2015  (Continued)
 
 
Trial name or title Retraining following hemianopia in acquired brain injury following stroke
Methods Comparison of 2 intensities of scanning training
Participants 20 participants
Interventions Visual scanning training using a light panel
Outcomes Includes quality of life measures and functional vision skills
Starting date  
Contact information ahayes@nvtsystems.com.au
Notes Unpublished. Recruitment has ended. ACTRN12610000494033
Hayes 2010 
 
 
Trial name or title Home-training for hemianopia (partial blindness)
Methods RCT (3 groups)
Participants Adults (aged at least 18) suffering with a nonprogressive visual field defect for at least 3 months
caused by a brain injury
Interventions Group 1 (intervention group 1): use the DREX program on a touchscreen tablet
Group 2 (intervention group 2): use the DREX program on a computer
Group 3 (control group): given their usual care and any treatments given by their doctors or thera-
pists
Outcomes "Reading and visual search abilities and also their quality of life"
ISRCTN16023965 
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Starting date June 2015
(study completion: December 2017)
Contact information azuwan.musa@durham.ac.uk
Notes ISRCTN16023965
ISRCTN16023965  (Continued)
 
 
Trial name or title Rehabilitation outcome in chronic neglect patients with associated visual field loss: results of a
blinded randomized cross-over study
Methods Masked randomised cross-over study
Participants Stroke patients with persistent neglect and visual field loss 6 months post-onset
Interventions Computer-aided visual restitution training versus compensatory eye movement training
Outcomes Visual field and neglect measures
Starting date  
Contact information bernhard.sabel@med.ovgu.de
Notes Currently in press. Results not available for this review
Komm 2009 
 
 
Trial name or title Fluoxetine for visual recovery after ischemic stroke (FLUORESCE)
Methods RCT
Participants MRI-confirmed acute ischaemic stroke resulting in an isolated homonymous visual field loss
Estimated enrolment: 40 participants
Interventions Experimental: fluoxetine - 20 mg fluoxetine capsule by mouth once daily for 90 days
Placebo comparator: placebo
Outcomes Primary outcome measure: improvement in size of visual field deficit (degrees)
Secondary outcome measures:
Improvement in size of visual field deficit (square degrees)
Improvement in parametric mean deviation
Functional field score
Visual Function Questionnaire-25 score
Patient Health Questionnaire-9 score
Modified Rankin Scale score
NCT02737930 
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Post-stroke changes in cortical visual representation as measured by functional magnetic reso-
nance imaging
Post-stroke changes in retinal nerve fibre layer thickness
Starting date May 2016
(Estimated study completion: June 2020)
Contact information bogachan_sahin@urmc.rochester.edu
Notes ClinicalTrials.gov identifier: NCT02737930
NCT02737930  (Continued)
 
 
Trial name or title Visual field restoration in patients with post-stroke homonymous hemianopsia (REVOIR)
Methods Randomised cross-over design
Participants Adults, 3 to 36 months post-stroke; presence of a homonymous visual field amputation after vascu-
lar retro-chiasmatic lesion of the occipital region (visual cortex alone or with optical radiations or
with other associated occipital areas)
Anticipated recruitment: 104 participants
Interventions Experimental: immediate rehabilitation ("a stimulus, in the blind field of hemianopsic patients, to
restore the vision of patients with homonymous hemianopsia consecutive to stroke")
Control: delayed rehabilitation
Outcomes Primary outcome measure: change in the sensitivity of detection of a visual stimulus after rehabili-
tation
Starting date September 2016
Contact information lsalomon@for.paris
Notes ClinicalTrials.gov Identifier: NCT02886663
NCT02886663 
DREX: Durham Reading & Exploration
PMD: perimetric mean deviation
RCT: randomised controlled trial
tDCS: transcranial direct current stimulation
VFD: visual field defect
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Restitutive interventions versus control, placebo or no intervention
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Visual field 1 19 Mean Difference (IV, Random, 95% CI) 1.02 [-1.37, 3.41]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2 Quality of life 1 30 Odds Ratio (M-H, Random, 95% CI) 13.0 [2.07, 81.48]
 
 
Analysis 1.1.   Comparison 1 Restitutive interventions versus
control, placebo or no intervention, Outcome 1 Visual field.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Kasten 1998 9 3.9 (3) 10 2.9 (2.2) 100% 1.02[-1.37,3.41]
   
Total *** 9   10   100% 1.02[-1.37,3.41]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.84(P=0.4)  
Favours control 105-10 -5 0 Favours restitutive
 
 
Analysis 1.2.   Comparison 1 Restitutive interventions versus
control, placebo or no intervention, Outcome 2 Quality of life.
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kasten 1998 13/18 2/12 100% 13[2.07,81.48]
   
Total (95% CI) 18 12 100% 13[2.07,81.48]
Total events: 13 (Experimental), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.74(P=0.01)  
Favours control 1000.01 100.1 1 Favours restitutive
 
 
Comparison 2.   Compensative interventions versus control, placebo or no intervention
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Visual field 2 95 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.92, 0.70]
1.1 Participants with visual field de-
fects (no visual neglect)
2 95 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.92, 0.70]
1.2 Participants with visual field de-
fects and (possibly) co-existing visu-
al neglect
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Extended activities of daily living 2 87 Std. Mean Difference (IV, Random, 95% CI) 0.49 [-0.01, 0.99]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.1 Participants with visual field de-
fects (no visual neglect)
2 87 Std. Mean Difference (IV, Random, 95% CI) 0.49 [-0.01, 0.99]
2.2 Participants with visual field de-
fects and (possibly) co-existing visu-
al neglect
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Reading 4 162 Std. Mean Difference (IV, Random, 95% CI) 0.26 [-0.05, 0.58]
3.1 Participants with visual field de-
fects (no visual neglect)
3 110 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.20, 0.56]
3.2 Participants with visual field de-
fects and (possibly) co-existing visu-
al neglect
1 52 Std. Mean Difference (IV, Random, 95% CI) 0.45 [-0.10, 1.00]
4 Quality of life 2 96 Mean Difference (IV, Random, 95% CI) 9.36 [3.10, 15.62]
4.1 Participants with visual field de-
fects (no visual neglect)
2 96 Mean Difference (IV, Random, 95% CI) 9.36 [3.10, 15.62]
4.2 Participants with visual field de-
fects and (possibly) co-existing visu-
al neglect
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Scanning - cancellation 2 97 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.40, 0.39]
5.1 Participants with visual field de-
fects (no visual neglect)
1 48 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.45, 0.68]
5.2 Participants with visual field de-
fects and (possibly) visual neglect
1 49 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.69, 0.44]
6 Adverse events 2 108 Odds Ratio (M-H, Random, 95% CI) 5.18 [0.24, 112.57]
 
 
Analysis 2.1.   Comparison 2 Compensative interventions versus
control, placebo or no intervention, Outcome 1 Visual field.
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.1.1 Participants with visual field defects (no visual neglect)  
De Haan 2015 26 57.8 (6.7) 23 62.6 (11.1) 50.24% -0.52[-1.1,0.05]
Rowe 2010 24 0.1 (0.1) 22 0 (0.2) 49.76% 0.3[-0.28,0.89]
Subtotal *** 50   45   100% -0.11[-0.92,0.7]
Heterogeneity: Tau2=0.26; Chi2=3.97, df=1(P=0.05); I2=74.78%  
Test for overall effect: Z=0.27(P=0.79)  
   
2.1.2 Participants with visual field defects and (possibly) co-existing visual ne-
glect
 
Subtotal *** 0   0   Not estimable
Favours control 105-10 -5 0 Favours compensative
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Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total *** 50   45   100% -0.11[-0.92,0.7]
Heterogeneity: Tau2=0.26; Chi2=3.97, df=1(P=0.05); I2=74.78%  
Test for overall effect: Z=0.27(P=0.79)  
Test for subgroup differences: Not applicable  
Favours control 105-10 -5 0 Favours compensative
 
 
Analysis 2.2.   Comparison 2 Compensative interventions versus control,
placebo or no intervention, Outcome 2 Extended activities of daily living.
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.2.1 Participants with visual field defects (no visual neglect)  
De Haan 2015 26 -2 (0.6) 23 -2.5 (0.7) 53.97% 0.72[0.14,1.3]
Rowe 2010 22 15.2 (4.4) 16 14.1 (6) 46.03% 0.21[-0.44,0.86]
Subtotal *** 48   39   100% 0.49[-0.01,0.99]
Heterogeneity: Tau2=0.03; Chi2=1.34, df=1(P=0.25); I2=25.31%  
Test for overall effect: Z=1.9(P=0.06)  
   
2.2.2 Participants with visual field defects and (possibly) co-existing visual ne-
glect
 
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total *** 48   39   100% 0.49[-0.01,0.99]
Heterogeneity: Tau2=0.03; Chi2=1.34, df=1(P=0.25); I2=25.31%  
Test for overall effect: Z=1.9(P=0.06)  
Test for subgroup differences: Not applicable  
Favours control 105-10 -5 0 Favours compensatory
 
 
Analysis 2.3.   Comparison 2 Compensative interventions
versus control, placebo or no intervention, Outcome 3 Reading.
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.3.1 Participants with visual field defects (no visual neglect)  
De Haan 2015 24 159 (33) 21 147 (34) 27.93% 0.35[-0.24,0.94]
Rowe 2010 25 13 (13.1) 21 14.6 (11.9) 28.88% -0.13[-0.71,0.46]
Spitzyna 2007 11 102.5 (34.7) 8 86 (22.9) 11.28% 0.52[-0.41,1.45]
Subtotal *** 60   50   68.09% 0.18[-0.2,0.56]
Heterogeneity: Tau2=0; Chi2=1.9, df=2(P=0.39); I2=0%  
Test for overall effect: Z=0.92(P=0.36)  
   
Favours control 105-10 -5 0 Favours compensative
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Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.3.2 Participants with visual field defects and (possibly) co-existing visual ne-
glect
 
Aimola 2011 28 132.5 (50.2) 24 109.1 (52.6) 31.91% 0.45[-0.1,1]
Subtotal *** 28   24   31.91% 0.45[-0.1,1]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.59(P=0.11)  
   
Total *** 88   74   100% 0.26[-0.05,0.58]
Heterogeneity: Tau2=0; Chi2=2.52, df=3(P=0.47); I2=0%  
Test for overall effect: Z=1.66(P=0.1)  
Test for subgroup differences: Chi2=0.63, df=1 (P=0.43), I2=0%  
Favours control 105-10 -5 0 Favours compensative
 
 
Analysis 2.4.   Comparison 2 Compensative interventions versus
control, placebo or no intervention, Outcome 4 Quality of life.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.4.1 Participants with visual field defects (no visual neglect)  
De Haan 2015 29 72 (10.1) 23 62.4 (15.1) 76.35% 9.59[2.43,16.75]
Rowe 2010 25 68.4 (20) 19 59.8 (22.7) 23.65% 8.6[-4.27,21.47]
Subtotal *** 54   42   100% 9.36[3.1,15.62]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.9); I2=0%  
Test for overall effect: Z=2.93(P=0)  
   
2.4.2 Participants with visual field defects and (possibly) co-existing visual ne-
glect
 
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total *** 54   42   100% 9.36[3.1,15.62]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.9); I2=0%  
Test for overall effect: Z=2.93(P=0)  
Test for subgroup differences: Not applicable  
Favours control 10050-100 -50 0 Favours compensatory
 
 
Analysis 2.5.   Comparison 2 Compensative interventions versus
control, placebo or no intervention, Outcome 5 Scanning - cancellation.
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.5.1 Participants with visual field defects (no visual neglect)  
De Haan 2015 23 2224 (838) 25 2140 (545) 49.46% 0.12[-0.45,0.68]
Subtotal *** 23   25   49.46% 0.12[-0.45,0.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
Favours compensative 105-10 -5 0 Favours control
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Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
   
2.5.2 Participants with visual field defects and (possibly) visual neglect  
Aimola 2011 25 101 (53) 24 107 (40) 50.54% -0.13[-0.69,0.44]
Subtotal *** 25   24   50.54% -0.13[-0.69,0.44]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.44(P=0.66)  
   
Total *** 48   49   100% -0.01[-0.4,0.39]
Heterogeneity: Tau2=0; Chi2=0.36, df=1(P=0.55); I2=0%  
Test for overall effect: Z=0.02(P=0.98)  
Test for subgroup differences: Chi2=0.36, df=1 (P=0.55), I2=0%  
Favours compensative 105-10 -5 0 Favours control
 
 
Analysis 2.6.   Comparison 2 Compensative interventions versus
control, placebo or no intervention, Outcome 6 Adverse events.
Study or subgroup Compensative
intervention
Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
De Haan 2015 0/26 0/23   Not estimable
Rowe 2010 2/30 0/29 100% 5.18[0.24,112.57]
   
Total (95% CI) 56 52 100% 5.18[0.24,112.57]
Total events: 2 (Compensative intervention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.3)  
Favours compensative 5000.002 100.1 1 Favours control
 
 
Comparison 3.   Substitutive interventions versus control, placebo or no intervention
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Functional Activities of Daily
Living
1   Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Participants not wearning
prisms during assessment
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Participants wearing
prisms during assessment
1 39 Mean Difference (IV, Random, 95% CI) -4.0 [-17.86, 9.86]
2 Visual field 2   Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Participants not wearing
prisms during assessment
1 46 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.46, 0.70]
Interventions for visual field defects in people with stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
102
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.2 Participants wearing
prisms during assessment
1 39 Std. Mean Difference (IV, Random, 95% CI) 1.12 [0.44, 1.80]
3 Extended activities of daily
living
2   Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Participants not wearing
prisms during assessment
1 38 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.44, 0.85]
3.2 Participants wearing
prisms during assessment
1 61 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.26, 0.75]
4 Reading 1   Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Participants not wearing
prisms during assessment
1 45 Mean Difference (IV, Random, 95% CI) 2.80 [-7.13, 12.73]
4.2 Participants wearing
prisms during assessment
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Falls 1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Participants not wearing
prisms during assessment
0 0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Participants wearing
prisms during assessment
1 39 Odds Ratio (M-H, Random, 95% CI) 1.21 [0.26, 5.76]
6 Quality of life 1   Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Participants not wearing
prisms during assessment
1 43 Mean Difference (IV, Random, 95% CI) 8.40 [-4.18, 20.98]
6.2 Participants wearing
prisms during assessment
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Scanning - cancellation 1   Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Participants not wearing
prisms during assessment
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Participants wearing
prisms during assessment
1 39 Mean Difference (IV, Random, 95% CI) 9.80 [1.91, 17.69]
8 Adverse events 1 59 Odds Ratio (M-H, Random, 95% CI) 87.32 [4.87,
1564.66]
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Analysis 3.1.   Comparison 3 Substitutive interventions versus control,
placebo or no intervention, Outcome 1 Functional Activities of Daily Living.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.1.1 Participants not wearning prisms during assessment  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
3.1.2 Participants wearing prisms during assessment  
Rossi 1990 18 50 (21.2) 21 54 (22.9) 100% -4[-17.86,9.86]
Subtotal *** 18   21   100% -4[-17.86,9.86]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
Test for subgroup differences: Not applicable  
Favours control 10050-100 -50 0 Favours substitutive
 
 
Analysis 3.2.   Comparison 3 Substitutive interventions versus
control, placebo or no intervention, Outcome 2 Visual field.
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.2.1 Participants not wearing prisms during assessment  
Rowe 2010 24 0.1 (0.1) 22 0 (0.2) 100% 0.12[-0.46,0.7]
Subtotal *** 24   22   100% 0.12[-0.46,0.7]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
   
3.2.2 Participants wearing prisms during assessment  
Rossi 1990 18 -5.8 (4.2) 21 -14.2 (9.2) 100% 1.12[0.44,1.8]
Subtotal *** 18   21   100% 1.12[0.44,1.8]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.23(P=0)  
Test for subgroup differences: Chi2=4.83, df=1 (P=0.03), I2=79.31%  
Favours control 105-10 -5 0 Favours substitutive
 
 
Analysis 3.3.   Comparison 3 Substitutive interventions versus control,
placebo or no intervention, Outcome 3 Extended activities of daily living.
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.3.1 Participants not wearing prisms during assessment  
Rowe 2010 22 15.2 (4.8) 16 14.1 (6) 100% 0.2[-0.44,0.85]
Subtotal *** 22   16   100% 0.2[-0.44,0.85]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
   
3.3.2 Participants wearing prisms during assessment  
Favours control 105-10 -5 0 Favours compensative
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Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bowers 2014 33 1.9 (3.3) 28 1.2 (2.2) 100% 0.24[-0.26,0.75]
Subtotal *** 33   28   100% 0.24[-0.26,0.75]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.94(P=0.35)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.92), I2=0%  
Favours control 105-10 -5 0 Favours compensative
 
 
Analysis 3.4.   Comparison 3 Substitutive interventions versus
control, placebo or no intervention, Outcome 4 Reading.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.4.1 Participants not wearing prisms during assessment  
Rowe 2010 24 17.4 (21.3) 21 14.6 (11.9) 100% 2.8[-7.13,12.73]
Subtotal *** 24   21   100% 2.8[-7.13,12.73]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.55(P=0.58)  
   
3.4.2 Participants wearing prisms during assessment  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours control 10050-100 -50 0 Favours compensative
 
 
Analysis 3.5.   Comparison 3 Substitutive interventions versus control, placebo or no intervention, Outcome 5 Falls.
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.5.1 Participants not wearing prisms during assessment  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Experimental), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
3.5.2 Participants wearing prisms during assessment  
Rossi 1990 4/18 4/21 100% 1.21[0.26,5.76]
Subtotal (95% CI) 18 21 100% 1.21[0.26,5.76]
Total events: 4 (Experimental), 4 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.24(P=0.81)  
Test for subgroup differences: Not applicable  
Favours substitutive 1000.01 100.1 1 Favours control
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Analysis 3.6.   Comparison 3 Substitutive interventions versus
control, placebo or no intervention, Outcome 6 Quality of life.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.6.1 Participants not wearing prisms during assessment  
Rowe 2010 24 68.2 (18.4) 19 59.8 (22.7) 100% 8.4[-4.18,20.98]
Subtotal *** 24   19   100% 8.4[-4.18,20.98]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.31(P=0.19)  
   
3.6.2 Participants wearing prisms during assessment  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours control 10050-100 -50 0 Favours substitution
 
 
Analysis 3.7.   Comparison 3 Substitutive interventions versus control,
placebo or no intervention, Outcome 7 Scanning - cancellation.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.7.1 Participants not wearing prisms during assessment  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
3.7.2 Participants wearing prisms during assessment  
Rossi 1990 18 -12.6 (12.5) 21 -22.4 (12.5) 100% 9.8[1.91,17.69]
Subtotal *** 18   21   100% 9.8[1.91,17.69]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.43(P=0.01)  
Test for subgroup differences: Not applicable  
Favours control 10050-100 -50 0 Favours substitutive
 
 
Analysis 3.8.   Comparison 3 Substitutive interventions versus
control, placebo or no intervention, Outcome 8 Adverse events.
Study or subgroup Compensative
intervention
Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Rowe 2010 18/30 0/29 100% 87.32[4.87,1564.66]
   
Total (95% CI) 30 29 100% 87.32[4.87,1564.66]
Total events: 18 (Compensative intervention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.04(P=0)  
Favours compensative 5000.002 100.1 1 Favours control
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Comparison 4.   Assessment or screening versus control, placebo or no intervention
Outcome or subgroup
title
No. of
studies
No. of partici-
pants
Statistical method Effect size
1 ADL 1 37 Mean Difference (IV, Random, 95% CI) -6.97 [-23.78, 9.84]
 
 
Analysis 4.1.   Comparison 4 Assessment or screening versus control, placebo or no intervention, Outcome 1 ADL.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Jarvis 2012 19 97.5 (22.8) 18 104.4 (28.8) 100% -6.97[-23.78,9.84]
   
Total *** 19   18   100% -6.97[-23.78,9.84]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.81(P=0.42)  
Favours control 10050-100 -50 0 Favours assessment/screen
 
 
A D D I T I O N A L   T A B L E S
 
Study Country Number of centres Setting for intervention Trial regis-
tration
Aimola 2011 UK Multicentre ("from local hospitals
or as self-referrals")
Community
(participants' own homes)
UK Clinical
Research
Network
Portfolio
(UKCRN, ID
7144)
Bainbridge
1994
USA Single NS NS
Bowers 2014 UK, USA Multicentre (13 study sites) University, hospital, private practice for fitting of
prisms
Then use at home (participants' own homes)
clinicaltrial-
s.gov
NCT00494676
De Haan
2015
Nether-
lands
2 ("Royal Dutch Visio and Bar-
timéus, the two centers of exper-
tise for blind and partially sighted
people in the Netherlands")
Training ... "was provided in Dutch at nine loca-
tions of Royal Dutch Visio and one location of
Bartiméus in the Netherlands".
Participants were also given homework assign-
ments.
ISRCTN Reg-
istry
ISRCTN16833414
Elshout 2016 Nether-
lands
Unclear ("Patients throughout
the Netherlands could sign up for
our study voluntarily by filling in
a form on our website")
Community
(participants' own homes)
NS
Table 1.   Demographics of included studies: settings of included studies 
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Gall 2013 Not clear NS NS NS
Jarvis 2012 UK Single Stroke unit, Warring and Halton Hospitals,
NHS Foundation Trust
NS
Jobke 2009 Germany NS NS NS
Kasten 1998 Germany NS Community
(participants' own homes)
NS
Kasten 2007 Germany NS Community
(participants' own homes)
NS
Keller 2010 Germany Single Neurological clinic NS
Modden
2012
Germany Single Rehabilitation centre (inpatients) NS
Plow 2010 USA Single Outpatient
(University clinic)
clinical-
trials.gov
NCT00921427
Poggel 2004 Germany Single Community
(participants' own homes)
NS
Rossi 1990 USA Single Rehabilitation
(inpatient)
NS
Roth 2009 Germany NS Community
(participants' own homes)
NS
Rowe 2010 UK Multicentre ("from stroke units
based in 15 United Kingdom (UK)
National Health Service (NHS)
trusts")
Any (hospital, community) Current Con-
trolled Trials
ISRCTN05956042.
Schuett 2012 Unclear.
Authors
from Aus-
tria, UK and
Germany.
"All partici-
pants were
native Ger-
man speak-
ers."
NS NS NS
Spitzyna
2007
UK NS Community
(participants' own homes)
NS
Szlyk 2005 USA Single; university Outpatient clinic NS
Table 1.   Demographics of included studies: settings of included studies  (Continued)
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NHS: National Health Service
NS: not stated
UK: United Kingdom
USA: United States of America
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Study Number of
participants
Age Gender Time since stroke/lesion Initial func-
tional abil-
ity
Type of stroke/le-
sion
Side of stroke/
lesion
Aimola 2011 70 partici-
pants recruit-
ed, 52 partici-
pants includ-
ed in analyses
Group 1
Mean 61.4 years, SD 10.3
Group 2
Mean 63.0 years, SD 10.9
Group 1
9 F
19 M
Group 2
7 F
17 M
NS NS Group 1
19 ischaemic stroke
4 haemorrhagic,
4 traumatic brain in-
jury
1 tumour
Group 2
20 ischaemic stroke
2 haemorrhagic
2 traumatic brain in-
jury
0 tumour
Side of field de-
fect
Group 1
L 15/R 13
Group 2
L11/R 13
Bainbridge
1994
18 NS NS NS NS NS NS
Bowers
2014
73 ran-
domised; 67
completed
first phase
(before cross-
over); 61 com-
pleted second
phase (after
cross-over)
For 61 participants included
after the cross-over:
median 58 years (range 18 to
89)
For 61 par-
ticipants in-
cluded after
the cross-
over:
M 40
F 21
For 61 participants included
after the cross-over:
median 18 months (range 3 to
396)
Overall
baseline
mobility dif-
ficulty, for
61 partic-
ipants in-
cluded after
the cross-
over:
mean -0.17
(SD 2.31)
logits for
n = 31 us-
ing oblique
prisms
For 61 participants
included after the
cross-over:
hemianopia was
caused by stroke for
47 (77%)
For 61 partici-
pants included
after the cross-
over:
L hemianopia
39 (64%)
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mean -0.06
(SD 1.89)
logits for n
= 30 using
horizontal
prisms
De Haan
2015
54 ran-
domised;
data from
49 analysed
(training
group n = 26,
control group
n = 23)
Training group 55 ± 10.1 years
Control group 57 ± 13.0 years
M 32
F 17
Training group 18 ± 22.5
months
Control group 22 ± 24.6
months
NS Ischaemic CVA 36
Haemorrhagic CVA 5
Traumatic brain in-
jury 3
Penetrating head
trauma 1
AVM extirpation 1
combined 3
L hemianopia
33
R hemianopia
16
Elshout
2016
40 recruited;
data present-
ed from first 3
cohorts of 10
only (n = 30);
data from 27
analysed
Mean age 51.2 years (range 29
to 74)
M 22
F 5
Mean 26.3 months
(range 11 to 111)
NS 5 haemorrhagic
stroke
22 ischaemic stroke
L-sided field de-
fect 14
R-sided field de-
fect 13
Gall 2013 39 (alternat-
ing current
stimulation n
= 15, sham n =
14)
NS NS NS NS NS ("patients with
post-chiasmatic visu-
al pathway lesions")
NS
Jarvis 2012 64 ran-
domised (ex-
perimental
group n = 33,
control n = 31)
Experimental: mean 70.4
years (SD 10.8)
Control: mean 69.4 years (SD
14.5)
M 40
F 24
NS NS Ischaemic 56
Haemorrhage 7
Combined 1
R-sided stroke
41
L-sided stroke
19
Bilateral 4
Jobke 2009 21 Group 1
Mean 51.5 years, SD 14.8
Group 1
M 7
Group 1
Mean 89.0 months, SD 59.9
NS Group 1
5 stroke/ischaemia
NS
Table 2.   Demographics of included studies: demographics of included participants  (Continued)
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Group 2
Mean 47.3 years, SD 13.4
F 1
Group 2
M 6
F 4
(range 67 to 225 months)
Group 2
Mean 89.4, SD 57.6
(range 40 to 236 months)
1 brain injury
1 tumour
1 surgery
Group 2
5 stroke/ischaemia
1 meningitis;
1 injury
3 surgery
Kasten 1998 19
(plus 19 with
pre-chiasmal
damage)
Data are pre-
sented for full
group of 38
Group 1
? Mean 47.7 years, ? SD 12.9
Group 2
? Mean 55.3 years, ? SD 16.2
It is assumed the data pre-
sented are mean and SD, but
this was not stated
Group 1
M 11
F 8
Group 2
M 13
F 6
Group 1
? Mean 6.8 months, ? SD11.4
Group 2
? Mean 7.2 months, ? SD 6.3
It is assumed the data pre-
sented are mean and SD, but
this was not stated
NS 19 participants with
post chiasmal in-
jury; 10 were due to
stroke, 4 due to trau-
ma and 5 due to oth-
er reasons
NS
Kasten 2007 23 Group 1
Mean 41.1 years, SD 16.9
Group 2
Mean 39.3 years, SD 10.9
Group 3
Mean 44.3 years, SD 9.1
Group 1
M 5
F 2
Group 2
M 6
F 1
Group 3
M6
F3
Group 1
10 to 83 months, Mean 34.2*,
SD 30.1*
Group 2
13 to 477 months, Mean 92.7*,
SD 170.6*
Group 3
10 to 143 months, Mean 47.6*,
SD 54.4*
NS Group 1
4 stroke
1 trauma
1 cerebral aneurys-
mal bleeding
1 hypoxia
Group 2
3 stroke
3 trauma
1 surgery
Group 3
3 stroke
NS
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2 trauma
1 surgery
1 hypoxia
2 other
Keller 2010 20 Group 1
Mean 54.7 years. SD 20.4
Group 2
Mean 63.6 years, SD 13.8
Group 1
M 6
F 4
Group 2
M 6
F 4
Group 1
Mean 8.5 weeks, SD 6.7
Group 2
Mean 4.2 weeks, SD 2.1
NS Group 1
9 vascular
1 tumour
Group 2
9 vascular
1 traumatic
Group 1
4 leM hemi-
anopia
3 right hemi-
anopia
1 UL quandran-
tanopia
1 LL quandran-
tanopia
1 UR quandran-
tanopia
Group 2
3 leM hemi-
anopia
3 right hemi-
anopia
3 UL quandran-
tanopia
1 LL quandran-
tanopia
Modden
2012
45 RT Group: Mean 58.3 ± 11.4
years
CT group: Mean 57.1 ± 8.3
years
OT group: Mean 59.0 ± 11.1
years
RT group:
M 10
F 5
CT group:
M 9
RT group:
Mean 4.7 weeks
CT group:
Mean 4.9 weeks
OT group:
NS RT Group:
occipital 7
temporo-occipital 2
temporomedial 5
parahippocampal 1
RT group
L stroke 7
R stroke 8
CT group
L stroke 5
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F 6
OT group:
M 7
F 8
Mean 4.3 weeks
"Patients were recruited on
average about 4 weeks after
their stroke."
CT Group:
occipital 6
temporo-occipital 3
temporomedial 5
parahippocampal 1
OT Group*:
occipital 4
temporo-occipital 3
temporomedial 5
parahippocampal 1
*numbers presented
in paper do not add
up to 15 (?)
R stroke 10
OT group:
L stroke 5
R stroke 10
Plow 2010 12 Mean 59.6 years, SEM 3.5
years
M 5
F 7
Mean 39.8 ± 16.2 months,
range 3 to 192 months
NS Stroke 8 (7 infarct, 1
haemorrhage)
Surgical trauma 2
L-affected side
4
R-affected side
8
Poggel 2004 20 partici-
pants recruit-
ed. Baseline
data only
available for
19 (data for
one dropout
not reported)
Group 1
Mean 41.9 years
Range 20 to 67 years
Group 2
Mean 43.2 years
Range 30 to 61 years
Group 1
M 6
F 3
Group 2
M 6
F 4
Group 1
Mean 49.1 months, SEM ?,
Range 6.7 to 189.9 months
Group 2
Mean 24.1 months, SEM 5.0,
Range 6.8 to 58.3 months
NS Group 1
vascular 1
infarct 8
cortical and radia-
tions 4
cortical 5
Group 2
vascular 2
infarct 7,
traumatic brain in-
jury 1
cortical and radia-
tion 5
Group 1
L 5/R 4
Group 2
L 5/R 5
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cortical 3
radiation 2
Rossi 1990 39 Group 1
Mean 72.6 years, SEM 1.8
Group 2
Mean 63.3 years, SEM 2.5
Group 1
M 10
F 8
Group 2
M 9
F 12
Group 1
Mean 4.4 weeks, SEM 0.3
Group 2
Mean 4.7 weeks, SEM 0.6
NS Group 1
15 infarct
3 haemorrhage
Group 2
18 infarct
3 haemorrhage
Group 1
16 R/2 L
Group 2
13 R/8 L
Roth 2009 30 partici-
pants recruit-
ed (data avail-
able for 28; 2
dropouts)
Group 1
Mean 60.5 years, SD 11.0, Me-
dian 65
Group 2
Mean 60.3 years, SD 11.7,
Median 63
Group 1
4 F
11 M
Group 2
F 7
M 8
Group 1
Mean 39.20 months, SD 54.59,
Median 26
Group 2
Mean 87.87 months, SD
186.66, Median16
NS Group 1
Stroke 11
Haemorrhage 1
Head injury 1
Abscess 1
AVM 1
Group 2
Stroke 11
Haemorrhage 3
Cyst 1
Affected side
Group 1
L 8/R 7
Group 2
L 7/R 8
Rowe 2010 87 partici-
pants recruit-
ed (full results
for 70 partic-
ipants at 26
weeks)
Group 1
Mean 69.9 years, SD 12.9, me-
dian 68.8, IQR, 14.4
Group 2
Mean 70.9 years, SD 11.2, me-
dian 72.9, IQR, 15.2
Group 3
Mean 66.2 years, SD 11.3, me-
dian 68.2, IQR, 16.2
Group 1
4 F
22 M
Group 2
13 F
17 M
Group 3
9 F
20 M
Group 1
Mean 75.5 days, SD 45.3, me-
dian 64.5, IQR 78.0
Group 2
Mean 73.8 days, SD 49.2, me-
dian 69.0, IQR 97.0
Group 3
Mean 81.2 days, SD 48.0, me-
dian 67.0, IQR 61.0
Barthel In-
dex score
Group 1
Mean 97.5,
SD 5.5, me-
dian 100.0,
IQR 0.0
Group 2
Mean 92.7,
SD 11.9, me-
dian 100.0,
IQR 15.0
Group 3
Group 1
25 ischaemic
1 haemorrhage
Group 2
28 ischaemic
2 haemorrhage
Group 3
28 ischaemic
1 haemorrhage
Side of infarct
Group 1
L 9/R 16/bilater-
al 1
Group 2
L 17/R 13/bilat-
eral 0
Group 3
L 11/R 17/bilat-
eral 1
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Mean 93.3,
SD 14.7, me-
dian 100.0,
IQR 5.0
Schuett
2012
36 Group 1
Mean 64.0 years, SD 11.1,
range 44 to 81
Group 2
Mean 63.7 years, SD 13.3,
range 42 to 83
Group 1
3 F
15 M
Group 2
3 F
15 M
Group 1
Mean 26.6 weeks, SD 14.5,
range 6 to 57
Group 2
Mean 20.1 weeks, SD 18.8,
range 4 to 74
NS Group 1
17 posterior infarc-
tion
1 tumour operation
Group 1
17 posterior infarc-
tion
1 tumour operation
Side of field
loss
Group 1
L 9/R 9
Group 2
L 7/R 11
Spitzyna
2007
22 Age at symptom onset
Group 1
Range 5 to 67 years, mean
42.5*, SD 20.5*
Group 2
Range 39 to 78 years, mean
63.1*, SD 12.2*
Group 1
M 6
F 5
Group 2
M 7
F 1
Time since symptoms onset
Group 1
Range 1 to 37 years, mean
7.5*, SD 10.9*
Group 2
Range 3 months to 5 years,
mean 1.6*, SD 1.7*
NS Group 1
3 infarct
1 tuberous sclerosis
2 traumatic brain in-
jury, 2 tumour
2 haemorrhage
1 cyst
Group 2
8 infarct
Group 1
All R
Group 2
All R
Szlyk 2005 10 Group 1
Range 16 to 74 years, mean
50.6*, SD 22.5*
Group 2
Range 34 to 73 years, mean
54.0, SD 14.4
Group 1
5 M
Group 2
5 M
NS NS Group 1
4 CVA
1 tumour: all occipi-
tal lobe
Group 2
4 CVA
1 AVM: all occipital
lobe
Group 1
L 3/R 2
Group 2
L 4/R 1
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* Figures calculated from raw data supplied in papers
AVM: arteriovenous malformation
CVA: cerebrovascular accident
CT: compensatory training
F: female
IQR: interquartile range
L: leM
LL: lower leM
M: male
NS: not stated
OT: occupational therapy
R: right
RT: restitutive training
SD: standard deviation
SEM: standard error of the mean
UL: upper leM
UR: upper right
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Study Methods of
visual field
assessment
Type/extent of field loss Macular
sparing
Presence of neglect?
Aimola
2011
Unspeci-
fied kinetic
perimeter
Esterman
measures
of static su-
perthreshold
Group 1
Hemianopia 20, quadrantanopia 8
Group 2
Hemianopia 20, quadrantanopia 4
Group 1
Mean
1.92° (SD
1.44)
Group 2
Mean
2.45° (SD
1.85)
Yes: stated "Three patients (2 in
the intervention group, 1 in the
control group) had comorbid ne-
glect as confirmed with the bells
test".
Bain-
bridge
1994
Harrington
Flocks Visual
Screener
Confronta-
tion
Not stated Not stated Yes: no details of inclusion crite-
ria or participants provided, but
objective stated "To study the
effect of ... on visual neglect or
hemianopsia following stroke".
Bowers
2014
Goldmann
perimetry
Not stated Not stated No: stated "no visual neglect". Vi-
sual neglect diagnosed with Bells
test and Schenkenberg Line Bi-
section Test.
De Haan
2015
Goldmann
perimetry
Training group
Functional field score 58 ± 7.8
Quadrantanopia 5 (3 lower leM, 1 upper leM, 1 lower
right)
Hemianopia 21
Control group
Functional field score 64 ± 11.4
Quadrantanopia 5 (3 lower leM, 2 upper leM)
Hemianopia 18
Not stated No: stated "Neglect was excluded
based on the Balloons, drawings,
Line Bisection and Rey Complex
Figure Test."
Elshout
2016
Goldman
perimetry
Humphrey
perimetry
Right field loss: hemifield 4, incomplete hemifield 5,
quadrant 2, scotoma 1
LeM field loss: hemifield 2, incomplete hemifield 9,
quadrant 1, scotoma 2
Bilaterial field loss
Incomplete: 1
"All sub-
jects
had mac-
ular spar-
ing of at
least 2°"
No: patients with visual neglect
were excluded (based on line bi-
section test)
Gall 2013 Standard
automated
perimetry
Not stated Not stated Not stated
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Jarvis
2012
Confronta-
tion
Ocular diagnosis:
low vision 30
visual field loss 38
eye movement deficit 41
perceptual impairment 24
("Note: patients may have had an isolated visual im-
pairment or combined visual deficits")
Not stated Yes: all patients with a "post-
stroke visual impairment were el-
igible for inclusion".
Jobke
2009
Standard
automated
perimetry
High resolu-
tion perime-
try (HRP)
NB: It did not state whether participants had visual
neglect or whether this was diagnosed.
Group 1
2 diffuse, 2 full homonymous hemianopia, 1 partial
homonymous hemianopia, 1 full quadrantanopia
2 partial quadrantanopia
Group 2
4 diffuse, 2 full homonymous hemianopia, 2 partial
homonymous hemianopia, 1 full quadrantanopia,
1 partial quadrantanopia
Group 1
7 spar-
ing, 1 not
sparing
Group 2
10 sparing
Not stated
Kasten
1998
Tubinger
automated
perimetry
(TAP)
High resolu-
tion perime-
try (HRP)
NB: data were presented for full group of 38 partici-
pants (including participants in parallel trial)
Group 1
TAP 90° - border position, mean 3.51° (degrees of vi-
sual angle from zero vertical meridian), SEM 1.0
TAP 90° - number of misses, mean 53.0, SEM 9.1
Group 2
TAP 90° - border position, mean 3.43° (degrees of vi-
sual angle from zero vertical meridian), SEM 0.99
TAP 90° - number of misses, mean 69.2, SEM 11.2
Not stated No: participants with neglect
were excluded. Method of diag-
nosis of neglect not stated.
Kasten
2007
Tubinger
automated
perimetry
(TAP)
High resolu-
tion perime-
try (HRP)
TAP 90° (number of blind stimuli positions)
Group 1
Right eye - mean 46.6, SD 6.9, leM eye - mean 43.9, SD
3.7
Group 2
Right eye - mean 50.3, SD 8.7, leM eye - mean 43.1, SD
7.6
Group 3
Right eye - mean 32.9, SD 6.8, leM eye - mean 37.9, SD
7.1
Not stated No: participants with neglect
were excluded. Method of diag-
nosis of neglect not stated
Table 3.   Demographics of included studies: visual problems of included participants  (Continued)
Interventions for visual field defects in people with stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
119
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
.Keller
2010
Goldmann
perimetry
Goldmann
suprathresh-
old
Group 1
4 leM hemianopia
3 right hemianopia
1 UL quandrantanopia
1 LL quandrantanopia
1 UR quandrantanopia
Group 2
3 leM hemianopia
3 right hemianopia
3 UL quandrantanopia
1 LL quandrantanopia
Group 1
6 with 0°
macular
sparing
4 with < 5°
macular
sparing
Group 2
6 with 0°
macular
sparing
4 with < 5°
macular
sparing
No: participants with neglect
were excluded. 3 neglect tests
were used: "line bisection, Mesu-
lam test, draw a clock face test".
Modden
2012
Visual field
assessment
from the Test
Battery of
Attentional
Performance
RT Group
10 hemianopia
5 quadrantanopia
TAP alertness without cueing, ms; mean 304.2, SD
80.8
TAP conjunction search, omissions; mean 9.1, SD 9.0
CT Group
12 hemianopia
3 quadrantanopia
TAP alertness without cueing, ms; mean 383.7, SD
205.2
TAP conjunction search, omissions; mean 10.7, SD
6.7
OT Group
10 hemianopia
5 quadrantanopia
TAP alertness without cueing, ms; mean 308.1, SD
58.6
TAP conjunction search, omissions; mean 10.3, SD
5.6
RT Group
3/15 par-
ticipants
with less
than 2°
sparing
CT Group
3/15 par-
ticipants
with less
than 2°
sparing
plus 1 par-
ticipant
with no
sparing
OT Group
3/15 par-
ticipants
with less
than 2°
sparing
No: participants with neglect
were excluded. Method of diag-
nosis of neglect not stated.
Plow 2010 Subjective
topographic
measure of
perceived vi-
sual field de-
fect
7 hemianopia
5 quadrantanopia
Not stated Not stated
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High resolu-
tion perime-
try (HRP)
Poggel
2004
Tubinger
automated
perimetry
(TAP)
High res-
olution
campimetry
High resolu-
tion perime-
try (HRP)
Group 1
Upper attention field (size of area of residual vision,
%), mean 18.2, SEM 4.0
Lower probe field (size of area of residual vision, %),
mean 21.3, SEM 3.1
Total visual field (size of area of residual vision, %),
mean 7.3, SEM 1.9
Group 2
Upper attention field (size of area of residual vision,
%), mean 16.9, SEM 2.4
Lower probe field (size of area of residual vision, %),
mean 15.5, SEM 4.0
Total visual field (size of area of residual vision, %),
mean 6.7, SEM 1.3
Not stated No: participants with neglect
were excluded. Method of diag-
nosis of neglect not stated.
Rossi 1990 Harrington
Flocks Visual
Screener
Tangent
screen mea-
sures
Group 1
Homonymous hemianopia 12
(Visual neglect 6)
Group 2
Homonymous hemianopia 15
(Visual neglect 6)
Not stated Yes: participants with "homony-
mous hemianopia or visual ne-
glect were recruited ....". Method
of diagnosis of neglect was Har-
rington Flocks Visual Screener.
39 participants recruited: 27 had
homonymous hemianopia; 12
had visual neglect.
Roth 2009 Tubinger
automated
perimetry
(TAP)
Scanning
laser oph-
thalmoscopy
Group 1
Homonymous hemianopia 12, quadrantanopia 3
Group 2
Homonymous hemianopia 12, quadrantanopia 3
Not stated No: participants with neglect
were excluded. Method of diag-
nosis of neglect was clock-draw-
ing and line-bisection tests.
Rowe
2010
Goldmann
perimetry
Esterman
measures
of static su-
perthreshold
Group 1
Homonymous hemianopia leM partial 8, Homony-
mous hemianopia right partial 3, Homonymous
hemianopia leM complete 9, Homonymous hemi-
anopia right complete 6
Group 2
Homonymous hemianopia leM partial 5, Homony-
mous hemianopia right partial 9, Homonymous
hemianopia leM complete 8, Homonymous hemi-
anopia right complete 8
Group 3
Not stated No: participants with neglect
were excluded. Method of diag-
nosis was clinical assessment:
"as assessed by the orthoptist".
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Homonymous hemianopia leM partial 8, Homony-
mous hemianopia right partial 5, Homonymous
hemianopia leM complete 10, Homonymous hemi-
anopia right complete 6
Schuett
2012
Tubingen
kinetic
perimetry
Group 1
Hemianopia 15, quadranopia 1, paracentral sco-
toma 2
Group 2
Hemianopia 10, quadranopia 4, paracentral sco-
toma 4
Group 1
Mean 2.3°
(SD 1.4)
Group 2
Mean 2.3°
(SD 1.2)
No: participants with neglect
were excluded. Method of diag-
nosis described as: "as assessed
by tests in accordance with the
Behavioural Inattention Test (line
bisection, letter and star cancel-
lation, figure and shape copying,
drawing from memory; Halligan
et al, 1991)."
Spitzyna
2007
Goldmann
perimetry
Humphrey
automated
perimetry
Group 1
Full homonymous hemianopia 8, partial homony-
mous hemianopia 1, lower quadrantanopia 1, upper
quadrantanopia 1
Group 2
Full homonymous hemianopia 6, lower quadran-
tanopia 1, upper quadrantanopia 1
Macular
sparing
defined as
2° of spar-
ing
Group 1
Sparing 5,
non-spar-
ing 6
Group 2
Sparing 3,
non spar-
ing 5
No: only participants with right-
sided homonymous hemianopic
were included; therefore, pres-
ence of neglect was assumed un-
likely.
Szlyk 2005 Goldmann
perimetry
Group 1
Goldmann III4e, range 45.2 to 125, mean 59.12*, SD
22.07*
Goldmann V4e, range 48.8 to 115, mean 70.56*, SD
26.15*
Group 2
Goldmann III4e, range 46.8 to 123.8, mean 68.0*, SD
31.71*
Goldmann V4e, range 50.67 to 132, mean 73.73*, SD
33.10*
Figures were calculated for the affected side only.
Not stated Not stated; however, although it
was not stated whether the par-
ticipants may have had visual ne-
glect, neglect is unlikely in oc-
cipital lesions, and only partici-
pants with occipital lesions were
included.
Table 3.   Demographics of included studies: visual problems of included participants  (Continued)
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UR: upper right
 
Interventions for visual field defects in people with stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
123
Interventions for visual field defects in people w
ith stroke (Review
)
Copyright ©
 2019 The Cochrane Collaboration. Published by John W
iley & Sons, Ltd.
124
StudyFunc-
tion-
al
abil-
i-
ty
in
ADL
Visual field
Outcome category (measure)
Func-
tion-
al
abil-
i-
ty
in
EADL
Read-
ing
FallsQuality
of life
Visual scan-
ning
Ad-
verse
events
Other Outcomes with data included within
meta-analyses
Aimo-
la
2011
  Kinetic Perimetry (unspecified kinetic
perimeter)
Static Superthreshold (Esterman mea-
sures of static superthreshold)
(NB not clear if recorded as outcome or
not; no results provided for visual field
data)
  Read-
ing
(cor-
rected
read-
ing
speed)
 1. VFQ 25
2. VIQ -
Visual
Impair-
ments
ques-
tionnaire
3. Sub-
jective
Reasons
ques-
tionnaire
1. visual
search - find
the number
(computer -
based)
2. visuomo-
tor search
- find items
on a shelf
  Tasks simulating ADL - 1. dri-
ving hazard perception (mean
score per hazard), 2. obstacle
avoidance (completion time), 3.
visuomotor search (time)
Attention tasks - 1. sustained
attention to response (mean
percentage error score), 2. test
of everyday attention
Reading: Analysis 2.3
Visual search: time to complete Analysis
2.5
QoL: data not included as only available
for individual questionnaire items
Bain-
bridge
1994
  Gross visual screening (Harring-
ton-Flocks Visual Field Score)
      Line Cancel-
lation Test
  Motor Free Visual Perception
Score
Line Bisection Test
No data included in meta-analyses (as
no control group). See Table 5
Bow-
ers
2014
    Mo-
bil-
i-
ty
ques-
tion-
naire
        Question: "If the study were
to end today, would you want
to continue with these prism
glasses (i.e. the prism glasses
worn in that period)?"
Functional ability in EADL: Analysis 3.3
De
Haan
2015
  Kinetic perimetry (Goldmann Perimetry,
Functional Field score)
In-
de-
pen-
dent
Mo-
bil-
i-
ty
ques-
1. Rad-
ner
read-
ing
test;
(a)
Rad-
ner av-
erage
read-
 1. NEI-
VFQ-25
(Visual
Func-
tional
ques-
tion-
naire)
2. Cere-
bral Vi-
1. visual
scanning -
dots test
2. visual
search - let-
ters (parallel
search test)
3. visual
search - let-
Not
re-
port-
ed
as
an
out-
come
mea-
sure,
Visual acuity, contrast sensitiv-
ity, hazard perception, simulat-
ing driving/tracking task, obsta-
cle course
Visual field: Functional Field score
Analysis 2.1
Reading: Radner average reading speed
Analysis 2.3
Visual scanning: Parallel search test,
time Analysis 2.5
QoL: NEI VFQ Analysis 2.4
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tion-
naire
ing
speed
(wpm),
(b)
min-
imal
read-
able
text
size
(Lo-
gRad)
2. Text
read-
ing
test;
(a) text
read-
ing
speed
(wpm),
(b) text
correct
an-
swers
sual Dis-
orders
ques-
tionnaire
ters (serial
search)
but
stat-
ed
no
ad-
verse
events
in
ei-
ther
group
Functional ability in EADL: mobility
questionnaire Analysis 2.2
Elshout
2016
  Goldman perimetry
Humphrey perimetry
  Read-
ing
speed
(words
per
minute)
- 15
point
Arial
font,
88 and
165
words
        No data included (as data not available
for before the cross-over)
Gall
2013
  Static Threshold Perimetry (Standard
automated perimetry)
     1. NEI
VFQ
39 (vi-
sion-re-
lated)
      No data included in meta-analyses (as
no suitable data presented in abstract)
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2. SF-12
(health-
related)
Jarvis
2012
FIM            1. Functional mobility (timed
walk)
2. Non-validated questionnaire
giving qualitative information
about their treatment ap-
proach
Functional ability in ADL: Functional In-
dependence Measure Analysis 4.1
Jobke
2009
  Static Threshold Perimetry (Standard
automated perimetry)
Resolution Perimetry (High resolution
perimetry)
  Radner
read-
ing test
 NEI VFQ     Zahlen-Verbindungs
test (ZVT) for measuring the
speed of connecting numbers
in
a paper-pencil test
No data included in meta-analyses (as
no control group). See Table 5 (for data
available before the cross-over)
Kas-
ten
1998
  Resolution Perimetry (High resolution
perimetry)
Static Threshold Perimetry (Tubinger
automated perimetry)
     Quali-
ty of life
ques-
tionnaire
    Visual acuity: Landolt ring to
give minimum angle of resolu-
tion
Visual field: Tubinger automated
perimetry: border position in degrees of
visual angle from zero vertical meridian
Analysis 1.1
Quality of life Analysis 1.2
Kas-
ten
2007
  Resolution Perimetry (High resolution
perimetry: number of hits, learning ef-
fects, fixation ability, false hits)
Static Threshold Perimetry (Tubinger
automated perimetry: no of hits, fixation
ability)
     Subjec-
tive visu-
al abili-
ty ques-
tionnaire
    1. Eye movements: "Chronos Vi-
sion Eye Tracker"
2. Visual acuity
3. "Zahlen-Verbindungs Test" of
visuo-spatial attention
4. "Alters-Konzentrationstest"
attention test for older people
5. "testbatterie zur Aufmerk-
samkeitspruefung" ability to
improve attention
No data included in meta-analyses (as
no control group). See Table 5 (for avail-
able data comparing group outcomes)
Keller
2010
  Kinetic Perimetry (Goldmann perimetry)
Static Superthreshold (Goldmann
suprathreshold)
  Read-
ing
time
(stan-
dard-
ised
 OT ad-
minis-
tered
ques-
tionnaire
(based
1. Visual ex-
ploration
test (num-
ber of omis-
sions)
  Electro-oculography No data included in meta-analyses (as
no control group). See Table 5
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read-
ing
test)
on Kerk-
hoff's
self-eval-
uation of
ADL)
2. Search
task (search
time)
Mod-
den
2012
Ex-
tend-
ed
Barthel
In-
dex
(Ger-
man)
Gross Visual Screening (Test Battery of
Attentional Performance:
visual field assessment)
  Read-
ing -
Weschler
memo-
ry tests
(errors)
  1. Visual
scan: from
the Test Bat-
tery of At-
tention-
al Perfor-
mance
2. Visual
search: can-
cellation
tasks from
Behavioural
Inattention
Test (BIT)
(omissions)
  Attention: Test Battery of Atten-
tional Performance (alertness)
No data included in meta-analyses (as
no control group). See Table 5
Plow
2010
  Resolution Perimetry (High resolution
perimetry: position of visual field border
and stimulus detection accuracy)
Gross Visual Screening (subjective topo-
graphic
measure of perceived visual field deficit)
     Impact
of Vision
Impair-
ment
(IVI) pro-
file
Low Vi-
sion-
Visual
Func-
tional
Ques-
tionnaire
(LV-VFQ)
    Measure of fixation perfor-
mance
No data included in meta-analyses (as
no control group). See Table 5
Poggel
2004
  Static Threshold Perimetry (Tubinger
automated perimetry (TAP))
Static Superthreshold (High resolution
campimetry)
            No data included in meta-analyses (as
no control group). See Table 5
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Resolution Perimetry (High resolution
perimetry (HRP))
Rossi
1990
Barthel
In-
dex
Gross Visual Screening (Harrington
Flocks Visual Screener)
Static Superthreshold (Tangent screen
examination)
    Num-
ber
of
falls
  Line cancel-
lation task
  Modified Mini Mental Status Ex-
amination,
Motor Free Visual Perceptual
Test,
Line Bisection Task
ADL: Barthel Index: Analysis 3.1
Visual Field: Analysis 3.2
Falls: number of falls Analysis 3.5
Visual scanning: cancellation Analysis
3.7
Roth
2009
  Static Threshold Perimetry (Tubinger
automated perimetry (TAP))
Resolution Perimetry (Scanning laser
ophthalmoscopy)
  Read-
ing
speed
 QoL:
World
Health
Organ-
isation
ques-
tionnaire
WHO-
QOL-BREF
1. Digit
search task
(response
time)
2. Natural
search task
(table test)
(response
time)
3. Natural
scene explo-
ration
4. Fixation
stability
(video eye
tracker)
    No data included in meta-analyses (as
no control group). See Table 5
Rowe
2010
  Kinetic Perimetry (Goldmann perimetry)
Static Superthreshold (Esterman mea-
sures of static superthreshold)
Not-
ting-
ham
ex-
tend-
ed
ac-
tiv-
i-
ties
of
dai-
ly
liv-
Read-
ing
ability
(Rad-
ner
test)
 1. VFQ
25-10 (vi-
sion re-
lated)
2. EQ-5D
3. SF-12
  Num-
ber
of
par-
tic-
i-
pants
and
num-
ber
of
ad-
verse
events
Rivermead Mobility Index Visual Field: relative change in visual
field area Analysis 2.1 and Analysis 3.2
QoL: VFQ 25-10 Analysis 2.4 and Analysis
3.6
Adverse events:Analysis 2.6; Analysis 3.8
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ing
(NEADL)
Schuett
2012
  Kinetic Perimetry (Tubingen kinetic
perimetry) (NB not recorded immediate-
ly after first phase)
  Read-
ing
(speed
and er-
rors)
  Cancellation
(speed and
errors)
    No data included in meta-analyses (as
no control group). See Table 5
Spitzy-
na
2007
  Kinetic Perimetry (Goldmann perimetry)
Static Threshold Perimetry (Humphrey
10-2 central threshold programme)
(NB not recorded immediately after first
phase)
  1. Text
read-
ing
speeds
2. Sin-
gle
word
read-
ing
speeds
      Eye movement characteristics:
- spatial characteristics of sac-
cadic amplitude, incoming sac-
cade amplitude and landing
position
- temporal characteristics
Reading (text reading speed): Analysis
2.3
Visual field -data not included as not col-
lected before cross-over.
Sz-
lyk
2005
  Kinetic Perimetry (Goldman Perimetry)           Indoor functional assessment
Outdoor functional assessment
Driving skills assessment
Psychophysical assessment
Satisfaction
Prisms use at 2 years
No data included in meta-analyses(as no
control group).
No data reported for before the cross-
over.
Table 4.   Outcome measures within included studies  (Continued)
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BIT: behavioural inattention test
EADL: extended activities of daily living
EQ-5D:standardised EuroQol health-related quality of life instrument
FIM: Functional Independence Measure
HRP: high resolution perimetry
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LogRad: a scale of reading acuity
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OT: occupational therapy
QoL: quality of life
SF-12: 12-Item Short Form Health Survey
TAP: tubinger automated perimetry
VFQ: visual function questionnaire
VIQ: visual impairment questionnaire
WHOQOL-BREF: World Health Organisation quality of life questionnaire
wpm: words per minute
ZVT: Zahlen-Verbindungs test
 
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
Study Interven-
tions
Outcome Mean (or
other re-
ported
result if
no mean
available)
Standard
deviation
Number
of partici-
pants
Statistical test/
results
Restitution: one restitution intervention versus another restitution intervention
Extrastri-
ate VRT
increase from baseline
of 5.9% (percentage of
HRP hits)
8 significant in-
crease: t = -5.262,
P = 0.0005
Jobke 2009
Standard
VRT
Visual field (high-resolution perime-
try, HRP)
increase from baseline
of 2.9% (percentage of
HRP hits)
10 significant in-
crease: t = -2.373,
P = 0.021
Parallel
co-stimu-
lation
increase of 2.4% detect-
ed stimuli
7
Moving
co-stimu-
lation
increase of 6.5% detect-
ed stimuli
7
Kasten 2007
Single
stimulus
Visual field (high-resolution perime-
try)
increase of 3.9% detect-
ed stimuli
9
No significant
difference "con-
firmed by non-
parametric
Kruskal–Wallis
ANOVA"
VRT + tD-
CS
shiM from baseline to
post-test from
4.11° ± 1.50° to 8.37° ±
2.29°, Wilcoxon signed-
rank test = 0, P = 0.068
4
VRT +
sham tD-
CS
Visual field (high-resolution perime-
try)
shiM from baseline to
post-test from 6.33° ±
2.59° to 7.03° ± 2.51°,
Wilcoxon signed-rank
test = 1, P = 0.144
4
Mann-Whitney
U = 0, P = 0.021
(significantly
greater shiM in
the visual field
border with VRT
+ tDCS than VRT
alone)
VRT + tD-
CS
shiM from baseline to
post-test from 32.25
± 5.30 to 28.25 ± 5.07;
Wilcoxon signed-rank
test = 0; P = 0.068
4
VRT +
sham tD-
CS
Functional ability in ADL (LV-VFQ)
shiM from baseline to
post-test from 28 ± 2.34
to 25.25 ± 1.11; Wilcox-
on signed-rank test = 1;
P = 0.285
4
Mann-Whitney U
= 5.5; P = 0.468
(non-significant)
Plow 2010
VRT + tD-
CS
Functional ability in ADL (LV-VFQ) -
6-month follow-up
29.00 3.58 5 Wilcoxon signed-
rank test = 4; P =
0.343
Table 5.   Results of studies comparing two similar active interventions (i.e. two interventions from the same
category) 
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VRT +
sham tD-
CS
26.80 2.11
VRT + tD-
CS
23.20 7.83
VRT +
sham tD-
CS
Quality of life - 6-month follow-up
16.8 4.62
5 Wilcoxon
signed-rank test
= 2.5; P = 0.357
VRT + at-
tentional
cueing
8.3 SEM 1.5 9Poggel 2004
VRT with
no atten-
tional
cueing
Visual field (high-resolution perime-
try) - percentage improvement, at-
tention field
2.9 SEM 0.8 10
P = 0.001 (in
favour of atten-
tional cueing)
Compensation: one compensation intervention versus another compensation intervention
Visual ex-
ploration
training
105.3 33.8 18
Reading
training
Reading speed
124.6 39.5 18
Not reported;
calculated as MD
-19.30 (-43.32 to
4.72) (see Figure
3)
Visual ex-
ploration
training
18.5 4.9 18
Schuett 2012
Reading
training
Cancellation test (exploration time)
36.8 7.2 18
Not reported;
calculated as MD
18.30 (14.28 to
22.32) (see Fig-
ure 3)
Audiovi-
sual ex-
ploration
training
(AVT)
1.5 (SE dis-
played on
graph on-
ly)
10
Visual ex-
ploration
training
Functional ability in ADL (ADL test
total score)
5.0 (SE dis-
played on
graph on-
ly)
10
ANOVA P = 0.036
(in favour of AVT)
Audiovi-
sual ex-
ploration
training
(AVT)
75 (SE dis-
played on
graph on-
ly)
10
Keller 2010
Visual ex-
ploration
training
Reading time (seconds)
178 (SE dis-
played on
graph on-
ly)
10
ANOVA P = 0.03
(in favour of AVT)
Table 5.   Results of studies comparing two similar active interventions (i.e. two interventions from the same
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Audiovi-
sual ex-
ploration
training
(AVT)
85.3 (SE dis-
played on
graph on-
ly)
10
Visual ex-
ploration
training
Visual scanning (percentage hits)
64.1 (SE dis-
played on
graph on-
ly)
10
ANOVA P = 0.01
(in favour of AVT)
Comput-
er-based
compen-
sation
therapy
2.9 4.0 15 Pre- to post-
treatment signif-
icant field expan-
sion (P = 0.013)
Standard
occupa-
tional
therapy
(compen-
sation)
Visual field enlargement (visual field
assessment from Test Battery of At-
tentional Performance)
1.3 4.7 15 Pre- to post-
treatment: no
significant field
expansion (P =
0.316)
Comput-
er-based
compen-
sation
therapy
(CT)
3.3 3.6 15
Standard
occu-
pation-
al thera-
py (OT)
(compen-
sation)
Functional ability in ADL (improve-
ment in Extended Barthel Index)
1.8 2.0 15
"No significant
treatment effects
were found when
comparing ... CT/
OT".
Comput-
er-based
compen-
sation
therapy
(CT)
-0.9 1.1 15
Standard
occu-
pation-
al thera-
py (OT)
(compen-
sation)
Reading - Improvement in reading
performance, reduction in number
of errors (from baseline)
-0.7 1.0 15
"Compared with
OT"... "CT did not
significantly re-
duce reading er-
rors."
Modden 2012
Comput-
er-based
compen-
sation
Visual scanning - reduction in num-
ber of omissions from baseline, can-
cellation tasks of the Test Battery of
Attentional Performance
-5.4 5.2 15 "Compared with
OT"... "CT did not
result in superior
improvements".
Table 5.   Results of studies comparing two similar active interventions (i.e. two interventions from the same
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therapy
(CT)
Standard
occu-
pation-
al thera-
py (OT)
(compen-
sation)
-2.3 5 15
Substitution: one substitution intervention versus another substitution intervention
Full-field
Fresnel
Prisms
2.9 2 10
Hemi-field
Fresnel
Prisms
Visual Field (Harrington Flocks Visu-
al Field Score)
7.2 3 8
States full-field
more improved
Full-field
Fresnel
Prisms
4.7 1.3 10
Bainbridge 1994
Hemi-field
Fresnel
Prisms
Scanning (Line cancellation test er-
rors)
0.3 0.6 8
P < 0.01, Stu-
dent's t-test (in
favour of full-
field prisms)
18.5 diop-
tre Got-
tlieb Vi-
sual field
aware-
ness
system
prisms
Szlyk 2005
Press-
on TM 20
Diopter
Fresnel
prisms
Visual skills category assessment
battery
"There was improve-
ment within all cate-
gories with both of the
prism systems rang-
ing from 36% for mo-
bility (with the Fres-
nel prisms) to 13% for
recognition (with the
Gottlieb VFAS)."
10 (da-
ta only
available
for after
cross-
over)
"There were no
statistically sig-
nificant differ-
ences between
improvements
with the Gottlieb
VFAS compared
with the
Fresnel prisms."
Table 5.   Results of studies comparing two similar active interventions (i.e. two interventions from the same
category)  (Continued)
ADL: activities of daily living
ANOVA: analysis of variance (statistical test of)
AVT: audiovisual exploration training
CT: compensation therapy
HRP: high-resolution perimetry
LV-VFQ: Low Vision Visual Functioning Questionnaire
MD: mean difference
OT: occupational therapy
SE: standard error
SEM: standard error of the mean
tDCS: transcranial direct current stimulation
VFAS: visual field awareness system
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VRT: visual restitution therapy
 
 
Study Interven-
tions
Outcome Mean (or
other re-
ported
result if
no mean
available)
Standard
deviation
Number
of partici-
pants
Statistical test/re-
sults
Compensation intervention versus restitution intervention
Comput-
er-based
restitution
therapy
3.9 4.9 15 Pre- to post-treat-
ment significant
field expansion (P =
0.003)
Comput-
er-based
compen-
sation
therapy
Visual field enlargement (visu-
al field assessment from Test
Battery of Attentional Perfor-
mance)
2.9 4.0 15 Pre- to post-treat-
ment significant
field expansion (P =
0.013)
Comput-
er-based
restitution
therapy
(RT)
1.5 2.8 15
Comput-
er-based
compen-
sation
therapy
(CT)
Functional ability in ADL (im-
provement in Extended Barthel
Index)
3.3 3.6 15
"No significant
treatment effects
were found when
comparing ... RT/
CT".
Comput-
er-based
restitution
therapy
(RT)
-0.9 2.4 15
Comput-
er-based
compen-
sation
therapy
(CT)
Reading: improvement in read-
ing performance, reduction in
number of errors (from base-
line)
-0.9 1.1 15
"There were no dif-
ferences between
RT and CT."
Comput-
er-based
restitution
therapy
(RT)
-5.3 10.5 15
Modden 2012
Comput-
er-based
compen-
Visual scanning: reduction in
number of omissions from base-
line, cancellation tasks of the
Test Battery of Attentional Per-
formance
-5.4 5.2 15
"... the improve-
ment of the CT
compared with
the RT group did
not meet the de-
fined significance
level after Bonfer-
roni correction (P
= .023)."
Table 6.   Results of studies comparing two di:erent types of active interventions (i.e. interventions from di:erent
categories) 
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sation
therapy
(CT)
Explo-
rative
scanning
train-
ing (EST)
(compen-
sation)
44.4 13.1 15
Flicker
stimula-
tion train-
ing (FT)
(restitu-
tion)
Visual field: Tubingen automat-
ed perimetry
35.7 15.2 13
"Neither the EST
group nor the FT
group showed any
differences in their
TAP or SLO out-
comes, quantified
as the total num-
ber of stimuli de-
tected in the blind
hemifield (lowest P
= 0.204)."
Explo-
rative
scanning
train-
ing (EST)
(compen-
sation)
12.93 1.67 15
Flicker
stimula-
tion train-
ing (FT)
(restitu-
tion)
Quality of life (WHOQOL-BREF)
13.23 1.3 13
"The EST group re-
ported greater im-
provements (T2 mi-
nus T1 scores) in
the WHOQOL so-
cial-relationships
domain (t test;
t(20) = 2.217, P =
0.038)" (but no sig-
nificant differences
for other domains).
Explo-
rative
scanning
train-
ing (EST)
(compen-
sation)
99.7 34.7 15
Roth 2009
Flicker
stimula-
tion train-
ing (FT)
(restitu-
tion)
Reading (reading speed)
140.2 20.9 13
"Although the EST
and FT groups dif-
fered in their read-
ing speeds at T1,
this difference re-
mained unchanged
[main effect of
group, F(1,26) =
133.074, P < 0.0001,
interaction, F < 1]".
Compensation intervention versus substitution intervention
Fresnel
prisms
(substitu-
tion)
0.052 0.1396 24Rowe 2010*
Visual
search
Visual Field (relative change in
visual field area)
0.0815 0.1488 24
ANOVA results: no
significant differ-
ences between
groups (P = 0.55, for
comparison across
3 treatment groups)
Table 6.   Results of studies comparing two di:erent types of active interventions (i.e. interventions from di:erent
categories)  (Continued)
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training
(compen-
sation)
Fresnel
prisms
(substitu-
tion)
15.2 4.8 22
Visual
search
training
(compen-
sation)
Extended activities of daily liv-
ing (change in EADL from base-
line)
15.2 4.4 22
"No evidence of dif-
ferences ..."
Fresnel
prisms
(substitu-
tion)
17.4 21.3 24
Visual
search
training
(compen-
sation)
Reading (change in Radner
reading speed)
13.0 13.1 25
"No evidence of dif-
ferences ..."
Fresnel
prisms
(substitu-
tion)
68.2 18.4 24
Visual
search
training
(compen-
sation)
Quality of life (VFQ-25 total
score)
68.4 20.0 25
"Visual function
(using the VFQ
25-10) improved at
26 weeks in the vi-
sual search train-
ing arm (60 [SD
19] to 68.4 [SD 20])
when compared to
the Fresnel prisms
(68.5 [SD 16.4] to
68.2 [18.4]) and
standard care arms
(63.7 [SD 19.4] to
59.8 [SD 22.7]: Ta-
ble 6, ANCOVA P =
0.05)."
Fresnel
prisms
(substitu-
tion)
18 participants 26 "Given the extent
and range of ad-
verse events report-
ed with prism wear,
caution must be ex-
ercised if prescrib-
ing prism glasses
as an intervention
for homonymous
hemianopia."
Visual
search
training
Adverse events (number of par-
ticipants with reported adverse
events during study)
2 participants 30  
Table 6.   Results of studies comparing two di:erent types of active interventions (i.e. interventions from di:erent
categories)  (Continued)
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(compen-
sation)
Table 6.   Results of studies comparing two di:erent types of active interventions (i.e. interventions from di:erent
categories)  (Continued)
*Rowe 2010 also had a control (standard care) group, and data were included in relevant meta-analyses for compensatory and substitution
interventions versus control.
ADL: activities of daily living
ANCOVA: analysis of covariance (statistical test of)
ANOVA: analysis of variance (statistical test of)
CT: compensation therapy
EADL: extended activities of daily living
EST: explorative scanning training
FT: flicker stimulation training
RT: restitution therapy
SD: standard deviation
SLO: Scanning Laser Ophthalmoscope
T1: outcome asssessment timepoint 1
T2: outcome assessment timepoint 2
TAP: Tuebingen automated perimetry
VFQ: visual function questionnaire
WHOQOL-BREF: World Health Organization Quality of Life Instrument
 
 
A P P E N D I C E S
Appendix 1. Cochrane Central Register of Controlled Trials (CENTRAL) Search Strategy
1. MeSH descriptor Cerebrovascular Disorders, this term only
2. MeSH descriptor Basal Ganglia Cerebrovascular Disease explode all trees
3. MeSH descriptor Brain Ischemia explode all trees
4. MeSH descriptor Carotid Artery Diseases explode all trees
5. MeSH descriptor Intracranial Arterial Diseases explode all trees
6. MeSH descriptor Intracranial Arteriovenous Malformations explode all trees
7. MeSH descriptor Intracranial Embolism and Thrombosis explode all trees
8. MeSH descriptor Intracranial Hemorrhages explode all trees
9. MeSH descriptor Stroke explode all trees
10.MeSH descriptor Brain Infarction explode all trees
11.MeSH descriptor Vasospasm, Intracranial, this term only
12.MeSH descriptor Vertebral Artery Dissection, this term only 
13.stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc* or cva* or apoplex* or SAH
14.(brain* or cerebr* or cerebell* or intracran* or intracerebral) near/5 (isch?emi* or infarct* or thrombo* or emboli* or occlus*)
15.(brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) near/5 (haemorrhage* or hemorrhage* or haematoma*
or hematoma* or bleed*)
16.MeSH descriptor Hemiplegia, this term only
17.MeSH descriptor Paresis explode all trees
18.hemipleg* or hemipar* or paresis or paretic 1735
19.(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)
20.MeSH descriptor Eye explode all trees
21.MeSH descriptor Visually Impaired Persons explode all trees
22.MeSH descriptor Ocular Physiological Processes explode all trees
23.MeSH descriptor Diagnostic Techniques, Ophthalmological explode all trees
24.MeSH descriptor Optometry explode all trees
25.MeSH descriptor Orthoptics explode all trees
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26.MeSH descriptor Eye Diseases, this term only
27.MeSH descriptor Vision Disorders, this term only
28.MeSH descriptor Eye Manifestations, this term only
29.MeSH descriptor Blindness, this term only
30.MeSH descriptor Diplopia explode all trees
31.MeSH descriptor Vision, Binocular, this term only
32.MeSH descriptor Vision, Monocular, this term only
33.MeSH descriptor Visual Acuity explode all trees
34.MeSH descriptor Visual Fields, this term only
35.MeSH descriptor Vision, Low, this term only
36.MeSH descriptor Perimetry, this term only
37.MeSH descriptor Ophthalmology, this term only
38.MeSH descriptor Vision Screening, this term only
39.MeSH descriptor Eye Diseases, Hereditary explode all trees
40.MeSH descriptor Eye Hemorrhage explode all trees
41.MeSH descriptor Lacrimal Apparatus Diseases explode all trees
42.MeSH descriptor Lens Diseases explode all trees
43.MeSH descriptor Ocular Hypertension explode all trees
44.MeSH descriptor Ocular Hypotension explode all trees
45.MeSH descriptor Ocular Motility Disorders explode all trees
46.MeSH descriptor Optic Nerve Diseases explode all trees
47.MeSH descriptor Orbital Diseases explode all trees
48.MeSH descriptor Pupil Disorders explode all trees
49.MeSH descriptor Refractive Errors explode all trees
50.MeSH descriptor Retinal Diseases explode all trees
51.MeSH descriptor Blindness, Cortical explode all trees
52.MeSH descriptor Hemianopsia explode all trees
53.MeSH descriptor Vitreoretinopathy, Proliferative explode all trees
54.MeSH descriptor Vitreous Detachment explode all trees
55.MeSH descriptor Scotoma, this term only
56.MeSH descriptor Abducens Nerve, this term only
57.MeSH descriptor Oculomotor Nerve, this term only
58.MeSH descriptor Trochlear Nerve, this term only
59.nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder* or retinal or retinopathy or macular
degeneration or glaucoma or cataract* or ophthalmol* or optic nerve
60.intranuclear ophthalmoplegia or parinaud's syndrome or weber's syndrome or skew deviation or conjugate deviation
61.one near/3 half syndrome
62.(visual* or vision or eye or eyes or eyesight or sight) near/5 (problem* or disorder* or impair* or disabilit* or loss or disease* or defect*
or manifestation* or screening or test* or examination*)
63.hemianop* or blindness or low vision or refractive errors or vitreoretinopathy or vitreous detachment or scotoma or diplopia or op-
tometr* or ocular or orthoptic*
64.oscillopsia or visual tracking or fresnel prism*
65.III or IV or VI or third or fourth or sixth near/3 nerve palsy
66.(#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37
OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR
#55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65)
67.(#19 AND #66)
68.MeSH descriptor Infant explode all trees
69.MeSH descriptor Child explode all trees
70.neonat* or child or children or childhood or juvenile or infan* or toddler
71.MeSH descriptor Neoplasms explode all trees
72.cancer* or carcinoma* or tumor* or tumour* or neoplasm*
73.(#68 OR #69 OR #70 OR #71 OR #72)
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74.(#67 AND NOT #73)
Appendix 2. MEDLINE (Ovid) Search Strategy
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or cere-
bral small vessel diseases/ or stroke, lacunar/ or exp intracranial arterial diseases/ or exp intracranial arteriovenous malformations/ or exp
"intracranial embolism and thrombosis"/ or exp intracranial hemorrhages/ or stroke/ or exp brain infarction/ or vasospasm, intracranial/
or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma
$ or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp eye/
9. exp visually impaired persons/
10. exp ocular physiological processes/ or exp diagnostic techniques, ophthalmological/
11. Optometry/ or Orthoptics/
12. eye diseases/ or vision disorders/ or eye manifestations/ or blindness/ or diplopia/
13. vision, binocular/ or vision, monocular/ or exp visual acuity/ or visual fields/ or vision, low/ or perimetry/ or ophthalmology/ or vision
screening/
14. exp ocular motility disorders/ or exp orbital diseases/ or exp pupil disorders/ or exp blindness, cortical/ or exp hemianopsia/ or sco-
toma/
15. abducens nerve/ or oculomotor nerve/ or trochlear nerve/
16. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve).tw.
17. (intranuclear ophthalmoplegia or parinaud's syndrome or weber's syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw.
18. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or defect$
or manifestation$ or screening or test$ or examination$)).tw.
19. (hemianop$ or blindness or low vision or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
20. (oscillopsia or visual tracking or fresnel prism$).tw.
21. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
22. or/8-21
23. Randomized Controlled Trials as Topic/
24. random allocation/
25. Controlled Clinical Trials as Topic/
26. control groups/
27. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical
trials, phase iv as topic/
28. double-blind method/
29. single-blind method/
30. Placebos/
31. placebo effect/
32. cross-over studies/
33. randomized controlled trial.pt.
34. controlled clinical trial.pt.
35. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
36. (random$ or RCT or RCTs).tw.
37. (controlled adj5 (trial$ or stud$)).tw.
38. (clinical$ adj5 trial$).tw.
39. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
40. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
41. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
42. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
43. (cross-over or cross over or crossover).tw.
44. (placebo$ or sham).tw.
45. trial.ti.
46. (assign$ or allocat$).tw.
47. controls.tw.
48. or/23-47
49. 7 and 22 and 48
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50. exp animals/ not humans.sh.
51. 49 not 50
52. (neonat$ or child or children or childhood or juvenile or infant or toddler).ti.
53. 51 not 52
Appendix 3. Embase Search Strategy
1. cerebrovascular disease/ or exp basal ganglion hemorrhage/ or exp brain hematoma/ or exp brain hemorrhage/ or exp brain infarction/
or exp brain ischemia/ or exp carotid artery disease/ or cerebral artery disease/ or exp cerebrovascular accident/ or exp cerebrovascular
malformation/ or exp intracranial aneurysm/ or exp occlusive cerebrovascular disease/ or stroke unit/ or stroke patient/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma
$ or hematoma$ or bleed$)).tw.
5. hemiparesis/ or hemiplegia/ or paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp eye/ or exp eye disease/ or exp visual disorder/
9. exp visual system examination/ or eye examination/ or exp vision test/
10. exp ophthalmology/ or orthoptics/ or exp visual system/ or exp visual system function/ or depth perception/
11. exp visual aid/
12. abducens nerve/ or oculomotor nerve/ or trochlear nerve/
13. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve).tw.
14. (intranuclear ophthalmoplegia or parinaud's syndrome or weber's syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw.
15. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or defect$
or manifestation$ or screening or test$ or examination$)).tw.
16. (hemianop$ or blindness or low vision or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
17. (oscillopsia or visual tracking or fresnel prism$).tw.
18. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
19. or/8-18
20. Randomized Controlled Trial/ or "randomized controlled trial (topic)"/
21. Randomization/
22. Controlled clinical trial/ or "controlled clinical trial (topic)"/
23. control group/ or controlled study/
24. clinical trial/ or "clinical trial (topic)"/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/
25. Crossover Procedure/
26. Double Blind Procedure/
27. Single Blind Procedure/ or triple blind procedure/
28. placebo/ or placebo effect/
29. (random$ or RCT or RCTs).tw.
30. (controlled adj5 (trial$ or stud$)).tw.
31. (clinical$ adj5 trial$).tw.
32. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
33. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
34. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
35. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
36. (cross-over or cross over or crossover).tw.
37. (placebo$ or sham).tw.
38. trial.ti.
39. (assign$ or allocat$).tw.
40. controls.tw.
41. or/20-40
42. 7 and 19 and 41
43. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not (human/
or normal human/ or human cell/)
44. 42 not 43
45. (neonat$ or child or children or childhood or juvenile or infant or toddler).ti.
46. exp Neoplasm/
47. (cancer$ or carcinoma$ or tumor$ or tumour$ or neoplasm$).tw.
48. 45 or 46 or 47
49. 44 not 48
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Appendix 4. CINAHL Search Strategy
S1. MH "Cerebrovascular Disorders+" or MH "stroke patients" or MH "stroke units"
S2. TI ( stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* ) or AB ( stroke or poststroke or post-stroke or cerebrovasc* or
brain vasc* )
S3. TI ( brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cerebell* or intracran* or intracerebral )
S4. TI ( ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus* ) or AB ( ischemi* or ischaemi* or infarct* or thrombo* or
emboli* or occlus* )
S5. S3 and S4
S6. TI ( brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachmoid ) or AB ( brain* or cerebr* or cerebell* or intracerebral
or intracranial or subarachnoid )
S7. TI ( haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* ) or AB ( haemorrhage* or hemorrhage* or haematoma*
or hematoma* or bleed* )
S8. S6 and S7
S9. MH "Hemiplegia"
S10. TI ( hemipleg* or hemipar* or paresis or paretic ) or AB ( hemipleg* or hemipar* or paresis or paretic
S11. S1 or S2 or S5 or S8 or S9 or S10
S12. MH "Eye+" or MH "Rehabilitation of Vision Impaired+" or MH "Optometry" or MH "Eye Diseases+"
S13. MH "Visual Acuity+" or MH "Perimetry+" or MH "Ophthalmology+" or MH "Vision Screening+" or MH "Ocular Physiology+"
S14. TI ( orthoptics or vision, monocular or vision, binocular ) or AB ( orthoptics or vision, monocular or vision, binocular )
S15. TI ( vitreous detachment or hemianopsia or hemianopia or quadrantanopia ) or AB ( vitreous detachment or hemianopsia or hemi-
anopia or quadrantanopia )
S16. MH "Abducens Nerve" or MH "oculomotor nerve" or MH "troclear nerve" or MH "optic nerve" or MH "nystagmus, pathologic
S17. TI ( smooth pursuit or saccades or gaze disorder* or retinal or retinopathy or ophthalmol* ) or AB ( smooth pursuit or saccades or gaze
disorder* or retinal or retinopathy or ophthalmol*)
S18. TI ( hemianop* or blindness or low vision or refractive errors or vitreoretinopathy or vitreous detachment or scotoma or diplopia
or optometry* or ocular or orthoptic* ) or AB ( hemianop* or blindness or low vision or refractive errors or vitreoretinopathy or vitreous
detachment or scotoma or diplopia or optometry* or ocular or orthoptic* )
S19. TI ( oscillopsia or visual tracking or fresnel prism* ) or AB ( oscillopsia or visual tracking or fresnel prism* )
S20. TI ( intranuclear ophthalmoplegia or parinaud's syndrome or weber's syndrome or skew deviation or conjugate deviation ) or AB
( intranuclear ophthalmoplegia or parinaud's syndrome or weber's syndrome or skew deviation or conjugate deviation )
S21. TI ( visual* or vision or eye or eyes or eyesight or sight ) or AB ( visual* or vision or eye or eyes or eyesight or sight )
S22. TI ( problem* or disorder* or impair* or disability* or loss or disease* or defect* or manifestation* or screening or test* or examina-
tion* ) or AB ( problem* or disorder* or impair* or disability* or loss or disease* or defect* or manifestation* or screening or test* or ex-
amination* )
S23. S21 and S22
S24. TI ( third or fourth or sixth ) or AB ( third or fourth or sixth )
S25. AB nerve palsy or TI nerve palsy
S26. S24 and S25
S27. S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S23 or S26
S28. S11 and S27
S29. (MH "Random Assignment") or (MH "Random Sample+")
S30. (MH "Crossover Design") or (MH "Clinical Trials+") or (MH "Comparative Studies")
S31. (MH "Control (Research)") or (MH "Control Group")
S32. (MH "Factorial Design") or (MH "Quasi-Experimental Studies") or (MH "Nonrandomized Trials")
S33. (MH "Placebo Effect") or (MH "Placebos") or (MH "Meta Analysis")
S34. (MH "Community Trials") or (MH "Experimental Studies") or (MH "One-Shot Case Study") or (MH "Pretest-Posttest Design+") or (MH
"Solomon Four-Group Design") or (MH "Static Group Comparison") or (MH "Study Design")
S35. (MH "Clinical Research") or (MH "Clinical Nursing Research")
S36. PT clinical trial
S37. PT systematic review
S38. TI random* or AB random*
S39. TI ( singl* or doubl* or tripl* or trebl* ) or AB ( singl* or doubl* or tripl* or trebl* )
S40. TI ( blind* or mask* ) or AB ( blind* or mask*)
S41. S39 and S40
S42. TI ( crossover or cross-over or placebo* or control* or factorial or sham ) or AB ( crossover or cross-over or placebo* or control* or
factorial or sham )
S43. TI ( clin* or intervention* or compar* or experiment* or preventive or therapeutic ) or AB ( clin* or intervention* or compar* or exper-
iment* or preventive or therapeutic)
S44. TI trial* or AB trial*
S45. S43 and S44
S46. TI ( counterbalance* or multiple baseline* or ABAB design ) or AB ( counterbalance* or multiple baseline* or ABAB design )
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S47. TI ( meta analysis* or metaanlaysis or meta-anlaysis or systematic review* ) or AB ( meta analysis* or metaanlaysis or meta-anlaysis
or systematic review* )
S48. S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S41 or S42 or S45 or S46 or S47
S49. S28 AND S48
Appendix 5. AMED Search Strategy
1. cerebrovascular disorders/ or cerebral hemorrhage/ or cerebral infarction/ or cerebral ischemia/ or cerebrovascular accident/ or stroke/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma
$ or hematoma$ or bleed$)).tw.
5. hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp eye/
9. eye disease/ or exp ocular motility disorders/ or exp vision disorders/ or optic nerve/
10. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve).tw.
11. (intranuclear ophthalmoplegia or parinaud's syndrome or weber's syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw.
12. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or defect$
or manifestation$ or screening or test$ or examination$)).tw.
13. (hemianop$ or blindness or low vision or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
14. (oscillopsia or visual tracking or fresnel prism$).tw.
15. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
16. or/8-15
17. clinical trials/ or randomized controlled trials/ or random allocation/
18. research design/ or comparative study/
19. double blind method/ or single blind method/
20. placebos/
21. (random$ or RCT or RCTs).tw.
22. (controlled adj5 (trial$ or stud$)).tw.
23. (clinical$ adj5 trial$).tw.
24. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
25. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
26. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
27. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
28. (cross-over or cross over or crossover).tw.
29. (placebo$ or sham).tw.
30. trial.ti.
31. (assign$ or allocat$).tw.
32. controls.tw.
33. or/17-32
34. 7 and 16 and 33
Appendix 6. PsycINFO Search Strategy
1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebral small vessel disease/ or cerebrovascular ac-
cidents/ or subarachnoid hemorrhage/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma
$ or hematoma$ or bleed$)).tw.
5. hemiplegia/ or hemiparesis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp "eye (anatomy)"/
9. optometry/ or ophthalmology/ or ophthalmologic examination/
10. exp eye disorders/ or exp eye movements/ or exp vision disorders/
11. binocular vision/ or monocular vision/ or visual acuity/ or visual field/ or peripheral vision/ or exp depth perception/
12. optic nerve/ or abducens nerve/
13. (nystagmus or smooth pursuit or saccades or depth perception or stereopsis or gaze disorder$ or ophthalmol$ or optic nerve).tw.
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14. (intranuclear ophthalmoplegia or parinaud's syndrome or weber's syndrome or skew deviation or conjugate deviation or (one adj3
half syndrome)).tw.
15. ((visual$ or vision or eye or eyes or eyesight or sight) adj5 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or defect$
or manifestation$ or screening or test$ or examination$)).tw.
16. (hemianop$ or blindness or low vision or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
17. (oscillopsia or visual tracking or fresnel prism$).tw.
18. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
19. or/8-18
20. clinical trials/ or treatment effectiveness evaluation/ or placebo/
21. (random$ or RCT or RCTs).tw.
22. (controlled adj5 (trial$ or stud$)).tw.
23. (clinical$ adj5 trial$).tw.
24. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
25. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
26. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
27. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
28. (cross-over or cross over or crossover).tw.
29. (placebo$ or sham).tw.
30. trial.ti.
31. (assign$ or allocat$).tw.
32. controls.tw.
33. or/20-32
34. 7 and 19 and 33
Appendix 7. PQDT Search Strategy
stroke AND hemianopia
OR
stroke AND "visual field"
OR
cerebrovascular AND hemianopia
OR
cerebrovascular AND "visual field"
Appendix 8. Trials Registers Search Strategies
US National Institutes of Health Ongoing Trials Register: ClinicalTrials.gov
(www.clinicaltrials.gov):
( hemianopia OR visual field OR vision defect OR eye diseases ) AND ( Brain Infarction OR Intracranial Hemorrhages OR Carotid Artery
Diseases OR Brain Ischemia OR Cerebral Hemorrhage OR Cerebrovascular Disorders OR Stroke ) [DISEASE]
World Health Organization International Clinical Trials Registry Platform
(apps.who.int/trialsearch):
stroke AND hemianopia OR stroke AND visual field
cerebrovascular AND hemianopia OR cerebrovascular AND visual field
W H A T ' S   N E W
 
Date Event Description
26 February 2019 New search has been performed Review updated, with searches completed in May 2018. The re-
view now includes 20 studies; previous (2009) version includ-
ed 13 studies. In this updated version, we have excluded three
of the studies from the 2009; therefore, this updated version in-
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Date Event Description
cludes 10 studies which were included in the previous (2009) ver-
sion and 10 new studies, with a total of 547 participants with
stroke.
11 October 2018 New citation required and conclusions
have changed
The update of this review has led to changes in the conclusions
relating to compensatory interventions (with greater uncertainty
around previous, limited evidence of effectiveness), and has in-
troduced new evidence relating to adverse events (particularly
headache) associated with substitutive interventions.
 
C O N T R I B U T I O N S   O F   A U T H O R S
For this version: Alex Pollock led the review update, identified relevant studies, provided methodological expertise, extracted data, en-
tered data, carried out analyses, and wrote the final draMs. Pauline Campbell ran searches, contributed to screening of titles, provided
methodological expertise, and read and commented on draMs. Christine Hazelton screened titles, identified relevant studies, extracted
data, acted as a second review author, provided content expertise, and contributed to final draMs. Fiona Rowe acted as a second review
author, provided content expertise, extracted and synthesised data relating to outcome measures, and contributed to final draMs. Sven
Jonuscheit and Ashleigh Kernohan applied inclusion criteria to abstracts and full papers, identified relevant studies, extracted data, and
read and commented on draMs. Jayne Angilley, Clair Henderson, and Peter Langhorne read and commented on draMs.
For the previous (2009) version: Alex Pollock led this review, provided methodological expertise, acted as a second review author, car-
ried out analyses, and wrote the final draMs. Christine Hazelton ran searches, identified relevant studies, acted as first review author, ex-
tracted data, entered data, provided content expertise, and contributed to final draMs. Clair Henderson acted as a second review author
for the identification of relevant studies. Baljean Dhillon, Heather Orr, Katrina Livingstone, Frank A Munro, Fiona Rowe, Uma Shahani,
Jayne Angilley, and Peter Langhorne provided additional content expertise, read and commented on final draMs, and acted as additional
reviewers where there was uncertainty or disagreement. Peter Langhorne also provided additional methodological expertise where there
was uncertainty about the methodological design of studies.
D E C L A R A T I O N S   O F   I N T E R E S T
Alex Pollock was involved in the VISION trial (Rowe 2010), which was funded by the Stroke Association. No other known interest.
Christine Hazelton has carried out non-randomised studies into the effectiveness of a number of scanning training interventions, including
the intervention studied by Roth 2009, and is developing further project proposals in this area. No other known interest.
Fiona Rowe was the chief investigator for the VISION trial (Rowe 2010), funded by the Stroke Association. She was a co-investigator for the
Jarvis 2012 trial, funded by the University of Liverpool.
Sven Jonuscheit: none known.
Ashleigh Kernohan: none known.
Jayne Angilley: none known.
Clair A Henderson: none known.
Peter Langhorne: none known.
Pauline Campbell: none known.
The work presented here represents the view of the review authors and not necessarily those of the funding bodies.
S O U R C E S   O F   S U P P O R T
Internal sources• No sources of support supplied
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External sources• Royal National Institute of Blind People (RNIB, Scotland), UK.
RNIB (Scotland) funded the first (2009) version of this review.• Chief Scientist Office, UK.
Alex Pollock and Pauline Campbell are employed by the Nursing, Midwifery and Allied Health Professions Research Unit, which is funded
by the Chief Scientist Office in Scotland.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Participants
In the 2011 version of the review, we included studies that investigated the effectiveness of visual scanning training and techniques even
if the population of participants had not been clearly defined as having visual field defects. This decision was made in consultation with
a multidisciplinary group of clinicians (CH, JA, BD,KL, PL, FM, HO, FR, US); the decision was that it was clinically relevant and useful to
include these studies. It is recognised that, in these studies, the visual scanning problems experienced by participants may have been due
to either visual field defects, visual neglect, or a combination of both. The results of these studies were therefore relevant to the population
of patients with 'visual scanning' problems, regardless of the physiological cause of the scanning problem. Data from these studies would
not be combined with data arising from studies which include a population of patients with visual field defects but not visual neglect. In
this update, this decision was reconsidered, and reversed: populations of participants with 'visual scanning problems', but no confirmed
visual field defect have been excluded.
Comparisons
In the 2011 version, we included one additional comparison that we did not outline in the protocol. This was a comparison of compensative
intervention versus restitutive interventions. Although not preplanned, discussion amongst the review authors led to the conclusion that
this was a clinically relevant comparison and ought to be included in this review. However, for this updated review, we reached consensus
that we should adhere to the prestated comparisons, but that we should include a summary of results data from any studies which com-
pared two active interventions (i.e. studies with no control group). This has been added as Table 5 and Table 6 and a narrative synthesis
included under Effects of interventions.
Subgroup analyses
The following subgroup analyses were listed as planned in the protocol and previous versions of this review, but have been removed,
as Cochrane guidance recommends restricting the number of subgroup analyses as large numbers can lead to spurious explanations of
heterogeneity (Higgins 2011):
• age (under 60 years, 60 years and over);• gender (men, women);• side of stroke (leM, right, bilateral);• presence of age-related visual problems (presence, absence);• presence of eye movement disorders (presence, absence);• level of motor impairment (mild, moderate, severe);• level of cognitive impairment (mild, moderate, severe).
Search strategy
Due to available time and resources for this latest update, and following a detailed consideration of the comprehensiveness of other
databases:
• we searched, for the 2011 version of this review, the following databases, but did not search them for this updated version:* British Nursing Index (searched 1985 to 31 December 2009);* PsycBITE (Psychological Database for Brain Impairment Treatment Efficacy) at www.psycbite.com (last searched December 2009).* Trials Central (www.trialscentral.org) (last searched February 2010).• for the 2011 version, but not for this updated version, we also:* searched the references supplied by commercial companies providing interventions aimed at restoration of visual field defect (in-
cluding NovaVision®);* performed citation tracking using Web of Science Cited Reference Search for all included studies;* handsearched proceedings of Association for Research in Vision and Opthalmology (www.arvo.org) (1969 to 2010); these abstracts
are now covered by MEDLINE, so were not included in the 2018 handsearching activities.
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I N D E X   T E R M S
Medical Subject Headings (MeSH)
Quality of Life;  Randomized Controlled Trials as Topic;  Stroke  [*complications];  Vision Disorders  [etiology]  [*rehabilitation];  Visual Fields
MeSH check words
Humans
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